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CLL and MCL
B-cell chronic lymphocytic leukemia 
B-cell chronic lymphocytic leukemia (CLL) is characterized by the clonal proliferation and 
accumulation of neoplastic B lymphocytes in peripheral blood, bone marrow and lymphoid tissue. The 
malignant B cells show the typical morphology of small lymphocytes with a narrow border of cytoplasm 
and a dense nucleus with partially aggregated chromatin and the immunophenotype of CD5, CD19, 
and CD23 in combination with low expression levels of surface immunoglobulin (Ig). The pathologic 
features of the lymph nodes are those of a small lymphocytic lymphoma. CLL is the most frequent 
type of leukemia in the western hemisphere with an incidence of 3 in 100,000. While the disease 
classically occurs in elderly people with a median age range at diagnosis of 65-68 years, an increasing 
number of patients are diagnosed at a younger age with now one-third of the patients under the age of 
60 1,2. Most patients present themselves with peripheral lymphocytosis and are asymptomatic at 
presentation. In symptomatic patients, the most common features are generalized lymphadenopathy, 
splenomegaly and cytopenias. The cytopenias can be due to progressive bone marrow infiltration or to 
the development of autoantibodies against self-antigens present on erythrocytes and/or platelets. 
Furthermore patients with CLL generally acquire an immunodeficiency, characterized by 
hypogammaglobulinemia, impaired production of secondary Ig isotypes and T-cell defects, resulting in 
an enhanced susceptibility for bacterial infections 3,4. It is now recognized that the clinical behaviour of 
patients with CLL is heterogeneous 5. A subset of patients with early stage CLL have a disease that 
will rapidly evolve to a more advanced, ultimately fatal disease whereas other patients remain with 
early stage for decades.
Mantle cell lymphoma
Mantle cell lymphoma (MCL) is a non-Hodgkin lymphoma (NHL), characterized by the 
t(11;14)(q13;q32) translocation involving the PRAD-1/bcl 1 gene resulting in overexpression of cyclin 
D1
6. Immunophenotyping shows expression of CD5, CD19, and surface Ig but lacks expression of 
CD23. Although longer recognized as a distinct clinicopathologic entity not until 1992 the consensus 
terminology of mantle cell lymphoma was used 7. MCL is an uncommon disease, accounting for only 
approximately 5% of NHL, occurring in patients with a median age of approximately 65 years 8,9. 
Clinically, patients with MCL present with advanced stage disease with frequent involvement of bone 
marrow, peripheral blood and extranodal sites. The clinical course of MCL is characterized by a high 
overall response rate to induction chemotherapy with a relatively short time to progression and a poor 
overall survival of approximately 3 to 4 years 8,10. Many chemotherapeutic regimens are highly active 
against the disease but relapses typically occur and patients usually die of their disease. Therefore, 
MCL is regarded incurable with the conventional cytotoxic therapies.
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Biology of CLL
Historically CLL cells were believed to represent a leukemic transformation of naïve B lymphocytes 
that had not undergone germinal center antigen exposure and subsequent somatic mutation of their Ig 
genes. Recent studies demonstrating that approximately 50% of CLL clones exhibit somatic mutation 
of their Ig chains, have altered the biological insights of CLL 11-13. Some CLL clones, expressing 
unmutated variable heavy chain Ig (IgVH) genes may originate from naïve B cells whereas other CLL 
clones with mutated IgVH genes may be derived from post-germinal center memory B cells. More 
importantly the presence or absence of somatic mutations of IgVH genes has been shown to 
distinguish between two disease subsets providing important prognostic information 11,12. Patients 
whose CLL cells express mutated IgVH  genes, defined as > 2% difference from the corresponding 
germ-line gene, have a distinctly longer median survival than CLL patients with unmutated IgVH genes 
11,12,14. Median survival in CLL patients with unmutated IgVH genes ranges between 79 and 119 
months whereas patients whose CLL cells express mutated IgVH genes have a significant longer 
median survival, reaching 293 months in one study 11,12,14,15. These survival differences between IgVH 
gene mutation status were even observed in patients with early stage disease, indicating that the 
mutation status is a powerful predictor of clinical outcome in CLL. The proportion of CLL cells with 
unmutated IgVH genes is close to 30-40%.
Gene expression profile studies identified a small number of genes that were differently expressed by 
mutated and unmutated CLL subtypes 16. One of these genes encodes 70-kD zeta-associated protein 
(ZAP-70), an intracellular tyrosine kinase required for the TCR signaling normally expressed by T cells 
and natural killer (NK) cells and not by normal B cells. Several studies have shown that ZAP-70 is 
preferentially expressed in CLL cells with unmutated IgVH genes and that its expression is associated 
with aggressive disease 17-19. In patients showing discordance between ZAP-70 level and the IgVH
mutational status, ZAP-70 was a better predictor of clinical course than the mutation status 17. Studies 
focusing on the role of ZAP-70 in the B-cell receptor (BCR) signaling demonstrated that CLL cells with 
ZAP-70 expression renders IgM signaling more effective than CLL cells lacking ZAP-70, thereby 
potentially enhancing survival and/of proliferation of ZAP-70 positive CLL cells 20. There is also 
increasing evidence for the role of antigen in the pathogenesis of CLL. The structurally similarity of the 
B-cell receptors and the observed limited diversity of antigen-binding pockets of CLL cells from various 
patients suggest a common promoting antigen relevant for the pathogenesis of CLL 21,22. Ongoing 
antigen-mediated activation of the leukemic cells through the BCR is suggested by the presence of 
cellular activation markers on the cell surface 23. Conceivably, it can be hypothesized that CLL cells 
that express unmutated IgVH genes, which typically also express ZAP-70 are susceptible to repetitive 
stimulation by a distinct yet unknown antigen resulting in proliferation of CLL cells and allowing them 
to avoid apoptosis 5,20. This could account in part for the more aggressive clinical behavior. Cellular 
kinetics studies using deuterated water illustrated the correlation between division rates of CLL cells 
and progressive disease 24.
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Genomic aberrations are often encountered in CLL. Interphase fluorescence in situ hybridization 
(FISH) enables to identify genetic abnormalities in 82% of the patients with CLL 24-26. 17p deletion 
(17p-) and 11q deletion (11q-) and dysregulation of the p53 gene, located on the short arm of 
chromosome 17, are independent prognostic factors identifying subgroups of patients with rapid 
disease progression and short survival times whereas 13q deletion (13q-) or a normal karyotype are 
associated with favorable outcomes 24-27. The high-risk genomic aberrations (11q-, 17p- and p53 
dysfunction) were strongly associated with the presence of unmutated IgVH genes 
15,27. As 
hypothesized above CLL cells with unmutated IgVH genes may have increased proliferative capacity 
and ability to survive and may be selectively prone to the acquisition of genetic changes, which may 
further impair the prognosis in these patients. Finally, in CLL upregulation of anti-apoptotic genes such 
as Bcl-2, MCL1 and surviving is observed, resulting in further accumulation of leukemic cells and 
enhanced survival 28,29. Other potential factors influencing apoptosis in CLL are interactions with 
stromal cells, “nurse-like” cells or activated CD4+ T cells, expressing CD40L 28,30. Cytokines produced 
by the micro-environment, such as interleukin (IL)-4 or vascular endothelial growth factor may further 
enhance expansion of CLL clones 31,32.
Biology of MCL
The genetic hallmark of MCL is the chromosomal translocation t(11;14)(q13;q32) leading to 
deregulation and overexpression of cyclin D1. Cyclin D1 , one of the key regulators of the cell cycle, 
controls after encountering cyclin-dependent kinase (CDK) the G1 phase and the G1/S-phase 
transition of the cell cycle. Hence, overexpression of cyclin D1 in MCL cells may accelerate G1/S-
phase transition and therefore tumor cell proliferation 33. The increase of intracellular cyclin D1/CDK 
leads to phosporylation of the retinoblastoma protein (Rb), that, in turn, loses its suppressive effect on 
cell cycle progression 34. The level of cyclin D1 expression appears to be directly correlated with the 
tumor cell proliferation rate in MCL 35. Several additional molecular alterations that target 
predominantly cell cycle regulatory elements have been described 33.
Another important pathogenetic mechanism in MCL is dysregulation of the DNA damage response 
pathway. 40-75% of MCL patients carry mutations of the ataxia-telangietasia mutated (ATM) gene, 
located on chromosome 11, resulting in inactivation of the gene 36. ATM plays a central role in the 
cellular response to DNA damage by activating p53 after DNA damage and by controlling 
phosphorylation of effector genes 33. ATM inactivation in MCL is associated with a high number of 
chromosomal alterations suggesting that it may be partly responsible for the chromosomal instability in 
these tumors. P53 is also frequently directly targeted by genetic alterations and as observed in CLL 
patients, these dysregulations are associated with a poor prognosis 37,38. A recent gene expression 
profiling study has defined a subset of proliferation-associated genes that may predict the length of 
survival in different subgroups of MCL patients 35.
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Therapy
Treatment of CLL
CLL still has been considered an incurable disease despite the availability of highly active 
chemotherapeutic agents and monoclonal antibodies 39,40. The decision to treat is guided by the stage 
of the disease, the presence of symptoms, disease activity as expressed by lymphocyte doubling time 
(LDT) and probably in the near future the presence of unfavourable prognostic factors, such as ZAP-
70 expression, unmutated IgVH genes and genetic aberrations, involving chromosome 11 and 17 as 
described in the biology of CLL paragraph. The staging classification of Rai and Binet are used to 
estimate the prognosis based on the extent of lymphadenopathy, hepatosplenomegaly measured by 
palpation and anemia and thrombocytopenia measured by blood counts. The clinical stages according 
to RAI and Binet are shown in table 1. These well validated clinical staging systems describe early 
(Rai 0, Binet A), intermediate (RAI I/II, Binet B) and advanced (RAI III/IV, Binet C) stages with 
estimated median survival times of >10, 5-7 and 1-3 years, respectively 41,42. 
Table 1. Clinical staging system according to Rai and Binet 41,42.
Binet classification Rai classification Median survival
Stage Definition % of patients Risk group Stage Definition % of patients
A < 3 lymphoid areas 60 low 0 lymphocytosis only 30
B > 3 lymphoid areas 30 intermediate I lymfadenopathy 25
II Hepato or splenomegalie +/-25
lymfadenopathy
C anemia and/or  10 high III lymfocytosis with anemia 10
thrombocytopenia IV lymfocytosis with anemia 10
and thrombocytopenia
 5-7
 1-3
(years)
>10
Since the use of immunophenotyping and automated differential blood counts, more early stage 
asymptomatic individuals with CLL are being diagnosed. For this group of patients the Rai and Binet 
staging systems lack the ability to prospectively identify those patients that will rapidly evolve to more 
aggressive disease. Importantly, new clinical and biological markers are determined which could be 
considered as additional prognostic factors. LDT, as indicator for disease kinetics, is the time required 
for doubling of the peripheral blood lymphocytes. Although a short LDT has prognostic value in 
patients with early stage disease, host factors can interfere with the LDT thereby influencing treatment 
decisions 43. Other interesting potential prognostic factors are ß-2 microglobulin or solubable CD23 but 
all these parameters needs to be validated in prospective trials 44. Importantly, treatment of unselected 
patients in early stage increased toxicity without improving overall survival, therefore these patients 
may be better off by monitoring with a watch and wait strategy 45. Consensus guidelines for treatment 
of patients with CLL and response criteria have been proposed by the National Cancer Institute (NCI) 
46. However, with the introduction of new more effective therapeutic strategies such as 
chemoimmunotherapy and allogeneic stem cell transplantion (SCT) following reduced-intensity 
conditioning (RIC) resulting in long duration of responses, revision of these NCI response criteria is 
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needed. Using 4-color flow cytometry and real-time quantitative polymerase chain reaction (PCR), 
assessment of minimal residual disease (MRD) after effective therapy is available. Elimination of MRD 
after therapy may become the therapeutic goal in the future 47.
Chemotherapy
Until recently the alkylating agent chloorambucil has been the cornerstone of treatment in patients with 
CLL. Three randomized trials have demonstrated that the nucleoside purine analog fludarabine 
yielded superior overall and complete response rates and longer progression-free survival (PFS) as 
compared with alkylator-based therapy. Unfortunately, all patients treated with fludarabine ultimately 
relapsed and no survival benefit was observed. 39,48-50. Based on these encouraging results, 
fludarabine was combined with cyclophosphamide as first-line therapy showing better overall 
response rates and PFS compare to fludarabine alone 51. Again after a follow-up period of 22 months, 
no difference in overall survival was noticed. To further enhance therapeutic efficacy and eradicate 
residual malignancy, fludarabine or fludarabine-based regimens were combined with monoclonal 
antibodies (MoAb).
Chemoimmunotherapy
Rituximab (anti-CD20 MoAb), a humanized MoAb, has single-agent activity in CLL 52,53. Probably due 
to low expression levels of CD20 on the CLL cells, its single agent efficacy is limited but it may be 
synergistic in combination with fludarabine or fludarabine and cyclophosphamide 54,55. The 
combination fludarabine and rituximab did not protect high-risk CLL patients with unmutated IgVH 
genes and unfavourable cytogenetics from disease progression 56. Alemtuzumab (anti-CD52 MoAb), 
currently approved for the treatment of refractory CLL, is highly active in both blood and bone marrow
but its efficacy is limited in the presence of bulky lymfadenopathy 47,57,58. In patients with refractory CLL 
(66% fludarabine-refractory) impressive response rates were reported with the combination 
fludarabine and alemtuzumab emphazing the complementary modes of actions and illustrating the 
synergistic effects the combination 59. Randomized controlled trials are now pivotal to define the 
optimal combination, dose and schedules for chemoimmunotherapy.
High dose chemotherapy followed by rescue autologous stem cell transplantation
Patients with chemotherapy-refractory CLL and/or patients with adverse prognostic markers might 
benefit from more intensive approaches aiming to prolong survival. The efficacy of autologous SCT 
relies exclusively on the cytotoxic therapy administered. In accordance with this concept outcomes 
were better for patients transplanted in earlier stage with chemotherapy sensitive CLL 60. Autologous 
SCT up front after initial treatment with fludarabine in previously untreated CLL patients was shown to 
be feasible with low treatment-related mortality (TRM). However, despite complete molecular 
remissions in a large cohort of patients shortly after autoSCT, ultimately all patients relapsed, 
indicating that this treatment modality is not curative for CLL 61. In high-risk CLL patients (90% 
unmutated IgVH genes) treated with an autologous SCT after myeloablative-conditioning regimen 
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including total body irradiation (TBI) no evidence of a plateau of DFS or survival was observed 62. In 
both studies, late TRM due to secondary malignancies such as myelodysplastic syndromes (MDS) 
negatively effected outcome 61,62. In conclusion, combinations of chemotherapy and MoAbs and/or 
dose intensification of chemotherapy in combination with autologous SCT do not have the capacity to 
definitely cure CLL.
Treatment of MCL
At diagnosis most patients have advanced disease, necessitating the administration of chemotherapy. 
Several chemotherapeutic regimens have proven efficacy as induction treatment with response rates 
of 80-95% 63,64. Although rituximab as a single agent has limited activity against MCL 65, in 
combination with anthracycline-based regimens such as CHOP (cyclophosphamide, doxorubicin, 
vincristine, and prednisolone) it significantly increased overall and complete response rates and time 
to treatment failure compared to CHOP but not progression-free and overall survival 66. A recent 
randomized study observed an improved overall survival in patients with relapsed or refractory MCL 
who were treated with a combination of rituximab and the purine nucleoside analog-based regimen 
fludarabine, cyclophosphamide and mitoxantrone (FCM) in comparision with FCM alone 63,67. 
Intensification of the chemotherapy by combining an anthracycline/based regimen with alternating 
cycles of rituximab and high dose methotrexate and cytarabine compared favourably with other 
studies at the cost of significant toxicity with 8% toxic deaths 68. Unfortunately, in none of the studies a 
plateau in the failure-free survival and overall survival curves was observed. Since these regimens do 
not offer cure, high-dose chemotherapy followed by autologous SCT has been studied in order to 
improve survival rates 40,69. High-dose chemotherapy followed by autologous SCT as consolidation 
therapy after successful induction therapy prolonged progression-free survival in comparison to 
interferon maintenance but not overall survival 70. Approaches to improve the preparative regimen for 
autologous SCT by adding rituximab or a radioimmunoconjugate or by applying rituximab 
maintenance therapy after autologous SCT may prolong survival but will probably not cure the disease 
64,71.
Cellular immunotherapy against CLL and MCL
Cognate interactions between antigen-presenting B and T cells are pivotal for immunologic responses. 
For an efficient immune response the antigen-presenting cell (APC) must present the peptide antigen 
in the context of the major histocompatibility complex (MHC) to deliver a signal to the T-cell receptor 
(TCR) of the antigen-specific T cells. Next, an antigen-nonspecific, MHC-nonrestricted costimulatory 
signal must be delivered to the T cell. CD40, a molecule of the family of tumor necrosis factor (TNF) 
receptors expressed throughout B-cell development, plays a critical role. Its ligand CD40L (CD154) is 
induced on activated CD4+ T cells upon antigen recognition by the TCR. CD40/CD40L interactions 
significantly enhances the antigen-presenting capacity of B cells by upregulating the adhesion 
molecules ICAM-1 (CD54) and LFA-3 (CD58) and the costimulatory molecules B7-1 (CD80), B7-2 
(CD86) and CD83. Binding of the costimulatory molecules by CD28 on the T cell surface induces T-
cell proliferation, activation and increase the production of IL-2 whereas binding by CTLA-4 on the T 
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cell results in T-cell anergy 72,73. Hence, professional APC like dendritic cells (DC) or activated 
monocytes or B cells, expressing high levels of adhesion and costimulatory molecules are capable of 
provoking strong antigen specific T-cell responses, whereas immature APCs lacking costimulation 
may lead to the induction of anergy or suppression.
Malignancies generally fail to induce a clinically significant antigen-specific antitumor response in the 
autologous host. The inability of tumor cells to induce autologous T-cell proliferation and cytotoxicity 
may be caused by insufficient numbers of functional antigen-specific T cells in the repertoire or a 
suppression of antigen-specific immune responses. Other explanations might be the absence or low 
expression levels of unique tumor-associated antigens or the low immunogenicity of these antigens. 
Finally, neoplastic cells may not be capable of functioning efficiently as APC. Ideally, tumor-associated 
antigens should be overexpressed or de novo expressed in tumor cells compared to normal cells, they 
should be bind to the MHC molecules and they should be recognized by the T-cell repertoire in MHC-
restricted fashion.
In B-cell malignancies the Ig is an unique clonal marker containing tumor-specific epitopes or idiotypes 
that can function as target for T-cell-mediated immune responses 74-76. In addition several other tumor-
associated antigens highly overexpressed in CLL and/or MCL have been identified. Autologous T-cell 
responses against bcl-2, survivin, fibromodulin and oncofetal antigen-immature laminin receptor have 
been reported 77-80. In these studies it was shown that the neoplastic B cells were not capable to 
adequately present the tumor antigen to the T cell due to lack of costimulatory molecules. Modification 
of the B-cell tumor into an APC phenotype or ex-vivo pulsing of professional DC with the tumor-
associated antigen was necessary for the recognition of the tumor antigen by autologous T cells 78-81. 
Since both normal B cells and malignant B cells highly express CD40, CD40 stimulation is an effective 
tool to activate tumor B cells and modify them into professional malignant APC with high expression 
levels of CD80 and CD86. Transformation of B-cell malignancies, including CLL, follicular lymphoma 
and hairy cell leukemia into APC has been studied previously, but the modification of MCL cells into 
APCs have not been reported 82-86. Using these malignant APC as stimulator cells, autologous T-cell 
responses in vitro could be induced 82,83. For CD40 stimulation, coculture of neoplastic B cells in the 
presence of CD40L-transfected feeder cells have been used 82,83,85-87. Another approach is the direct 
gene transfer of CD40L into CLL cells via adenovirus vectors or the ex vivo infection with vectors 
encoding for multiple costimulatory molecules 84,88,89. To translate these results into clinical practice 
vaccination strategies with tumor-specific idiotype vaccines 75,90,91, CD40L-transduced CLL cells 88 and 
tumor antigen-pulsed DC 78 were developed. Clinical trials have illustrated the feasibility of this 
immunotherapeutic strategies and showed clinical responses after the vaccinations 88,90,91. However, 
these clinical responses were transient and did not lead to the induction of sustained durable anti-
tumor T-cell response. More importantly, best responses were seen in patients with relative indolent 
disease whereas patients with aggressive and/or bulky disease minimal response rates were 
observed. In conclusion, although autologous T cells capable of reacting against tumor-associated 
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peptides may exist in the T-cell repertoire of the patient, tolerance for tumor antigens or suppression of 
tumor-specific T cells might be induced.
In patients with CLL several abnormalities involving the T cell as well as composition of T-cell 
populations, possibly impairing tumor-specific immune responses, have been reported. Recently, 
significantly increased amounts of regulatory T cells (Treg) were found in CLL patients compared to 
healthy individuals and the highest frequencies were observed in untreated patients and progressing 
patients presenting with extended disease 92. Treg are CD4
+CD25+ T cells that can suppress antigen-
specific T-cell immune responses and may be partly responsible for the lack of antitumor immune 
responses 93. Additional immune suppressive factors including cytokines TGF-ß, interleukin (IL)-10 
and IL-4 may further suppress T-cell activation, expansion and T-cell effector functions. High 
expression levels of these immuno-modulatory cytokines in CLL cells and autocrine IL-10 production 
by the MCL cells have been described 94-96. Finally, CD4+ and CD8+ T cells from CLL patients showed 
reduced expression of CD40L and CD28 respectively, thereby possibly interfering with T cell-APC 
interaction 3,97. The usage of a limited oligoclonal TCR repertoire by CD4+ T cells in patients with CLL 
further suggest that these cells might be involved in the disease process 98. The T-cell compartment of 
the patient is further impaired by the administration of chemotherapy and MoAbs. The introduction of a 
whole new T-cell repertoire derived from a healthy donor may be an attractive approach to reconstitute 
T-cell reactivity against tumor antigens. More importantly, after an allogeneic SCT a variety of 
alloantigens, expressed by the malignant cells, may serve as potential targets for alloreactive donor T-
cells thus definitely eradicating persistent disease.
Allogeneic SCT
Following myeloablative conditioning or reduced-intensity conditioning (RIC) allogeneic SCT leads to 
fully or partially replacement of recipient-derived hematopoiesis by donor hematopoiesis. Once 
durable donor engraftment is established the administration of non-tolerized donor T cells is possible. 
The transfer of non-selected donor T cells in the stem cell graft or in the DLI have beneficial effects 
through reactivity against (allo)antigens on leukemic cells, the graft-versus-leukemia (GvL) effect but 
may also have detrimental alloreactive activity against non-hematopoietic tissue resulting in graft-
versus-host disease (GvHD). After allogeneic HLA partially mismatched SCT T-cell responses may be 
directed against the differentially expressed HLA complex from the patient. Transplantation over HLA 
barriers will thus lead to alloreactivity against the polymorphic part of the HLA molecules. Following 
HLA-matched allogeneic SCT, T-cell responses can be directed against minor histocompatibility 
antigens (mHag). MHag are immunogenic peptides encoded by polymorphic genes that can be 
recognized by alloreactive T cells in the context of “self” HLA-molecules 99,100. In donor/recipient pairs 
of allogeneic SCT mHag can be differently expressed in various tissues and can induce T-cell 
responses that contribute to GvHD and GvL activity 99,100. Ubiquitously expressed mHag, such as the 
male-specific mHag 101 and the HA-8 mHag 102 may serve as target for T-cell responses associated 
with GvHD. In contrast, T-cell reactivity against mHags such as HA-1, HA-2 or BCL2A1 that are 
selectively expressed in hematopoietic cells including leukemic cells, but not widely expressed in non-
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hematopoietic tissue may be preferentially associated with GvL activity 103-106. The B-cell lineage 
restricted mHag HB-1 was capable of eliciting donor-derived cytotoxic T lymphocyte (CTL) reactivity 
against B-cell acute lymphoblastic leukemia 107. Recently, a novel B-cell restricted mHag, encoded by 
an alternative transcript of the proliferation associated nuclear element 1 (PANE1) was identified that 
is selectively expressed in B-lymphoid cells with the highest levels of expression in resting B cells and 
CLL cells 108. Because of the B-cell and CLL-restriction of this mHag, it might be a potential 
therapeutic target for mHag-specific adoptive cellular immunotherapy in patients with persistent CLL 
after allogeneic SCT.
Allogeneic SCT in patients with CLL and MCL
Allogeneic SCT provides new therapeutic opportunities for cure of advanced chronic B-cell 
malignancies. New prognostic markers (see “the biology of CLL” paragraph) enable to identify high-
risk CLL patients with a poor prognosis who will merit this experimental treatment modality with 
curative intent. As illustrated in figure 1, the much lower incidence of relapse after allogeneic SCT 
compared to autologous SCT as well as the elimination of post-transplant residual disease by adoptive 
cellular therapy such as donor lymphocyte infusions (DLI) suggests susceptibility of CLL cells and 
MCL cells to a GvL effect 60,109-112 . However, overall survival rates after allogeneic SCT reported to be 
only 40-60% at 4-5 years follow-up due to substantial toxicity associated with allografting using 
standard myeloablative regimens 60,110,113-115. High TRM up to 40% was observed caused by organ 
toxicity, infectious complications related to the impaired immune system following the conditioning 
regimen and graft-versus-host disease (GvHD) in an extensively pretreated older patient population.
Figure 1. Relapse rate in patients with CLL entering complete remission after SCT. Series from the 
International Group on CLL/Transplants.
Chapter 1
20
Various strategies of reducing the preparative regimen’s toxicity while preserving its 
immunosuppressive effect necessary to prevent graft rejection and to establish donor chimerism have 
been developed. Using RIC, short-term TRM was significantly reduced while maintaining the GvL-
mediated curative potential of allogeneic SCT 116-119. Since incidences of acute and chronic GvHD 
were not substantial altered following RIC, the reduced mortality was specifically related to a decrease 
of infectious complications 117,119. However, considerable toxicity due to a high incidence of acute 
GvHD (>40%) and extensive chronic GvHD (30-60%), caused by alloreactive T cells, was observed 
117,119,120. The use of alemtuzumab to deplete for donor and recipient T cells as part of the RIC strategy 
effectively reduces GvHD 111,118,121. A beneficial effect of using alemtuzumab for T-cell depletion is its 
intrinsic anti-CLL activity thus offering a time frame after allogeneic SCT to optimize the potential of 
adoptive immunotherapy. Due to profound T-cell depletion in vitro and/or in vivo using this approach 
no GvL effect without additional treatment with donor T cells is anticipated 117,118. The two-step 
approach of allogeneic SCT following RIC by first the use of T-cell depleted grafts avoiding the risk of 
GvHD, followed by the postponed administration of DLI was demonstrated to be feasible even in older 
patients 118,121.
Donor lymphocyte infusion
Incorporation of alemtuzumab in the RIC to deplete recipient and incoming donor T cells has resulted 
in durable engraftment in sibling and unrelated donor transplantations while significantly reducing the 
risk for GvHD. The reduced antitumor activity of such protocols necessitates the use of adjuvant DLI 
infusions to promote GvL activity 109,111,118,121. The efficacy and curative effect of DLI has been 
demonstrated in a variety of hematopoietic malignancies and was dependent on the sensitivity of the 
malignancy to the effects of DLI 122. The remarkable sensitivity of chronic myeloid leukemia (CML) to 
DLI had led to the successful use of T-cell depleted protocols with salvage DLI early in the course of 
the disease relapse 123. Several studies have shown that CLL and MCL are susceptible to DLI 
111,118,124. However, continuous relapses after allogeneic SCT and the application of DLI were 
frequently observed with relapse rates 3 years after transplantation of 50% for the MCL patients and 
44% for CLL patients in one study 111 and 27% of CLL patients, relapsing after 2 years in another 
recent study 120. In these patients escalating doses of DLI were necessary to achieve disease control, 
resulting in considerable toxicity due to GvHD. Performing the transplantation procedure while patients 
were in CR resulted in significantly better DFS. These data indicate that in some patients with CLL or 
MCL, treated with an allogeneic SCT and DLI alloreactive donor T cells are not capable of eliciting a 
GvL effect against persisting leukemic cells. Therefore both the specificity of the alloimmune response 
as well as the magnitude of the T-cell response has to be improved to achieve long-term disease 
control and ultimately cure. Strategies for adoptive immunotherapy augmenting the GvL reactivity and 
reducing the GvHD are urgently needed.
Adoptive cellular immunotherapy with in vitro generated tumor-reactive CTL
The frequently observed relapses after allogeneic SCT and DLI reflecting the incapacity of donor T 
cells to definitely eradicate resistant CLL or MCL after allogeneic SCT may likely be caused by the 
inappropriate APC function of the malignant cells. B-cell malignancies can be modified into malignant 
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professional APCs 82,83,85,125. Tumor-reactive T cells can be generated by repetitive stimulation of 
donor-derived T cells with the transformed malignant B cell as stimulator cell. These in vitro generated 
and expanded CTLs can then be infused in the patient. The feasibility and success of this approach 
has been demonstrated by the induction of CR in a patient with resistant leukemia after allogeneic 
SCT 126. Alternatively, mHags with a relatively hematopoiesis-restricted or even more preferable B-cell 
lineage-restricted expression may serve as tumor-specific antigen. The in vitro generation of mHag-
specific CTLs by stimulating donor T cells with professional APC from the donor loaded with mHag 
peptide may also be an approach to enhance GvL reactivity without causing GvHD. Whether 
transformed CLL and MCL cells as stimulator cells has the capacity to initiate a primary T-cell 
response in a HLA-matched setting and what the optimal conditions are to generate such a immune 
response needs to be determined.
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Aim of the study
With the introduction of less toxic preparative conditioning regimens, resulting in reduced TRM, 
allogeneic SCT is now considered a potential curative treatment modality for patients suffering from 
chronic B-cell malignancies such as CLL and MCL. However, the observation that after allogeneic 
SCT and the administration of DLI relapses frequently occur, suggests that these neoplastic B cells 
are capable of escaping T-cell mediated immunity. Furthermore, considerable morbidity due to GvHD 
caused by alloreactive T cells was observed. In this thesis we investigated the APC capacity of 
primary CLL and MCL cells and analyzed opportunities to effectively transform them into professional 
malignant APC. To mimic the clinical transplantation setting, the induction of primary T-cell responses 
against the malignant APCs were performed using T cells from HLA-matched donors. To elucidate the 
nature of graft-versus-CLL responses and to gain more insight into the success and failure of cellular 
adoptive immunotherapy, T-cell responses involved in the GvL and GvHD in patients treated with DLI 
were studied.
In chapter 2 we analyzed the expression levels of adhesion and costimulatory molecules on CLL 
cells. The most optimal method to transform CLL into efficient APC cells using activating cytokines, by 
triggering toll-like receptors (TLR) using microbial pathogens and by CD40 stimulation with CD40L-
transfected fibroblast was determined. The production of immunostimulatory cytokines by these 
modified malignant cells was established. Finally, the allostimulatory capacity of the obtained CLL 
APCs and the primary CLL was examined in a HLA class I-matched setting.
To further translate the results from chapter 2 into a clinically applicable transplantation model, and to 
investigate whether modified CLL cells are sufficiently immunogenic to initiate an adequate 
alloimmune response in a complete HLA-matched sibling setting, primary T-cell responses against 
CLL-APCs were generated. In chapter 3 we described the results of these experiments and we 
further analyzed the specificity of the obtained CLL-reactive CTL clones.
In chapter 4 we described the phenotypic characteristics of MCL cells from six different patients. Pro-
inflammatory, MCL- and B-cell activating cytokines were tested for their costimulatory upregulating 
capacity. Futhermore, CD40 activation was performed to modify MCL cells into an antigen-presenting 
phenotype. The generation of MCL-reactive CTL lines and clones using MCL APC was investigated.
In chapter 5 we report the clinical outcomes and response rates in patients with advanced CLL, 
treated with allogeneic SCT following RIC with in vitro T-cell depletion using alemtuzumab. To improve 
our understanding of the graft-versus-CLL activity we characterized allogeneic immune responses in a 
patient, successfully treated with DLI and in a patient suffering from progressive disease despite the 
administration of escalating doses of DLI. To investigate the CLL-reactive T-cell repertoire in the 
unprimed donor, primary T-cell responses against the CLL and the transformed CLL were assessed.
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In chapter 6 the results of these studies are summarized. Alternative strategies in cellular 
immunotherapy in the context of RIC allogeneic SCT to improve the specificity and efficacy of GvL 
responses are discussed. Finally, suggestions to apply these results into a clinical protocol are 
provided.
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Abstract
Allogeneic stem cell transplantation following reduced-intensity conditioning is being evaluated in 
patients with advanced B-cell chronic lymphocytic leukemia (CLL). The curative potential of this 
procedure is mediated by donor-derived alloreactive T cells, resulting in a graft-versus-leukemia effect. 
However, CLL cells may escape T cell-mediated immune reactivity since these cells lack expression 
of costimulatory molecules. We examined the most optimal method to transform CLL cells into efficient 
antigen presenting cells (APC) using activating cytokines, by triggering toll-like receptors (TLRs) using 
microbial pathogens and by CD40 stimulation with CD40L-transfected fibroblasts. CD40 activation in 
the presence of IL-4 induced strongest upregulation of costimulatory and adhesion molecules on CLL 
cells and induced the production of high amounts of IL-12 by the leukemic cells. In contrast to primary 
CLL cells as stimulator cells, these malignant APCs were capable of inducing the generation of CLL-
reactive CD8+ CTL lines and clones from HLA class I-matched donors. These CTL lines and clones 
recognized and killed primary CLL as well as patient derived lymphoblasts, but not donor cells. These 
results show the feasibility of ex-vivo generation of CLL-reactive CD8+ CTL’s. This opens new 
perspectives for adoptive immunotherapy, following allogeneic stem cell transplantation in patients 
with advanced CLL.
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Introduction
Chronic lymphocytic leukemia of B cell origin (CLL) can not be cured with conventional chemotherapy 
1. Although novel chemotherapeutic agents including purine analogues 2 and targeted therapy with 
monoclonal antibodies (MoAb) like alemtuzumab or anti-CD20 3-5 are promising, these treatment 
modalities rarely lead to cure of the disease. Autologous stem cell transplantation (SCT) did not result 
in longer relapse-free survival than conventional therapies 6. Allogeneic SCT is increasingly 
considered for treatment of patients with advanced CLL. The rationale for allogeneic SCT relies on 
adoptive transfer of donor-derived alloreactive T cells that may eradicate refractory or recurrent CLL.
Complete sustained remissions in CLL patients have been observed after allogeneic SCT suggesting 
a susceptibility of CLL cells to a graft-versus-leukemia (GvL) effect 6-8. However, the application of 
allogeneic SCT in CLL has been hampered by high treatment-related mortality (TRM) in this 
extensively pretreated older patient population 6-8. Reduced-intensity conditioning (RIC) may reduce 
short-term TRM 8-10. Longterm follow-up of CLL patients treated with allogeneic SCT after dose-
reduced conditioning regimens is limited, but short-term follow-up showed reduction of TRM with 
preservation of GvL reactivity 7-10. Acute or chronic graft-versus-host disease (GvHD) remains a major 
cause of morbidity and mortality 7,11. An approach to reduce GvHD reactivity while conserving GvL 
activity is to perform allogeneic SCT with in vitro T-cell depletion followed by treatment using in vitro-
selected cytotoxic T lymphocytes (CTLs) with relative specificity for the CLL or using hematopoiesis-
restricted minor histocompatibility antigen (mHag)-specific CTLs 12,13.
Although CLL cells show high expression of HLA class I and II molecules necessary for presentation 
of antigens to T cells, CLL cells are unable to stimulate normal allogeneic T cells in a mixed 
lymphocyte reaction (MLR) due to inadequate expression of costimulatory and adhesion molecules 14-
16. For the induction of a sustained T-cell response, the expression of the costimulatory molecules 
CD80 or CD86 on the antigen-presenting cells (APC) is essential 17. Both normal B cells and CLL cells 
highly express CD40, and stimulation of these cells via the CD40-CD40L pathway may enhance the 
immunogenicity of these cells by upregulating costimulatory molecules 14,18-21. Hence, CD40-activated 
CLL cells may induce specific T-cell responses capable of reacting with leukemic cells 14,19,22. 
Modification of B cells, monocytes or immature DC into efficient APCs can also be initiated by 
microbial products such as endotoxin (LPS), viral double-stranded RNA, or immunostimulatory 
bacterial CpG-DNA sequences (CpG) 23-25. These microbial pathogens can be recognized by distinct 
toll-like receptors (TLRs) expressed on APC. Signaling through TLRs strongly activates APC to 
upregulate costimulatory molecules and to synthesize and release inflammatory cytokines 23. Normal 
and neoplastic B cells express most TLRs at low or undectable levels except TLR9 and TLR10, which 
are abundantly expressed in B cells 26,27. Unmethylated CpG motifs, characteristic of bacterial DNA, 
are detected by TLR9, and may therefore stimulate normal and malignant B cells 26-28.
In this study, we investigated the most optimal method to modify CLL cells into efficient malignant 
APCs using several proinflammatory cytokines including interleukin (IL)-1, IFN-α, and TNF-α, and 
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cytokines IL-2, IL-3 and IL-4, known to upregulate costimulatory molecules in plasmacytoid dendritic 
cells (DC) and B cells 29,29-31,31. We further tested whether activation of TLRs by various microbial 
pathogens or triggering CD40 with CD40L-transfected fibroblasts could induce further upregulation of 
costimulatory molecules. Moreover, the additional stimulatory effects of TLRs triggering by microbial 
products on CD40-activated CLL cells were studied. To examine the potential use of in vitro
manipulated CLL for adoptive immunotherapy after allogeneic SCT, we used the modified CLL cells as 
APCs to generate allogeneic CLL-reactive CD8+ CTL lines and clones from HLA class I-matched 
donors. Stimulation of CD40 on CLL cells in the presence of IL-4 induced the strongest upregulation of 
costimulatory molecules. Using these malignant APCs as stimulator cells, CLL-reactive CD8+ CTL 
lines and clones were generated from three HLA class I-matched donors. These CTL lines and clones 
recognized and killed primary CLL as well as PHA blasts or EBV transformed B cells (EBV-LCL) from 
the patient, but not donor specific cells. Our findings indicate that ex-vivo generation of CLL-reactive 
CD8+ CTL lines and clones from HLA class I-matched donors is feasible.
Material and methods
Cell samples
After informed consent peripheral blood samples were obtained from 14 untreated patients with CLL, 
and from 3 healthy donors. Peripheral blood mononuclear cells (PBMC) of CLL patients were isolated 
from blood samples by Ficoll density separation and cryopreserved. As assessed by flow cytometry, 
more than 90% of the PBMC from CLL patients coexpressed CD19 and CD5 surface molecules. 
Three HLA class I-matched patient / donor pairs were used to induce a T-cell response against CLL 
cells. In two of the three patient / donor combinations a one locus HLA class II mismatched donor was 
available. The HLA types of these patients and donors are shown in table 1.
Table 1. HLA type of donor and patients.
CLL 3 A2 A3 B7 B14 Cw7 DR13 DR7 DQ1 DQ2
donor A2 A3 B7 B14 Cw7 DR13 DR7 DQ1 DQ7*
CLL 4 A3 A31 B7 B27 Cw2 Cw7 DR2 DQ1
donor A3 A31 B7 B27 Cw2 Cw7 DR15* DR4* DQ1 DQ3
CLL 13 A2 A26 B7 B44 Cw5 Cw7 DR4 DR15 DQ3 DQ6
donor A2 A26 B7 B44 Cw5 Cw7 DR13* DR15 DQ6
HLA class IIHLA class I
HLA-A, -B, and -C typing was performed by standard serology methods, and HLA-DR and -DQ typing was done 
by DNA analysis using sequence specific primers. *donor-patient disparate alleles
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Modification of CLL cells into APCs
CLL cells were cultured in IMDM (BioWhittaker, Verviers, Belgium) containing 10 % human serum at 
37˚C in a 5% CO2 humified atmosphere in 24-well plates (Costar, Cambridge, MA, USA) at a 
concentration of 106 cells/well in a total volume of 1 mL per well. Leukemic cells were cultured in the 
presence or absence of the cytokines IL-1α (10 ng/mL, Hoffmann-La Roche, New Jersey, USA), IL-2 
(100 U/mL, Chiron, Amsterdam, Netherlands), IL-3 (50 ng/mL, Novartis, Basel, Switzerland), IL-4 (500 
U/mL, Schering-Plough, Amsterdam, the Netherlands), TNF-α (10 ng/mL, Boehringer Ingelheim, 
Ingelheim am Rhein, Germany) or interferon-α (IFN-α,1000 U/mL, Hoffmann-La Roche), or in the 
presence or absence of the cytokine combinations IL-3 and IL-4, IL-4 and IFN-α, or IL-4 and TNF-α .
For activation of innate immunity, CLL cells were incubated with synthetic CpG oligodeoxynucleotide 
2006 (CpG; 5' TCGTCGTTTTGTCGTTTTGTCGTT-3', 10 µg/mL; Eurogentec, Seraing, Belgium), 
lipopolysaccheride (LPS, 100 ng/mL, Sigma-Aldrich, St.Louis, MO, USA) or polyriboinosinic 
polyribocytidylic acid (Poly(I:C), 50 µg/mL, Sigma-Aldrich) in the presence or absence of IL-4 (500 
U/mL). Finally, to enhance further upregulation of costimulatory molecules, CLL were cocultured on ltk 
murine fibroblast cells transfected with the human CD40-ligand 32 (tCD40L; kindly provided by 
Dr.C.van Kooten, Department of Nephrology, Leiden University Medical Center). The fibroblasts were 
irradiated (70 Gy), and seeded at a concentration of 1x105 cells/well in 24-well plates (Costar). CLL 
were added at a concentration of 1x106 cells/well in presence or absence of cytokines, cytokine 
combinations and/or immunostimulators. After 24, 48, 96 or 144 hours of culture, CLL cells were 
harvested and washed. Morphology of the cells was analyzed, the number of viable cells was counted 
using eosin exclusion, and the cells were analyzed by flow cytometry.
Immunophenotyping and cytokine measurement
To perform immunophenotyping, mouse MoAbs conjugated with fluorescein isothiocyanate (FITC), 
phycoerythrin (PE) or phycoerythrin cyanine 5 (PE-Cy5) were used. These MoAbs included FITC-
conjugated IgG1 antibodies specific for CD5, CD25, CD40, CD54 or CD86, and FITC-conjugated 
IgG2a antibodies specific for CD58 or HLA-DR. PE-conjugated IgG1 antibodies specific for CD14, 
CD19, CD23, CD56, CD80 or CD123, PE-conjugated IgG2a antibodies specific for CD8, PE-
conjugated IgG2b antibodies specific for CD83, and PE-Cy5-conjugated IgG1 antibodies specific for 
CD3 were used. Appropriate isotype controls (IgG1, IgG2a and IgG2b) were used. All MoAbs were 
purchased from Becton Dickinson (BD, San Jose, CA, USA) except for anti-CD40 and anti-CD58 
(Serotec, Oxford, England), anti-CD54 (CLB, Amsterdam, the Netherlands), anti-CD8 and anti-CD83 
(Caltag, Burlingame, AL, USA) and anti-CD80 (Immunotech, Marseille, France). 105 cells were 
incubated with MoAbs for 30 minutes at 4˚C, washed twice, and analyzed on a FACScan (BD). 
Results were analyzed using the CellQuest software (BD). The relative expression of surface antigen 
is described as the mean fluorescence intensity ratio (MFIR). This value is calculated by dividing MFI 
of cells stained with a specific MoAbs by the MFI of cells stained with an isotype-control MoAbs. If the 
percentage of positive events was more than 10 % the leukemic sample was considered positive for 
that surface marker, and then the MFIR was calculated. Cell-free supernatants were harvested after 
96 hours of culturing the CLL cells with or without cytokines, microbial pathogens, and tCD40L cells. 
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Cytokine measurements were performed using commercial IL-10 (CLB) or IL-12 p40/p70 (U-CyTech, 
Utrecht, the Netherlands), ELISA kits according to the manufacturer's instructions.
Generation of CLL-reactive CTL lines and clones
PBMC from unrelated healthy HLA class I-matched donors (table 1.) at a concentration of 0.5 x 106
cell/well in 24-well plates (Costar) were stimulated with irradiated primary CLL, or CLL cells cultured 
under various conditions at a responder/stimulator (R/S) ratio of 10:1. IL-2 (100 IU/mL) was added at 
day 6, and 2 days after each (re)stimulation. At day 9, the T cell lines were harvested, and depleted of 
CD4+ T cells using anti-CD4-conjugated magnetic beads (Milteny Biotec, Bergisch Gladbach, 
Germany). The T cell lines were restimulated with irradiated stimulator cells at the same R/S ratios at 
days 9, 16 and 23. T cells were harvested 4-5 days after the third or fourth stimulation for phenotypic 
analysis, and used as effectors in cytotoxicity assays. T cell clones were generated from CLL-reactive 
CD8+ CTL lines by cell sorting using a FACS-Vantage flow cytometer (BD). Viable CD8+ cells were 
sorted into 96-well microtiter plates at a concentration of one cell per well (single cell/well sorting). The 
T cell clones were expanded in the presence of irradiated CD40-activated CLL cells (5 x 103 cells / 
well), irradiated allogeneic feeder cells (5 x 104 cells / well) in medium consisting of IMDM plus 10% 
human serum, IL-2 (100 U /mL) and phytohemagglutinin (PHA, 800 ngr/mL, Murex Biotech Limited, 
Dartfort, UK). After 21-24 days, proliferating T cell clones were tested for specific lysis of the primary 
CLL cells, CD40 activated CLL cells, or PHA blasts and/or EBV-LCL from patient and donor in a 51Cr-
release assay.
Cytotoxicity assay
51Cr-release assays were performed as described previously 33. Briefly, primary CLL cells, or CLL cells 
cultured under various conditions, EBV-LCL or PHA blasts from patient or donor were used as target 
cells. Effector cells and 5,000 51Cr labeled target cells were added to wells of U-bottom microtiter 
plates at E/T ratios ranging from 30:1 to 1:1. Spontaneous release was measured by addition of 100µl 
IMDM with 10% human serum, and maximum release by adding 100µl 1% Triton X-solution to target 
cells. After 4 hours of incubation at 37ºC 51Cr release was measured in a luminescence counter 
(Topcount-NXT, Packard, Meriden, CT, USA). The percentage lysis was calculated using the following 
formula: 100x [(experimental release cpm – spontaneous release cpm) / (maximum release cpm –
spontaneous release cpm)]. T cell lines and clones showing more than 10% specific lysis of target 
cells were considered cytotoxic. To determine HLA class I- and class II-restriction of the recognition of 
the target cells, blocking studies were performed in selected experiments. Target cells were incubated 
with anti-HLA class I antibodies (W6/32) or anti-HLA class II antibodies (PdV5.2, kindly provided by 
Dr.A. Mulder, Department of Immunohematology and Bloodtransfusion, Leiden) at final concentrations 
of 10 µg/mL for 30 minutes before effector cells added. Blocking experiments at effector level were 
performed by adding anti-CD8 MoAb (FK18, RIVM, Bilthoven, the Netherlands) at a final dilution of 
8µg/mL 30 minutes prior addition of target cells.
Statistical analysis
Differences between experimental groups were analyzed using the Student’s t-test.
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Results
Upregulation of costimulatory and adhesion molecules on CLL cells
Cell surface expression of adhesion molecules CD54 and CD58, and costimulatory molecules CD40, 
CD80, CD86 and CD83 on freshly isolated CLL cells are shown in table 2. All patients showed 
intermediate (MFIR 20 to 50) or high expression (MFIR >50) of HLA class I and II. CD58 was 
expressed at low levels (MFIR <20) in all patients. CD54 expression was negative in 3 patients and 
low or intermediate in the other patients. CD40 was expressed at intermediate levels in all patients. In 
only 5 patients expression of CD80 and/or CD86 was observed. 
To upregulate the expression of adhesion and costimulatory molecules on CLL cells, we first tested
several cytokines, including IL-1, IFN-α, TNF-α, IL-2, IL-3, and IL-4. Next, upregulation of the 
molecules on CLL cells by triggering TLRs using LPS, poly(I;C) or CpG as microbial components in 
combination with the various cytokines was tested. Finally, upregulation was investigated after CD40 
activation of the CLL cells by tCD40L in the presence of cytokines and/or microbial products. Figure 1 
summarizes the FACS analysis of the most optimal combinations to upregulate adhesion and 
costimulatory molecules on CLL cells. The data are presented as percentages positive CLL cells for a 
specific molecule (figure 1A) and the MFIR (figure 1B), and were obtained after a culture period of 96 
hours. No significant upregulation of adhesion and costimulatory molecules with the cytokines or 
cytokine combinations alone was found (data not shown). Of the tested microbial components, only 
CpG in combination with IL-4 induced an increased expression of costimulatory and adhesion 
molecules. As shown in figure 1, this combination increased the percentage of positive CLL cells for 
CD86 1.8 fold (MFIR 2.4 fold, p=0.015), for CD83 3.8 fold (MFIR 4.0 fold, p<0.01) and for CD54 1.3 
fold (MFIR 2.3 fold, p=0.015). CD40 activation significantly increased the percentage positive CLL 
cells (p<0,01) for all adhesion and costimulatory molecules and the expression levels (p<0,001) and 
transformed CLL cells into characteristic APC phenotypes with high expression of CD80, CD86 and 
CD83. CD40 triggering in the presence of IL-4 further increased the expression levels of CD80 (MFIR 
1.5 fold, p=0.05) and of CD86 (MFIR 1.3 fold, p=0.14). Additional stimulation with the microbial 
products did not further enhance the upregulation.
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Figure 1. Expression and upregulation of costimulatory and adhesion molecules on CLL cells activated 
by IL-4, CpG and/or tCD40L. (A) Combinations using CD40 activation give significant higher percentages of 
positive CLL cells for CD80, CD85, CD54 and CD83 (p<0.01) (B) CD40 activation of CLL cells caused significant 
upregulation of expression levels of all costimulatory and adhesion molecules (p<0.001) and the addition of IL-4 
further enhanced the expression levels of CD80 and CD86 (p=0.05 and p=0.14 respectively). CLL cells were 
cultured for 96 hours in the presence or absence of IL-4 (500 UI/mL) , CpG (10 μg/mL) and/or tCD40L. 
Expression of CD80, CD86, CD54 and CD83 was analyzed by flow cytometry. Mean fluorescence intensity ratio 
(MFIR) was calculated as described in Material and Methods section, only if percentage of positive cells was 
>10%. Results are expressed as mean ± SD of number of CLL patients as shown in figure.
To determine the optimal time period of CD40 and IL-4 stimulation, phenotypic analysis of CLL cells 
was performed 48, 96 and 144 hours after stimulation. As shown in figure 2, IL-4 and CD40 activation 
of CLL cells caused strong upregulation of CD80, CD86, CD83 and CD54 within 48 hours. After 96 
hours of stimulation a further enhancement of expression levels of CD80 (MFIR 1.2 fold, p= 0.07) and 
CD86 (MFIR 1.4, p=0.05) was observed. However, after 48 hours a significant downregulation of 
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percentages and expression levels of CD83 were found (p<0.05). Therefore, we considered activation 
of the CLL cells with tCD40L and IL-4 to be optimal after 96 hours.
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Figure 2. Kinetics of upregulation of costimulatory molecules on CLL cells activated by tCD40L and IL-4.
CLL cellls were incubated with tCD40L and IL-4. MFIR and percentage of CLL cells positive for CD80, CD86, 
CD83 and CD54 were analyzed at different time points by flow cytometry. Data are shown as means ± SD for 4 
patients.(straight line: % positive cells, dotted line MFIR).
Stimulation of tCD40L induced a dendritic-like morphology in 60-80% of the CLL cells and as 
determined by forward /sideward analysis using flowcytometry a 2 to 3 fold increase in size of CD40-
activated CLL cells was seen (data not shown). Recovery of viable CLL cells after 96 hours was 29% 
± 11% (mean ± SD) for CLL cells cultured in medium alone. Enhanced survival of 45% ± 12 % was 
found when CLL cells were cultured on tCD40L in medium containing IL-4. In conclusion, stimulation 
of CLL cells by tCD40L and IL-4 for a period of 96 hours caused the strongest upregulation of 
costimulatory and adhesion molecules and modified CLL cells into morphologically and phenotypically 
characteristic APC.
Production of IL-10 and IL-12 by activated CLL cells
As demonstrated in figure 3, after 96 hours of culture primary CLL cells and CpG/IL-4 activated CLL 
cells produced only minimal amounts of IL-12 (65 ± 22 pg/mL and 50 ± 27 pg/mL, respectively, n=7, 
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mean ± SD). However, significant higher levels of IL-12 were produced by tCD40L-activated CLL cells 
(2539 ± 2301 pg/mL, p=0.005, n=6). Additional stimulation with IL-4 or CpG further enhanced the 
production of IL-12 to 7953 ± 3980 pg/mL (n=7) and 5632 ± 3310 pg/mL (n=5) respectively. In all 
conditions only low amounts of IL-10 were produced (<20 pg/mL).
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Figure 3. IL-12 and IL-10 production by CLL cells in response to different stimuli. Significant higher levels of 
IL-12 were produced by tCD40L-activated CLL cells than primary CLL cells (2539 ± 2301 pg/mL and 65 ± 22 
pg/mL respectively, p=0.005, n=6). CLL cells were incubated with different stimuli for 96 hours. IL-12 and IL-10 
was measured in the supernatant by ELISA. Data are shown as means ± SD of 5-7 experiments.
Proliferation and cytotoxicity of allogeneic CD8+ T cells from HLA-class I-matched donors 
stimulated with tCD40L/IL-4 activated CLL cells as APCs
Since CD40 activation by xenogeneic fibroblasts is limiting its clinical applicability, we investigated 
whether CpG/IL-4 activated CLL cells were capable of inducing CTL responses against CLL or that 
CD40 ligation was essential for the induction of a CLL-reactive T-cell response. For the generation of 
allogeneic CLL reactive T-cell responses, the stimulatory capacity of primary CLL cells, CpG/IL-4 
activated CLL cells and tCD40L/IL-4 activated CLL cells was tested. Figure 4 illustrates the phenotypic 
characterization of the three different types of CLL stimulator cells tested, obtained after 96 hours of 
activation. 
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Figure 4. Change of phenotype of CLL cells from one representative patient stimulated with CpG and IL-4, 
or with tCD40L and IL-4 or unstimulated. (A) Representative examples of CLL cells, obtained from one patient, 
cultured for 96 hours in medium alone. (B) stimulated with CpG (10µg/mL) and IL-4 (500U/mL) (C) stimulated with 
tCD40L and IL-4. Unshaded histogram represent staining of CLL cells with the appropriate isotype control MoAb 
and shaded histogram the staining of CLL cells with specific MoAb
T cells from three unrelated HLA-class I-matched donors (see table 1) were stimulated with the three 
types of stimulator cells. Since donors were HLA-class II mismatched, CD4 depletion was performed 
to eliminate undesirable allo-HLA responses. The growth kinetics of the CD8+ T cells in response to 
the different stimulator cells are shown in figure 5. No proliferation of donor T cells was seen using 
primary CLL as stimulator cells. Using CpG/IL-4 activated CLL cells as stimulators, in two of the three 
patient / donor pairs limited proliferation of CD8+ T cells was observed. In contrast, using tCD40L/IL-4 
activated CLL cells as APCs in all three patient/ donor combinations tested a 12 to 15-fold increase of 
CD8+ T cells was observed. 
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Figure 5. Proliferation of allogeneic CD8+ T cells in response to primary CLL, CpG/IL-4 activated CLL, or 
tCD40L/IL-4 activated CLL cells. Higher numbers of CD8+T cells at day 23 were obtained using tCD40L/IL-4 
activated CLL as stimulators than CpG/IL-4 stimulated CLL cells (26,5 ± 12,01 and 6,18 ± 2,36 x106 cells 
respectively, p <0.01, n=3). Proliferation of allogeneic CD8+T cells in response to weekly stimulation. CD8+T cells 
in PBMC plated on day 0 were 1.5 x 106. The results represent the mean ± SD of experiments performed using 3 
donor/patients pairs.
The cytotoxic activity of the CTL lines was tested using primary CLL, tCD40L/IL-4 activated CLL cells, 
PHA blasts or EBV-LCL from patients and donors as target cells. In all three tested patient / donor 
pairs, CTL lines generated in response to tCD40L/IL-4 activated CLL cells as stimulators, effectively 
killed at E/T ratios of 30:1, the primary CLL (41.1 ± 24.7%, mean ± SD, n=3), the tCD40L/IL-4 
activated CLL cells (46.3 ± 26.2%), and PHA blasts or EBV-LCL of patients (52.8 ± 10.8%) in a 4-hour 
51Cr release assay. In contrast, PHA blasts or EBV-LCL from the donor were not killed (4.3 ± 3.0%, 
n=3). Cytotoxicity of the generated CTLs is shown in figure 6. In only one of the three donor / patients 
pairs, cytotoxicity of a CTL line generated using CpG/IL-4 activated CLL cells as APCs could be 
tested, illustrating cytotoxicity to the CLL-specific targets and PHA blasts from the patient as shown in 
figure 6A2. In summary, in contrast to primary CLL cells, tCD40L/IL-4 activated CLL cells can be used 
as stimulator cells to generate CTL lines recognizing and killing CLL-specific targets and PHA blasts 
or EBV-LCL from the patients. To exclude HLA-non-restricted killing and to exclude that the cytotoxicy 
of the CTL lines was exerted by allo-HLA-driven contaminating CD4+ T cells, blocking studies were 
performed using a representative example of a generated CLL-reactive CTL line. Cytoxicity was 
completely blocked by anti-HLA class I or anti-CD8 antibodies and not by the addition of anti-HLA 
class II (figure 6D). These results confirmed HLA class I-restricted recognition of the targets by the 
CD8+ CTL lines.
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Figure 6. Cytotoxic activity of donor-derived CTL lines from three different HLA class I-matched donors 
and HLA class I-restriction of cytotoxicity. (A) Cytotoxic activity of CTL lines in donor / CLL 3 combination, 
generated using tCD40L/IL-4 activated CLL cells as stimulator cells, measured in 4-hour 51Cr release assays (1.) 
or using CpG/IL-4 activated CLL cells as stimulators (2.) (B) Cytotoxicity of CTL lines in donor / CLL 4 (C) 
Cytotoxicity of the CTL line in donor / CLL 13 combination. Results are the mean ± SD of two independent 
experiments (in A1. and B.) or are results of a single experiment (A2. and C.) (D) HLA class I-restriction of 
cytotoxicty was demonstrated by the following blocking experiments using EBV-LCL of the patient as target at an 
E/T ratio of 10:1. CTL effectors were preincubated for 30 minutes with anti-CD8 antibodies or the target cells were 
30 minutes preincubated with anti-HLA class I (W6/32) or anti-HLA class II (PdV5.2) antibodies prior to the CTL 
assay.
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Generation of CLL-reactive CTL clones
To determine whether the cytotoxicity of the generated CTL lines was exerted by cytotoxic T cells with 
different specificity, a CLL-reactive CTL line was sorted one cell per well, at day 23. A total of 25 
proliferating CD8+ T-cell clones were obtained. Ten of the 25 clones showed sustained proliferation 
after restimulation, allowing testing for cytotoxicity. Four of these CD8+ clones specifically lysed 
primary CLL cells (13,9 ± 5,9%, mean ± SD) , tCD40L/IL-4 activating CLL cells (39,4 ± 14,4%) and 
PHA blasts from the patient (42,3 ± 19,0%) and not PHA blasts from the donor (3,0 ± 1,5%), when 
tested at an E/T ratio of 10:1 (figure 7). The other 6 clones showed antigen-driven proliferation, but 
were not cytotoxic to CLL specific targets (data not shown).
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Figure 7. Cytotoxicity of the four donor-derived CD8+ CTL clones. CTL clones were generated in donor / CLL 
3 combination by one cell / well sorting of the donor-derived CTL line at day 23. At day 0 and 14, the T cell was 
stimulated with irradiated tCD40L/IL-4 activated CLL cells and allogeneic feeder cells in medium with IL-2 and 
PHA. Proliferating clones were tested in a 51Cr release assay against primary CLL, tCD40L/IL-4 activated CLL 
and PHA blasts from patient and donor at day 21.
Discussion
The aim of this study was to investigate the best method to modify CLL cells into malignant APCs and 
to test their capacity to activate allogeneic T cells to generate CLL-reactive T cell reponses. CD40 
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activation in the presence of IL-4, was shown to most effectively transform CLL cells into efficient 
APCs, capable of producing high amounts of IL-12. In all three HLA class I-identical donor / patient 
pairs tested, using these malignant APC as stimulator cells, allogeneic CD8+ T cell lines were 
generated, recognizing CLL as well as patient derived PHA blasts. Cloning of these CLL-reactive T-
cell responses revealed that single CTL clones recognized both non malignant patient-derived and 
CLL-specific targets.
Primary CLL cells have previously been demonstrated to be unable to stimulate donor T-cell 
proliferation and activation. This has been explained by the inadequate expression of costimulatory 
and adhesion molecules 14,19,22,34. CD40 ligation has been shown to be an effective tool to upregulate 
costimulatory molecules on the surface on CLL cells 14,19,20,22,34. CD40-triggered CLL cells, as 
stimulator cells, can activate allogeneic T cells in MLRs and can induce allogeneic immune responses 
against CLL 14,15,19,22,34,35. In attemps to improve the immunogenicity of CLL cells without using the 
CD40 system, we investigated several alternatives. We first explored the ability of several cytokines to 
upregulate costimulatory molecules. The proinflammatory cytokines, proliferating cytokines, 
plasmacytoid-DC stimulatory factors (IL-3) or B-cell activating cytokines (IL-4) tested 29-31,36 did not 
cause significant upregulation of costimulatory molecules. Recent studies have demonstrated that 
normal, but also malignant B cells, express a distinct TLR expression profile in which TLR9 and 
TLR10 predominate 26,27,37,38. We therefore tested triggering of TLRs on CLL cells and showed that 
CpG, agonist of TLR 9, in combination with IL-4, increased the expression of costimulatory molecules. 
However, CD40 activation significally further enhanced the expression levels of all costimulatory and 
adhesion molecules and was superior to all combinations tested without CD40 ligation. The addition of 
IL-4 further enhanced the expression of CD80 and CD86, thus confirming results from other studies 
14,19,20,22,34. Although CD40 activation can upregulate the expression levels of TLR9 in B cells and can 
increase the responsiveness to CpG 26,27, no additional upregulating effect but rather a downregulating 
effect was observed by adding CpG.
Professional APCs can express and secrete IL-12 after challenge with microbial stimuli or after 
CD40L-CD40 interactions between T cells and the APCs 39. IL-12 is a pivotal cytokine in the Th1-
response to antigen and its effect includes enhanced CTL activity of CD8+ T cells and natural killer 
cells, and further differentation of antigen activated CD4+ and CD8+ T cells 40. We demonstrated that 
CD40 activation is essential for the IL-12 production by CLL cells and showed that additional activation 
using CpG or IL-4 resulted in a higher IL-12 production. These results are in accordance with studies 
showing that CD40 activation induced enhanced IL-12 mRNA expression in normal and neoplastic B 
lymphocytes, including follicular lymphoma and mariginal zone lymphoma cells, resulting in IL-12 
secretion by these B cells 41,42. In summary, the CD40-CD40L pathway is critical to modify CLL cells 
into phenotypically professional APC, capable of producing significant amounts of IL-12. Cytokines 
and / or microbial pathogens are insufficient to stimulate CLL cells.
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Expression of adhesion and costimulatory molecules on APCs is necessary to induce efficient T-cell 
responses. We confirmed that T cells demonstrate very low proliferative responses upon restimulation 
with unmodified CLL cells. Since CpG/ IL-4 activated CLL cells could be generated under good 
manifacturing practice (GMP) conditions, we analyzed whether the minimal upregulation of 
costimulatory molecules on CpG/IL-4 acitvated CLL cells was sufficient to overcome T-cell anergy. In 
two of three HLA class I-matched combinations proliferation and in one of the three couples tested, 
cytotoxicity against CLL- and patient-derived targets of CD8+ CTL lines using these APCs was 
obtained. Although our results extend reports from others 35, only very limited proliferation of donor T 
cells in response to CpG/IL-4 activated CLL cells was observed (figure 5) and the generation of a CLL-
reactive CTL line was successful in only one of three donors tested. The importance of high 
expression of costimulatory molecules on APCs was demonstrated by the capacity of tCD40L/ IL-4-
activated CLL cells to induce vigorous expansion of CLL-reactive CD8+ CTL lines. We were able to 
generate CD8+ CTL lines from HLA class I-matched donors with high cytotoxic activity against primary 
and modified CLL cells. Moreover, using one cell / well sorting several CLL-reactive proliferating CD8+
CTL clones from a HLA class I-matched donor could be obtained, illustrating that the cytotoxicity could 
not be due to contaminating allo-HLA class II CD4 responses. Furthermore the cytotoxicity of the 
generated CD8+ CTL lines was completely abrogated by anti-HLA class I antibodies and not by anti-
HLA class II antibodies.
In conclusion, this study not only demonstrates that CD40-activated CLL cells have the stimulatory 
capacity to induce an alloresponse over a MHC barrier, but more importantly it shows the feasibility to 
generate CD8+ CTL lines and clones from HLA class I-matched donors, recognizing leukemia-specific 
as well as non-malignant patient-derived targets. These results suggest that the antigens recognized 
by the CTL lines and clones are not tumor-specific but rather mHag-specific19,22,34,35. Whether the 
mHags, recognized by the CTL lines and clones are hematopoiesis-restricted and/or B-cell-specific 
remains to be elucidated.
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Abstract
Objective: Allogeneic stem cell transplantation (SCT) following reduced-intensity conditioning provides 
new therapeutic opportunities for cure of advanced B-cell chronic lymphocytic leukemia (CLL). 
Although treatment of relapsed or persistent CLL after allogeneic SCT with donor lymphocyte 
infusions (DLI) can lead to complete sustained remissions, illustrating susceptibility of CLL for the 
graft-versus-leukemia (GvL) effect, effectiveness of this therapy is limited due to low immunogenicity 
of CLL cells and the lack of specificity resulting in concurrent development of graft-versus-host-
disease (GvHD). To improve the specificity of the immune response, we investigate whether modified 
CLL cells are sufficiently immunogenic to initiate an adequate alloimmune response in vitro in a 
complete HLA-matched setting representing a clinical applicable transplantation model.
Methods: First, CLL cells were modified into efficient antigen-presenting cells (CLL-APC) by CD40 
triggering in the presence of IL-4. Next, T cells derived from three unprimed HLA-matched sibling 
donors were stimulated with primary CLL or CLL-APCs from the patients.
Results: In contrast to primary CLL, CLL-APC cells as stimulators were capable of inducing cytotoxic 
CD8+ and CD4+ T-cell (CTL) clones from all three sibling donors. These CTL clones effectively lysed 
CLL-specific and patient-derived targets but not non-hematopoietic targets of the patient or donor-
specific targets. The recognition of all clones was HLA-restricted and most likely mHag-specific.
Conclusion: In all three donor-recipient pairs tested, CLL-APC as stimulators were capable of inducing 
mHag-specific and CLL-reactive T cells clones. These results allow the development of new cellular 
immunotherapeutic interventions to further exploit the GvL effect following allogeneic SCT.
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Introduction
B-cell chronic lymphocytic leukemia (CLL) is clinically and biologically heterogeneous 1,2. Some 
patients may have an indolent course with long-term survival, whereas others have a rapidly fatal 
disease despite intensive therapy 1,3. In addition to characteristic cytogenetic abnormalities, new 
molecular and protein markers such as the mutation status of the immunoglobulin variable heavy (VH) 
genes, expression of ZAP-70, and profiling of the expression of genes, enables to predict better 
patients, who will suffer from an aggressive and ultimately fatal course 4-8. For this group of patients 
new effective treatment modalities are needed. 
Recently, it has been demonstrated that allogeneic stem cell transplantation (SCT) may overcome the 
adverse prognosis of patients with CLL with unmutated VH genes 9. Since allogeneic SCT following 
reduced-intensity conditioning (RIC) has resulted in lower short term treatment-related mortality (TRM) 
10-14 this treatment modality is increasingly being explored in patients with advanced CLL 11,15,16. Donor 
T cells in the graft, recognizing leukemia-associated antigens or minor histocompatibility antigens 
(mHag) on CLL cells may initiate a robust alloimmune response and thus eradicate persisting or 
relapsing CLL in the recipient. Complete remissions have been reported after allogeneic SCT 
illustrating susceptibility of CLL cells to a graft-versus-leukemia (GvL) effect 11,15,17. We and others 
demonstrated the feasibility of a two-step approach of allogeneic transplantation and immunotherapy 
following RIC by the use of T-cell depleted grafts avoiding the risk of graft-versus-host disease 
(GvHD), followed by a postponed administration of donor lymphocyte infusion (DLI) 13,18,19. The 
approach was feasible even in older patients, but acute or chronic GvHD caused by the administration 
of donor lymphocytes remained a major cause of morbidity 13,20. Furthermore, in some patients in vivo
alloimmune responses sufficient to completely suppress the CLL cells could not be evoked. Therefore, 
further selection of donor T cells with high avidity for CLL cells, and further enrichment of leukemia-
reactive donor T cells may be pivotal to achieve long-term control of the disease after allogeneic SCT.
Enrichment of donor T-cells for leukemia-reactive T-cell specificity may be achieved by in vitro
stimulation of donor lymphocytes with leukemic cells from the patient 21,22. This approach appears to 
select for T-cell responses against mHag that are relatively specifically expressed on hematopoietic 
cells 22. However, although CLL cells highly express HLA class I and II molecules, they are 
inappropriate to function as antigen-presenting cells (APC) due to inadequate expression of 
costimulatory molecules 23-27. We and others demonstrated that by CD40 triggering in the presence of 
IL4, CLL cells can be modified into efficient malignant APC, capable of inducing vigorous allogeneic T-
cell responses 23,25-27. CLL-reactive mHag specific cytotoxic T lymphocytes (CTL) derived from 
unrelated HLA class I-matched donors could be generated 27.
To further translate these results in a clinically applicable transplantation model, and to investigate 
whether modified CLL cells are sufficiently immunogenic to initiate an adequate alloimmune response 
in a complete HLA-matched setting, T cells derived from three unprimed HLA-matched sibling donors 
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were stimulated with CLL-APCs from the patients. In all three donor-recipient pairs, CLL-APC as 
stimulators were capable of inducing mHag-specific and CLL-reactive T cells clones. These results 
support the potential of this approach to treat disease recurrence after allogeneic SCT.
Material and methods
Cell samples
Three patients treated for advanced CLL and eligible for allogeneic SCT using HLA-identical sibling 
donors were included in this study. After informed consent peripheral blood (PB) samples were 
obtained from the patients, and from their HLA-identical sibling donors. The HLA types of patients and 
donors are shown in Table 1. Mononuclear cells (MNC) were isolated from the samples by Ficoll 
density separation, and cryopreserved. As assessed by flow cytometry, more than 90% of the MNC 
from the CLL patients coexpressed CD19 and CD5 surface molecules. Phytohemagglutinin (PHA) 
activated T cells (PHA blasts) and stable transformed B cell lines (EBV-LCL) were generated as 
described previously 28. Mesenchymal stem cells (MSC) were derived from the bone marrow (BM) of 
one patient by culturing the adherent cells for several weeks on DMEM supplemented with L-alanyl-L-
glutamine, sodium pyruvate, 1 mg/mL glucose, and pyridoxine (Gibco BRL), and 10% fetal bovine 
serum (FBS)
Table 1. HLA types of patient/donor pairs.
Pair 1 A3 A31 B8 B35 Cw4 Cw7 DR1 DR3 DQ2 DQ5 DP2 DP3
Pair 2 A2* A68 B51 B53 Cw4 Cw1 DR4 DR1 DQ3 DQ6 DP2 DP4
Pair 3 A1 A2† B8 B35 Cw4 Cw7 DR3
DR1
4 DQ2 DQ5 DP2
HLA class I HLA class II
* patient was negative for HA-1, donor was positive for HA-1. † patient was positive for HA-1, donor was negative 
for HA-1
Modification of CLL cells into CLL-APC
CLL cells were transformed into CLL-APC as recently described 27. Briefly, CLL cells were cocultured 
on ltk murine fibroblast cells transfected with the human CD40-ligand (tCD40L; kindly provided by 
Dr.C.van Kooten, Department of Nephrology, Leiden University Medical Center). The fibroblasts were 
irradiated (70 Gy), and seeded at a concentration of 1x105 cells/well in 24-well plates (Costar, 
Cambridge, MA, USA). CLL cells were added at a concentration of 1x106 cells/well in medium 
consisting of IMDM (BioWhittaker, Verviers, Belgium) with 10% human serum and IL-4 (500 U/mL, 
Schering-Plough, Amsterdam, The Netherlands). After 4 days of culture at 37˚C in a 5% CO2 humified 
atmosphere, the CLL cells were harvested and washed twice. Viable cells were counted using eosin 
exclusion, analyzed by flow cytometry, and used as stimulator cells.
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Phenotypic analysis of the CLL-APC and the cytotoxic T cell lines and clones
To perform immunophenotyping of the CLL-APC and of the generated T cell lines and clones, mouse 
MoAbs conjugated with fluorescein isothiocyanate (FITC), phycoerythrin (PE) or phycoerythrin cyanine 
5 (PE-Cy5) were used. These MoAbs included FITC-conjugated antibodies specific for CD3, CD5, 
CD40, CD54, CD58, CD86, or HLA-DR, PE-conjugated antibodies specific for CD4, CD19, CD23, 
CD56, CD80 or CD83, and Cy5-conjugated anti-CD8. All MoAbs were purchased from Becton 
Dickinson (BD, San Jose, CA, USA) except for anti-CD40 and anti-CD58 (Serotec, Oxford, England), 
anti-CD54 (CLB, Amsterdam, the Netherlands), anti-CD8 and anti-CD83 (Caltag, Burlingame, AL, 
USA) and anti-CD80 (Immunotech, Marseille, France). PE-labeled tetrameric complexes of HA-1 
peptide bound to HLA-A2 molecules were prepared and used as described previously 22. After 
labelling all cell samples were analyzed on a FACScan (BD).
Generation of CLL-reactive CTL lines and clones
MNC from the three healthy HLA matched sibling donors at a concentration of 0.5 x 106 cell/well in 24-
well plates (Costar) were stimulated with irradiated CLL-APC at a responder/stimulator (R/S) ratio of 
10:1. IL-2 (100 IU/mL, Chiron, Amsterdam, Netherlands) was added at day 6, and 2 days after each 
(re)stimulation. The T cell lines were restimulated with irradiated stimulator cells at the same R/S ratios 
at days 9, 16 and 23. T cells were harvested 4-5 days after the third or fourth stimulation for 
phenotypic analysis, and used as effectors in cytotoxicity assays. T cell clones were generated from 
CLL-APC reactive CTL lines by single cell / single well sorting using a FACS-Vantage flow cytometer 
(BD). To exclude dead cells the suspensions were counterstained with propidium iodide (PI; Sigma, 
St.Louis, USA) at a final concentration of 0.5 µg/ml immediately prior to cell sorting. PI negative cells 
within the lymphocyte gate were sorted, and plated as single cells per well (single cell/well sorting) into 
96-well microtiter plates containing 100 µl of feeder mixture consisting of culture medium, IL-2 (100 
IU/mL), phytohemagglutinin (PHA, 800 ng/mL, Murex Biotech Limited, Dartfort, UK) and 15 Gy-
irradiated allogeneic feeder cells (5 x 106 /mL). Proliferating T cell clones were selected, and 
restimulated with feeder-mixture. From day 21 the clones were functionally analyzed. The 
nomenclature used for each T cell clone represents the patient number followed by clone number. 
Analysis of cytotoxicity and cytokine production
To determine the cytotoxicity of the T cell lines and clones standard 4 hours and 10-16 hours 51Cr-
release assays were performed as described previously 27. Primary CLL cells, CLL-APC cells, EBV-
LCL or PHA blasts from patient or donor were used as target cells. T cell lines and clones showing 
more than 10% specific lysis of target cells were considered cytotoxic. To determine HLA class I- and 
II-restriction of the recognition of the target cells, blocking studies were performed in selected 
experiments. Target cells were incubated with α-HLA class I antibodies (W6/32) or α-HLA class II 
antibodies (PdV5.2) at final concentrations of 10 µg/mL for 30 minutes before effector cells added. A 
human MoAb specific for HLA-B8 (BVK5B10) was used to determine HLA-B8 restricted recognition of 
the targets by CTL clones derived from donor 3. For analysis of interferon (IFN) γ production by the T 
cells against MSC, 5,000 T cells were cocultured on a monolayer of 5,000 plated MSC in 96 wells flat-
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bottom plates. After 24 hours, supernatants were harvested and the concentration of IFN-γ was 
measured by ELISA (CLB, Amsterdam, The Netherlands). 
T-cell receptor (TCR) analysis
The T-cell receptor (TCR) α and ß chains of the CTL clones were determined by polymerase chain 
reaction and sequencing, as previously described 29. The sequences of the TCRß chains were named 
according to the nomenclature described by Arden et al 30.
Results
Generation of CLL-reactive CTL lines and clones
Our previous study had illustrated that CD40 activation in the presence of IL-4 is an effective tool to 
increase APC function of CLL cells 27. Four days of CD40 and IL-4 stimulation effectively transformed 
CLL cells, derived from the three patients in this study, into CLL-APC with high expression of the 
costimulatory molecules CD54, CD58, CD80 and CD86 and enhanced expression of CD83 (figure 1). 
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Figure 1. Expression of costimulatory and adhesion molecules on primary CLL and CLL-APC derived 
from patient 2. All costimulatory and adhesion molecules on the CLL cells were significantly upregulated by 
CD40 activation in the presence of IL-4. Primary CLL cells from patient 2 were cultured in 24 wells plate (1x106) 
for 96 hours in the presence or absence of IL-4 and tCD40L. The expression of CD54, CD58, CD80, CD86, and 
CD83 was analyzed by flow cytometry. Mean fluorescence intensity ratio (MFIR) was calculated as MFI cells 
stained by a specific MoAb / MFI cells stained by isotype-control MoAb, only if the percentage of positive cells 
was >10%. Results are representative for all three patients.
These CLL-APC and primary CLL cells were used as stimulator cells for T cells from the HLA-identical 
sibling donors. In all three donor-patient pairs, no proliferation but a decrease of T cells was observed 
in response to primary CLL cells as stimulator cells. In contrast, using CLL-APC as stimulators, 
vigorous expansion of donor T cells was observed, resulting in a 6-10 fold increase of the T cell 
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population after three weekly stimulations. Experiments to generate CLL-reactive CTL lines were 
performed twice for each patient-donor combination. The CTL lines derived from donor 1 consisted of 
84  4% (mean  SD) CD4+ T cells and of 12  2% CD8+ T cells, and the T cell line derived from 
donor 2 consisted of 91  2% CD4+ T cells and 4  2% CD8+ T cells. Flow cytometric analysis of the 
CTL lines derived from donor 3 at day 21 showed a large population CD3-CD56+ cells (78 ± 4%) and 
only 11 ± 6% CD4+ T cells and 6 ± 3% CD8+ T cells. All T cell lines generated were examined for their 
ability to kill primary CLL and CLL-APC as well as patient- and donor-derived other hematopoietic 
targets (PHA-blasts and/or EBV-LCL). Due to very low (<1%) normal B-cell counts in the MNC of 
patient 1 and 2, no EBV-LCL from these two patients could be generated. As illustrated in figure 2, 
CLL-APCs induced T cell lines with cytolytic activity against CLL-APC and patient-derived 
hematopoietic targets in all donor-patient pairs. No cytotoxicity was observed against primary CLL. In 
our previous study we had demonstrated that primary CLL could adequately be recognized and killed 
by alloreactive donor-derived T cells 27. Therefore, to determine whether low precursor frequencies of 
mHag-specific and/or CLL-specific cytotoxic T cells within the predominantly CD4+ T cell and the 
CD56+ populations were responsible for the low cytolytic activity against CLL targets, and to select for 
these cytotoxic T cells, cloning experiments of the α-CLL and the α-CLL-APC CTL lines in the donor-
patients pairs were performed. 
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Figure 2. Cytotoxicity of CTL lines, derived from the three HLA-identical sibling donors, generated against 
primary CLL cells or against CLL-APC cells. (A) Using primary CLL as stimulator cells, no cytotoxicity was 
observed in the first donor-recipient pair (1), reactivity against patient-derived PHA blasts was observed in the 
second couple (2), and reactivity against CLL-APC was observed in the third couple (3), as measured in a 4-
hours 51Cr-release assay. (B) Stimulation with CLL-APC induced cytolytic ctivity against CLL-APC in all donors 
and cytotoxicity against patient-derived targets in donor 2 and 3. Results are representative for two experiments 
for each donor-recipient combination.
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In donor-recipient combination 1, from the α-CLL-T cell line, 5% of the 1 cell/well clonal T cells showed 
proliferation. None of the 11 CD4+ and the 3 CD8+ T cell clones were cytotoxic. The plating efficiency 
in the donor-recipient pair 1, from the α-CLL-APC T cell line, was 11%, resulted in 31 proliferating 
clones. As shown in figure 3A 3 out of 8 CD8+ T cell clones and 4 out of 23 CD4+ T cell clones exerted 
cytotoxic activity against CLL-specific targets and not against other patient- and donor-derived targets. 
In the donor-recipient pair 2, from the α CLL-T cell line, two proliferating CD8+ clones and 12 CD4+
clones were obtained (plating efficiency 3%) with one CD8+ T cell clone recognizing CLL-APC and 
PHA blasts from the patient but not primary CLL (data not shown). 
A total of 110 proliferating clones were generated from the α-CLL-APC T cell line from donor-recipient 
pair 2. As illustrated in figure 3B, nine out of 48 CD8+ T cell clones and one out of 62 CD4+ T cell 
clones recognized CLL- and patient-specific but not donor-derived targets. Only two CTL clones (clone 
2.57 and 2.89) show reactivity against primary CLL cells whereas the other clones recognized the 
CLL-APC and/or PHA blasts from the patient (figure 3B). Because the CTL clones generated were not 
highly effective in killing primary CLL cells and because we did not succeed to generate EBV-LCL 
from the patients, these CTL clones were not further analyzed for HLA-restriction. 
In the third donor-patient combination 101 proliferating clones (72 CD4+ and 29 CD8+ T cell clones) 
were obtained from the α-CLL CTL line and none of these clones exhibited patient- or CLL-specific 
cytotoxicity. Single cell sorting of the α-CLL-APC CTL line resulted in high clonal expansion efficiency 
of 22% of the cells isolated. Four out of 208 T cell clones (112 CD4+ and 96 CD8+ T cell clones) were 
reactive against patient-derived and CLL-specific targets. These CD8+ CTL clones failed to stain with 
the HA-1 specific tetramer. As illustrated in Figure 3C, three clones (clone 3.76, 3.82 and 3.87) were 
highly cytotoxic against primary CLL (42 ± 11%, mean ± SD, n=3), CLL-APC (82 ± 10%), EBV-LCL of 
the patient (88 ± 12%) and not against donor-derived EBV-LCL (3 ± 1%) in a 16 hour 51Cr-release 
assay. Clone 3.62 exhibited reactivity against CLL-APC (lysis 47%) and EBV-LCL of the patient (68%) 
but not against primary CLL and donor-derived targets. Significant although lower cytotoxicity (38 ± 
7%) was observed against PHA blasts (figure 3), indicating that the clones are mHag-specific and that 
the recognized mHag is not B lineage-restricted.
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Figure 3. Cytotoxicity and specificity of CTL clones derived from HLA-matched sibling donors, generated 
against CLL-APC as stimulator cells. (A) In donor-patient pair 1 four CD4+ and three CD8+ CTL clones, 
recognizing CLL-specific targets but not patient- or donor-derived targets, were generated using CLL-APC as 
stimulators. (B) Out of 110 proliferating T cell clones, one CD4+ (clone 2.57) and 9 CD8+ CTL clones were 
obtained. Primary CLL as target was only recognized by clone 2.57 and clone 2.89, whereas CLL-APC and PHA 
blasts from the patient were recognized by most CTL clones. (C) Four CD8+ T cell clones out of 208 T cell clones 
showed cytotoxicity against primary CLL, CLL-APC and patient- derived targets and not against donor-derived 
EBV-LCL and PHA blasts. Clone 3.62 recognized CLL-APC and EBV-LCL and PHA blasts from the patient but 
not primary CLL cells whereas the other clones efficiently killed all CLL-specific and patient-specific targets and 
not donor-derived targets. All four clones stained negative with the HA-1 specific tetramer. Cytotoxicity was tested 
at E/T ratios of 10:1 and measured in a 10-16 hour 51Cr-release assay. The 51Cr-release assay was performed 
twice for each CTL clone. Results are representative for these experiments.
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Figure 4. Characterization of the CLL-reactive clones derived from donor 3.(A) HLA class I-restriction of 
cytotoxicity. EBV -LCL of the patient were used as target cells at an E/T ratio of 10:1 in a 10-hour 51Cr-release 
assay and anti-HLA class I MoAb (W6/32) and anti-HLA class II MoAb (PdV5.2) were used to block recognition by 
the CTL clones. (B) Determination of the HLA class I-restricting element. To determine the HLA class I-restricting 
element, the CD8+ CTL clone 3.87 was tested for reactivity against a panel of EBV-LCL from unrelated 
individuals. The recognition of EBV-LCL targets by clone 3.87 was shown to be HLA-B8 restricted. mHag 
specificity was further illustrated by differential recognition of two individuals who were siblings, unrelated to the 
donor-recipient pair (see *). (C) Confirmation of HLA-B8 restricted recognition of the CTL clone 3.87 by blocking 
with anti-HLA B8 MoAb. (D) Hematopoietic-restricted recognition by the CLL-reactive CTL clone 3.87. 
Recognition of hematopoietic cells of the patient (EBV-LCL and PHA blasts), the non-hematopoietic 
mesenchymal stem cells (MSC) of the patient and EBV-LCL of the donor by the CTL clone 3.87 as measured by 
IFN-γ ELISA.
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Cytolytic activity of the CTL clones could completely be abrogated using the α-HLA class I MoAb and 
not by α-HLA class II MoAb (figure 4A), confirming HLA class I restricted recognition. The TCRs of the 
CLL-reactive CTL clones were analyzed by PCR and showed that clone 3.76, 3.82 and 3.87 were 
identical (AV3 AV21 BV1). To further analyze the HLA class I-restricting element of these identical 
CTL clones, clone 3.87 was tested for reactivity against a panel of EBV-LCL from unrelated individuals 
that shared an HLA molecule with the recipient. As shown in figure 4B, the recognition of the targets 
was HLA-B8 restricted. To confirm HLA-B8 restricted recognition, a blocking study using α-HLA B8 
MoAb (BVK5B10) was performed and showed no cytolytic activity of clone 3.87 in the presence of this 
MoAb (figure 4C). From patient 3, we were capable of culturing MSC from the BM of the patient. 
These cells were used as targets to determine the possible reactivity of the CLL-reactive T cells 
against non-hematopoietic tissues of the patient (figure 4D). Whereas the leukemia-reactive T cells 
produced significant amounts of IFN-γ against EBV-LCL (221 pg/mL) or PHA blasts (72 pg/mL) of the 
patient, no IFN-γ was produced after coculture on the MSC or against donor-derived EBV-LCL. 
In conclusion, in contrast to primary CLL cells, CLL-APCs strongly induced a proliferative response of 
T cells from HLA-identical donors. In all CTL lines generated low precursor frequencies of CLL-
reactive and mHag-specific T cells were present. Repetitive stimulation with CLL-APCs and single cell 
per well cloning enriched for these CLL-reactive T cells. In the third donor-patient pair the CLL-APCs 
were characterized to have induced mHag-specific HLA-B8 restricted CTL clones, highly effectively 
killing CLL-specific targets and not non-hematopoietic cells. 
Discussion
Allogeneic SCT following RIC has resulted in lower TRM and may prolong survival in patients with 
advanced CLL 11,15. Although several studies have shown the susceptibility of CLL cells to a GvL effect 
relapses and/or progression of the disease after allogeneic SCT do occur indicating that a more 
efficient alloimmune anti CLL response is pivotal to achieve long-term remissions 9,11,12,15. Recently, 
we demonstrated the feasibility to generate CLL-reactive CTLs in an unrelated HLA class I-matched 
setting 27. Following these results this translational study was performed to evaluate whether T cells 
from HLA-identical sibling donors can be triggered to preferential kill CLL-specific targets, allowing 
application of these CTLs as adoptive immunotherapy to treat disease recurrence after allogeneic 
SCT.
It has been demonstrated that activation of the CLL cells by IL-4 and CD40 triggering is essential to 
overcome allogeneic T cell anergy towards primary CLL cells 23-27. In this study, no proliferative 
impulse of donor T cells was observed in response to primary CLL cells and repetitive stimulation with 
these malignant cells, expressing low levels of costimulatory molecules, failed to induce CLL- or 
mHag-specific T-cell responses. Only CLL-APC as target was recognized by the CTL line derived from 
donor 3. In contrast CLL-APC as stimulators induced proliferation of T cells in all three donor-patient 
combinations. These CTL lines showed enhanced cytotoxicity against patient-derived targets and 
CLL-APC. As illustrated in figure 2, the CTL lines showed no activity against the primary CLL. We 
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have demonstrated that primary CLL as target can be efficiently lysed by T cells, derived from HLA 
class I-matched donors 27. Therefore, to analyze whether low precursor frequencies of mHag-specific 
and/or CLL-specific cytotoxic T cells were present within the predominantly CD4+ T cell and the CD3-
CD56+ populations single cell per well cloning was performed of the α-CLL and the α-CLL-APC CTL 
lines to identify cytotoxic T cells with reactivity against primary CLL and/or patient-derived targets.
Only one cytotoxic CTL clone was obtained from one of the three donor-α CLL T cell lines. In contrast, 
from each donor-α CLL-APC T cell line several CTL clones, recognizing CLL-specific and patient-
derived targets, were generated (see figure 3). In accordance with the observed cytotoxicity of the α-
CLL-APC CTL lines, the CTL clones generated, preferentially recognized CLL-APC as target. 
However, in addition several CTL clones (e.g. clone 1.28, clone 2.57, clone 2.89 and clone 3.76) 
showed cytotoxicity against primary CLL. Some clones were active against patient-derived 
hematopoietic targets and CLL-APC (clone 2.45, clone 2.105 and clone 3.62) and not against primary 
CLL. These CTL clones may be able to recognize the CLL cells, once these leukemic cells become 
activated or start dividing. One might speculate that for an adequate alloimmune reponse in patients 
with disease recurrence after allogeneic SCT, CTL clones with different specificities might be 
necessary to control the disease. Our results indicate that CLL-APC as stimulator cells are sufficient 
immunogenic to induce T-cell responses in HLA-matched sibling donors and enrich for precursor T 
cells with reactivity to CLL- and patient-specific targets. Three CTL clones, derived from donor 3 
effectively lysed primary CLL as well as EBV-LCL from the patient. Further analysis of the specificity of 
these CTL clones showed that these clones were mHag-specific, recognized their targets in a HLA-B8 
restricted manner and used the same TCR. These clones were not reactive to MSC, cultured from BM 
of the patient, suggesting that the recognized mHag is not widely expressed in non-hematopoietic 
tissue. Our study illustrates that CLL-APCs are capable of stimulating mHag-specific CLL-reactive T 
cells, present at low precursor frequencies in unprimed MNC of the donor. Although other patient-
derived APC may also be capable of eliciting mHag-specific T-cell responses, we think that CLL-
derived APC will likely skew the immune response toward recognition of CLL-specific antigens of 
mHags, highly expressed on the CLL cells thus leading to a more specific and efficient T-cell 
response.
Our two-step approach of T cell-depleted allogeneic SCT following RIC using alemtuzumab with its 
intrinsic anti-CLL activity followed by the postponed administration of DLI was shown to be feasible in 
CLL patients 13. With the data from our study several strategies to limit the occurrence of severe GvHD 
after adoptive immunotherapy while preserving and enhancing GvL activity can be considered. High 
doses of CLL-reactive and relatively hematopoiesis-restricted mHag-specific T cells or low dose DLI in 
combination with these leukemia-reactive T cells can be administered. In addition, CD8+ alloreactive 
T-cells are considered to be main effectors of GvHD and may not be necessary for the GvL reactivity 
31.
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Since only 5% of all T cell clones tested showed cytotoxicity against CLL-specific targets, our study 
clearly demonstrates that the use of extensive in vitro culture periods is not very efficient in selecting 
and isolating leukemia-specific T cells, is labor intensive. Early detection and isolation of leukemia-
reactive T cells in the immune response using the IFN-γ capture assay may result in higher efficiency 
rates of CLL-reactive CTL clones 29,32.
In conclusion, this study illustrates that mHag-specific CLL-reactive CTL clones, derived from HLA-
identical sibling donors, can be generated using CLL-APCs as stimulator cells. Recently, follow-up of a 
large cohort of patients with chemo-refractory CLL, treated with an allogeneic SCT following RIC, 
showed the feasibility of the transplant procedure, but also reported a relapse rate of 26% after 2 
years 15. In this setting adoptive immunotherapy with donor-derived mHag-specific CTLs, which 
preferently kill CLL cells and not non-hematopoietic targets could be of great value and could treat or 
even prevent disease recurrence after allogeneic SCT.
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Abstract
Purpose: In patients, treated with allogeneic stem cell transplantation (SCT) for advanced mantle cell 
lymphoma (MCL), complete sustained remissions have been observed illustrating susceptibility of 
MCL cells to a graft-versus-lymphoma (GvL) effect. To potentiate this GvL effect adoptive transfer of in 
vitro-selected MCL-specific cytotoxic T cells (CTLs) can be an attractive approach. The lack of 
expression of costimulatory molecules on MCL cells hampers the generation of MCL-reactive T cell-
responses. The purpose of this study was to modify MCL cells into antigen-presenting cells (APC) and 
to use these MCL-APC to induce allogeneic MCL-reactive T-cell responses.
Experimental Design: Interleukin (IL)-4, IL-10, CpG, and CD40 activation were tested for their capacity 
to upregulate costimulatory molecules on MCL cells. Primary MCL cells or the modified MCL-APC 
were then used to evaluate the induction of MCL-reactive T-cell responses in HLA matched donors.
Results: Ligation of CD40 on MCL cells was essential to upregulate costimulatory molecules and to 
induce production of high amounts of IL-12. In contrast to primary MCL cells, MCL-APC cells as 
stimulators were capable of inducing cytotoxic CD8+ T-cell (CTL) lines from HLA class I-matched 
donors. High numbers of CTL clones could be generated capable of efficiently killing the primary MCL 
cells and MCL-APC but not donor-specific targets.
Conclusion: These results demonstrate the feasibility to generate primary allogeneic T-cell responses 
against MCL-APC, and may provide new immunotherapeutic tools to further exploit the GvL effect 
following allogeneic SCT in patients with MCL.
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Introduction
Mantle cell lymphoma (MCL) is a non-Hodgkin lymphoma (NHL), characterized by the 
t(11;14)(q13;q32) translocation involving the PRAD-1/bcl 1 gene resulting in overexpression of cyclin 
D1 
1. Patients with MCL frequently present with advanced-stage disease and have a median survival of 
only 3 to 4 years 2. Although in general MCL is initially responsive to conventional chemotherapy or to 
high-dose chemoradiotherapy followed by autologous stem cell transplantation (SCT), persistent 
remissions are usually not achieved reflected in the absence of a plateau phase in the survival curves 
3,4. The addition of rituximab to autologous SCT as an in vivo purging agent or as maintenance therapy 
appears promising, but has not yet definitively shown to result in a survival benefit 5-7.
Allogeneic SCT is currently being explored as a treatment modality in patients with advanced or 
relapsed chemosensitive MCL. Complete sustained remissions have been observed after allogeneic 
SCT illustrating susceptibility of MCL cells to a graft-versus-lymphoma (GvL) effect 5,8. High treatment 
related mortality (TRM) has hampered large scale application of allogeneic SCT in this extensively 
pretreated older patient population. Allogeneic SCT following reduced-intensity conditioning (RIC) has 
been shown to be feasible and resulted in a lower TRM, allowing the application of non-selected donor 
lymphocyte infusion (DLI) 9-12. However, acute and chronic graft-versus-host disease (GvHD) caused 
by alloreactive T cells present in the graft and/or in the DLI and persistence or recurrence of MCL after 
allogeneic SCT has limited favourable long-term outcomes 13. Therefore, both the specificity of the 
immune reactivity in the context of allogeneic SCT, as well as the magnitude of the immune response 
specific for MCL cells have to be improved. The use of T-cell depleted grafts avoiding the risk of 
GvHD, followed by in vitro selected alloreactive T cells with specificity for the MCL cells or for 
hematopoiesis-restricted minor histocompatibility antigens (mHag) could be an attractive approach, 
and may induce complete remissions with only minor graft-versus-host disease (GvHD) 14.
Malignant B cells inefficiently induce allogeneic T-cell responses despite their strong expression of 
HLA class I and class II due to inadequate expression of costimulatory and adhesion molecules 15-17. 
However, both normal and malignant B cells highly express CD40 molecules. Ligation of these 
receptors induces expression of the costimulatory molecules CD80 and CD86, adhesion molecules 
such as CD54 and CD58, and upregulates cytokine production 16-21. Stimulation of normal B cells can 
also be initiated by activating toll-like receptor (TLR) 9. TLR 9, expressed on normal and various 
neoplastic B cells 22-25, detects CpG motifs within bacterial DNA and induces upregulation of 
costimulatory molecules on these cells. Synthetic CpG oligodeoxynucleotide (ODN) 2006 mimic 
microbial DNA and has the ability to activate normal and malignant B cells 26. Transformation of B cell 
malignancies, including B-cell chronic lymphocytic leukemia, follicular lymphoma and hairy cell 
leukemia, into antigen-presenting cells (APC) has been studied previously 15,17,20,21,27-29, but the 
modification of MCL cells into APC and the generation of MCL-reactive T-cell responses have not 
been reported.
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In this study, we hypothesized that by transforming MCL cells into professional APC and using these 
MCL-APC to stimulate HLA-matched donor T cells, the generation of MCL-reactive cytotoxic T 
lymphocytes (CTL) lines will be possible. We first examined the stimulatory capacity of cytokines, 
including the proinflammatory cytokines TNF- and interferon-, the B-cell activating cytokine 
interleukin (IL)-4 30, and the MCL-stimulating cytokine IL-10 31 and the additional triggering of the TLR9 
by the synthetic agonist CpG ODN 2006, or triggering CD40 with CD40 ligand transfected fibroblasts 
(tCD40L) to upregulate costimulatory molecules on MCL cells, and to induce the production of IL-12 
by these cells. Using CD40-activated MCL cells as stimulator cells, we could demonstrate that MCL-
reactive mHag-specific CTL lines and clones from HLA class I-matched donors could be generated. 
These anti-MCL T-cell responses may be used to treat patients, suffering from relapse of MCL after 
allogeneic SCT.
Material and methods
Cell samples
After informed consent peripheral blood samples were obtained from 6 patients with MCL in the 
leukemic phase. The diagnosis of MCL was confirmed by detection of cyclin D1 overexpression using 
cytohistochemical staining and verification of the t(11;14) translocation by karyotype or interphase 
fluorescence in situ hybridization (FISH) 32. The patient characteristics are shown in table 1. 
Table 1. Patient characteristics.
Patient sex/age/stage phenotype   cyclin D1 t (11;14)
MCL 1   M / 68 / IV CD5+CD23- + +
MCL 2    M / 44 / IV CD5+CD23- + +
MCL 3    M / 56 / IV CD5+CD23- + +
MCL 4    M / 88 / IV CD5+CD23± + +
MCL 5    V / 52 / IV CD5+CD23- + +
MCL 6    M / 64/ IV CD5+CD23- + +
M, male; F, female. Cyclin D1 overexpression was detected using cytohistochemical staining. The t(11;14) 
translocation was verified by karyotype or FISH analysis.
Mononuclear cells (MNC) were isolated from peripheral blood samples by Ficoll density separation, 
and cryopreserved. The percentage of CD5+/CD19+ MCL cells in the MNC fraction was always higher 
than 90%. HLA-A, -B, and -C typing of patients was performed by standard serology methods, and 
HLA-DR and –DQ typing was done by DNA analysis using sequence specific primers. To induce T-cell 
responses, MNC from a fully HLA class I-matched URD and an HLA-A- and HLA-B-matched unrelated 
donor (URD) were tested against MCL 3 and MCL 4, respectively (table 2).
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Table 2. HLA type of patients and unrelated donors (URD).
Donor/patient
MCL 3 A2 A33 B15 B58 Cw3   DR13* DR15 DQ6*
URD A2 A33 B15 B58 Cw3   DR17 DR15  DQ1 DQ3
MCL 4 A1 A11 B37 B44 Cw6 Cw16*  DR7*  DR15   DQ2*   DQ6*
URD A1 A11 B37 B44 Cw6 Cw5  DR3 DR4  DQ1   DQ7
HLA class IIHLA class I
HLA-A, -B, and -C typing was performed by standard serology methods. HLA-DR and -DQ typing was done by 
DNA analysis using sequence specific primers. *donor-patient disparate alleles
Transformation of MCL cells into APCs
MCL cells were cultured in medium consisting of IMDM (BioWhittaker, Verviers, Belgium) with 10 % 
human serum in 6-well plates (Costar, Cambridge, MA, USA) at a concentration of 106 cells/mL in a 
total volume of 5 mL per well. MCL cells were cultured in the presence or absence of the cytokines IL-
4 (500 U/mL, Schering-Plough, Amsterdam, the Netherlands), IL-10 (10 ng/mL, Sanquin, Amsterdam, 
The Netherlands), TNF-α (10 ng/mL, Boehringer Ingelheim, Ingelheim am Rhein, Germany) or 
interferon-α (IFN-α 1000 U/mL, Hoffmann-La Roche, Basel, Switzerland), or in the presence or 
absence of the cytokine combinations IL-4 and IL-10. For triggering TLR 9, MCL cells were incubated 
with its ligand synthetic CpG ODN 2006 (CpG; 5' TCGTCGTTTTGTCGTTTTGTCGTT-3', 10 µg/mL; 
Eurogentec, Seraing, Belgium) in the presence or absence of the cytokine combination IL-4 and IL-10. 
Finally, to further enhance upregulation of costimulatory molecules MCL cells were cocultured on ltk 
murine fibroblast cells transfected with the human CD40-ligand 33 (tCD40L; kindly provided by Dr. C. 
van Kooten, Department of Nephrology, Leiden University Medical Center). The fibroblasts were 
irradiated (70 Gy), and seeded as a feeder layer at a concentration of 5x105 cells/well in 6-well plates 
(Costar). MCL cells were added at a concentration of 5x106 cells/well in presence or absence of the 
cytokines, cytokine combinations and/or immunostimulators as described above. After 1, 2, 4 or 6 
days of culture, MCL cells were harvested and washed. Cytospin preparations were made on day 4 for 
morphological assessment by May-Grunwald-Giemsa (MGG) staining. The number of viable cells was 
counted using eosin death cell exclusion, and the cells were analyzed by flow cytometry.
Immunophenotyping and cytokine analysis
To perform immunophenotyping, a panel of mouse MoAbs conjugated with fluorescein isothiocyanate 
(FITC) or phycoerythrin (PE) was used. These MoAbs included FITC-conjugated IgG1 antibodies 
specific for CD3, CD4, CD5, CD40, CD54 or HLA-DR, and FITC-conjugated IgG2a antibodies specific 
for CD58. PE-conjugated IgG1 antibodies specific for CD14, CD19, CD23, CD56 or CD80, PE-
conjugated IgG2a antibodies specific for CD8, and PE-conjugated IgG2b antibodies specific for CD83 
and CD86 were used. Appropriate isotype controls (IgG1, IgG2a and IgG2b) were used. All MoAbs 
were purchased from Coulter (Coulter Corporation, Miami, Florida, USA) except anti-CD40 (Serotec, 
Oxford, England). Cytoplasmatic TLR9 was measured using PE-conjugated IgG2a antibodies 
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(eBioscience, Anaheim, CA, USA). A quantity of 25 µL of each MoAb in the appropriate dilution was 
added to 105 cells in 50 µL PBS containing 0.8 g/L albumin (Sanquin). After 30 minutes of incubation 
at 4˚C, the cells were washed twice, and analyzed on a Coulter FACScan (Coulter). Results were 
analyzed using the Coulter Expo 32 software (Coulter). The relative expression of surface antigens is 
described as the mean fluorescence intensity ratio (MFIR). This value is calculated by dividing the MFI 
of cells stained with fluorochrome-conjugated antigen-specific MoAb by the MFI of cells stained with 
fluorochrome-conjugated isotype-control MoAb. If the percentage of positive events was more than 
10% the leukemic sample was considered positive for that surface marker, and then the MFIR was 
calculated. Cell-free supernatants were harvested after 96 hours of culturing the MCL cells with or 
without cytokines, with or without CpG, and in the presence or absence of irradiated tCD40L cells. 
Cytokine measurements were performed using commercial IL-10 (Sanquin), IL-12 p40/70 (U-CyTech, 
Utrecht, the Netherlands) and IL-12 p70 (U-Cy Tech) ELISA kits according to the manufacturer's 
instructions.
Mixed lymphocyte reaction
A modification of the allogeneic mixed lymphocyte reaction (MLR)34 was used to analyze the functional 
significance of IL-10 and IL-12 to the APC capacity of the MCL cells. Freshly thawed or CD40-
activated MCL cells from patients 3, 4 and 5 were used as stimulator cells. MNC from a healthy donor 
was used as responder cells. In a 96-well flat-bottom culture plates (Costar) responder cells at 
concentration of 1.5x104 were stimulated with 1x105 irradiated (15Gy) stimulator cells in the presence 
of IL-10 (10ng/mL), IL-12 (5 U/mL) or without cytokines. After 4 days of culture in IMDM with 10% 
human serum, 1 µCi of [3H]thymidine (Amersham, Roosendaal, The Netherlands) was added and after 
additional 18 hours of culture [3H]thymidine incorporation was measured. As a control, [3H]thymidine 
incorporation in wells containing responder or stimulator cells only was used. All counts were 
corrected by subtracting the mean stimulator control counts (18-fold) and the mean of responder 
control counts (6-fold). A Stimulation Index (SI) was calculated by dividing the counts, measured in 
wells with different stimulators and culture conditions, by the counts produced by unstimulated 
responder cells, cultured in medium alone.
Generation of MCL-reactive CTL lines and clones
MNC from two unrelated healthy HLA class I-matched donors at a concentration of 106 cells / well in 6-
well plates (Costar) were stimulated with irradiated (30 Gy) primary MCL cells, or CD40-activated MCL 
cells at responder/stimulator (R/S) ratios of 10:1 in medium consisting of IMDM (BioWittaker) and 10 
% human serum. IL-2 (Chirion, Amsterdam, the Netherlands) at a final concentration of 100 U/mL was 
added at day 6. Twice weekly, half of the medium was refreshed with IL-2 containing medium. At day 
9 the T cells lines were harvested, and depleted of CD4+ T cells using anti-CD4-conjugated magnetic 
beads (Milteny Biotec, Bergisch Gladbach, Germany) since the donors were HLA class II-mismatched. 
The T cell lines were restimulated with irradiated stimulator cells at the same R/S ratios at days 9, 16 
and 23. T cells were harvested 5-7 days after the third or fourth stimulation for phenotypic analysis, 
and used as effectors in cytotoxicity assays. To generate MCL-reactive CTL clones, the donor-derived 
leukemia-reactive CTL lines were plated at frequencies of 3, 1 and 0.3 cells/well in 96-well microtiter 
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plates, and expanded in the presence of irradiated allogeneic feeder cells (5 x 104 cells / well) in 
medium consisting of IMDM plus 10% human serum, IL-2 (100 U /mL) and phytohemagglutinin (PHA, 
800 ng/mL, Murex Biotech Limited, Dartfort, UK). When sufficient cell numbers were reached T cell 
clones were harvested, and tested for specific cytolytic activity against the primary MCL cells, CD40 
activated MCL cells, and PHA blasts from patient and donor. As read-out system for T-cell-mediated 
cytotoxicity, our recently developed carboxyfluorescein diacetate succinimidyl ester (CFSE)-based 
cytotoxicity assay was used 35.
CFSE-based cytotoxicity assay
The CFSE-based cytotoxicity assay facilitates the quantitative analysis of susceptibility to T-cell-
mediated lysis of malignant cell types within a heterogeneous target cell population. Briefly, after 
washing with phosphate-buffered saline (PBS) the target cells were resuspended at 20 x 106 cells/mL 
and labeled with 10 µM CFSE (Molecular Probes Europe, Leiden, the Netherlands) for 10 minutes at 
37°C. The reaction was stopped by the addition of an equal volume of fetal calf serum (FCS), followed 
by a 2-minute incubation at room temperature. After 2 washes the CFSE-labeled target cells were 
resuspended in culture medium at a cell concentration of 5 x 104 cells/mL, and 100 µL/well was plated 
in 96-well microtiter plates. CTLs were added at different effector/target (E/T) ratios ranging from 0.3:1 
to 10:1. After 5 hours and 12 hours of incubation in a humidified atmosphere of 5% CO2 and 37°C the 
wells were harvested, and to allow quantitative analysis of the cell populations 10,000 Flow-Count 
Fluorospheres (Coulter Corporation, Miami, FL) were added. To stain for dead cells, propidium iodide 
(0.5 µg/mL) was added, samples were mixed properly, and directly analyzed by flow cytometry. For 
each sample 5,000 microbeads were acquired and the absolute number of surviving cells was 
determined at each time point by calculation of the ratio between the number of viable cells and the 
number of beads. The percentage of survival was calculated as follows: % survival = [absolute # viable 
CFSE+ target cells (t = x)]/[absolute # viable CFSE+ target cells (t = 0)] x 100. Percentage of specific 
lysis was defined as: 100% - % survival. To analyze the HLA class-I or -II restriction of the target cell
lysis blocking studies were performed. Target cells were incubated with saturating concentrations of 
anti-HLA class I or anti-HLA class II MoAb (W6/32 and PdV5.2, respectively) for 30 minutes before 
effector and target cells were cocultured. Blocking experiments at effector level were performed by 
adding anti-CD8 MoAb (FK18, RIVM, Bilthoven, the Netherlands) at a final dilution of 8µg/mL 30 
minutes prior to the addition of target cells.
Statistical analysis
Statistical significance of differences was determined by the paired two-tailed Student’s t-test or by the 
Wilcoxon test using the absolute values.
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Results
Expression and upregulation of adhesion and costimulatory molecules on MCL cells.
To determine cell surface expression of the adhesion molecules CD54 and CD58, and the 
costimulatory molecules CD40, CD80, CD86 and CD83, immunophenotyping of freshly isolated MCL 
cells from 6 patients was performed.
Table 3. Phenotype of isolated MCL cells.
Patient
MCL   1 +++ (97) + (42) ++ (26) ± (13) 0 (4) 0 (9) ++ (95)
MCL   2 +++ (97) ++ (37) 0 (6) ± (11) ± (10) 0 (2) + (91)
MCL   3 +++ (94) + (83) + (93) ± (52) 0 (3) 0 (2) ++ (88)
MCL   4 +++ (99) + (13) + (29) + (84) 0 (3) + (20) ++ (88)
MCL   5 + (72) + (14) + (15) 0 (2) 0 (5) 0 (2) ++ (83)
MCL   6 +++ (96) + (17) ++ (28) 0 (7) 0 (1) 0 (7) ++ (96)
CD54 CD58
Adhesion
MHC  II
Recognition
CD80 CD86 CD83 CD40
MFIR (% positive cells)
Costimulation
Mean fluorescence intensity ratio (MFIR) is mean fluorescence intensity (MFI) of cells stained with a 
fluorochrome-conjugated antigen-specific MoAb divided by MFI of cells stained with a fluorochrome-conjugated 
isotype-control MoAb. If the percentage of positive events was <10 %, MFIR of the leukemic sample was not 
calculated and is expressed as 0. If the percentage of positive events was ≥ 10 % then the MFIR is calculated and 
depicted as: ± < 10; + 10 – 20; ++ 20 – 50; +++ 50 – 100
As shown in table 3, the MCL cells of all patients strongly expressed HLA class II (MFIR >50). In most 
patients (n=5), a minority of the MCL cells (<45%) expressed CD54 at low levels (MFIR <20). One 
patient (MCL 2) had intermediate levels (MFIR 20-50) of CD54 expression, but lacked CD58 
expression. In MLC 3, almost the entire population (>80%) expressed the adhesion molecules but 
expression levels were low. Two out of six patients showed intermediate levels of CD58. In only one 
patient (MCL 4) some expression of CD80 and CD83 was observed, all other MCL cases expressed 
no or neglectable levels of CD80, CD86 and CD83. Only the costimulatory molecule CD40 was 
expressed by all MCL cells at intermediate levels. In summary, in accordance with other B cell 
malignancies, inadequate expression of costimulatory molecules on MCL cells was observed.
To upregulate the expression of adhesion and costimulatory molecules on MCL cells, we first 
examined several cytokines, including IFN-α, TNF-α, IL-4 and IL-10. Next, activation through TLR 9 by 
its synthetic ligand CpG ODN 2006 in combination with the various cytokines was tested. Finally, 
CD40 engagement as stimulus to modify MCL cells into APCs was analyzed in the presence of 
cytokines and/or CpG. Figure 1 summarizes the FACS analysis data of the most optimal combinations 
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to upregulate adhesion and costimulatory molecules on MCL cells. The data are presented as 
percentages of positive MCL cells (figure 1A) and the MFIR (figure 1B), and were obtained after a 
culture period of 96 hours.
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Figure 1: Expression and upregulation of costimulatory and adhesion molecules on MCL cells activated 
by IL-10, CpG and/or tCD40L. (A) Combinations using CD40 activation give significant higher percentages of 
positive MCL cells for CD80 and CD86 (p<0.01) (B) Stimulation of MCL cells by tCD40L gives maximal 
upregulation of expression levels of CD80 and CD86. MCL cells were cultured for 96 hours in the presence or 
absence of IL-10 (10 ng/mL), CpG (10 μg/mL) and/or tCD40L. Expression of CD80, CD86, CD54 and CD83 was 
analyzed by flow cytometry. Mean fluorescence intensity ratio (MFIR) was calculated as described in Material and 
Methods section, only if percentage of positive cells was >10%. Results are expressed as mean ± SD of 6 
patients with MCL. 
None of the tested cytokines caused any upregulation. CpG increased the percentage of MCL cells 
positive for costimulatory molecules tested, but only the expression level of CD80 was enhanced. 
Using flowcytometry, only weak expression of TLR9 was observed (data not shown). Accordingly, only 
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minor changes were observed after stimulation of MCL cells with CpG. CD40 activation by tCD40L 
significantly increased the percentage of positive MCL cells for all adhesion and costimulatory 
molecules (p<0.01). As demonstrated in figure 1B, the expression levels of all these molecules, 
especially CD80 (MFIR 21.3 fold, p=0.001) on MCL cells were strongly upregulated, and transformed 
MCL cells into characteristic APC phenotypes with high expression of CD80, CD86 and CD54. 
Additional stimulation with CpG or IL-10 did not further enhance the upregulation.
To investigate the optimal time period of stimulation for full activation of MCL, phenotypic analysis of 
MCL cells of all six patients was performed 2, 4 and 6 days after stimulation with tCD40L. As shown in 
figure 2, CD40 activation of MCL cells by tCD40L caused strong upregulation of CD80, CD86, and 
CD54 within 2 days. After 4 days of stimulation a further enhancement of expression levels of CD80 
(MFIR 2.9 fold, p= 0.01) and CD86 (MFIR 3.5, p=0.02) was observed. Although a significantly higher 
percentage of leukemic cells expressed CD83 after CD40 stimulation, the expression levels of CD83 
were only minimally upregulated.
0
100
200
300
400
500
600
1d 2d 4d 6d
0
25
50
75
100
0
60
120
180
1d 2d 4d 6d
0
25
50
75
100
0
25
50
75
100
1d 2d 4d 6d
0
25
50
75
100
0
70
140
210
1d 2d 4d 6d
0
25
50
75
100
CD 80 
CD 83
CD 86
%
 p
o
si
ti
ve
 c
el
ls
 M
F
IR
CD 54
Figure 2. Kinetics of upregulation of costimulatory molecules on MCL cells activated by tCD40L. MCL cells 
were activated by tCD40L. MFIR and percentage of MCL cells positive for CD80, CD86, CD83 and CD54 were 
analyzed at different time points by flow cytometry. Data are shown as means ± SD for 6 patients. Straight lines 
indicate % positive cells, dotted lines represent MFIR.
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Cytospin preparations of both unstimulated and tCD40L-activated MCL cells showed that after CD40 
triggering, MCL cells increased 2-fold in size and obtained a dendritic cell-like morphology with a high 
degree of vacuolization. In conclusion, in the absence of CD40 activation minimal upregulation was 
observed in response to IL-10 and CpG. Stimulation of MCL cells by tCD40L for a period of 4 days
caused the strongest upregulation of costimulatory and adhesion molecules, and modified MCL cells 
into morphological and phenotypical characteristic APC.
To examine the functional capacity of the different MCL APC to produce IL-10 and IL-12, supernatants
from cultures of activated MCL cells after 96 hours were measured. Whereas unstimulated MCL and 
CpG activated MCL cells were not capable of producing significant amounts of IL-12 (median <15 
pg/mL), high levels of IL-12 were produced by tCD40L-activated MCL cells with major variability 
between different patients (median 1,054 pg/mL; range 67-8,800 pg/mL, n=6). Neglectable amounts of 
IL-12p70 (mean 6 pg/mL) and IL-10 (mean 14 pg/mL) were produced by the CD40-activated MCL 
cells. Additional stimulation with CpG induced some increase in IL-12 production (median 1,370 
pg/mL) and IL-12p70 (mean 31 pg/mL) but also induced the production of IL-10 (mean 299 pg/mL).
MLR using primary or MCL-APC as stimulator cells in the presence or absence of IL-10 and IL-
12 
To investigate the functional significance of IL-12 or IL-10 on the stimulatory capacity of MCL cells, a 
MLR was performed using primary MCL cells or MCL-APC as stimulator cells, and MNC from a donor 
as responder cells in medium with or without IL-10 or IL-12. As expected, primary MCL cells, derived 
from three different patients, had minimal allostimulatory capacity (see figure 3). IL-12 had a weak 
stimulatory effect on the proliferation of the allogeneic T cells, whereas IL-10 demonstrated some 
inhibition of T cell activation. In contrast, the stimulation index in response to MCL-APC as stimulators, 
was 25-50, illustrating the impressive immunostimulatory capacity of these malignant APC. As shown 
in figure 3, further increase of IL-12 concentrations did not enhance T cell proliferation nor did IL-10 
suppress the induction of proliferation. In conclusion, tCD40L-activated MCL cells were considered the 
best MCL-APC, and were further used as stimulator cells in the subsequent experiments.
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Figure 3. The proliferation and cytotoxicity of allogeneic CD8+ T cells in response to primary MCL and 
MCL-APC cells. (A) In contrast to primary MCL, MCL-APC cells as stimulators induced strong proliferation of 
CD8+ donor T cells in the URD anti-MCL-APC 3 and URD anti-MCL-APC 4 combinations.(B) cytotoxic activity of 
the CTL lines generated against MCL-APC 3 or MCL-APC 4 measured in a 12-hours CFSE-based cytotoxicity 
assay.
The generation of MCL-reactive CTL lines and clones from HLA-matched donors 
To analyze the antigen-presenting capacity of primary MCL cells and tCD40L-activated MCL (MCL-
APC) T cells from a fully HLA class I-matched donor and an unrelated HLA-A- and HLA-B-matched 
donor were stimulated with primary MCL or MCL-APC cells. CD4 depletion was performed at day 9 to 
eliminate allo-HLA class II responses. As demonstrated in figure 4, primary MCL cells were not 
capable of inducing T-cell proliferation and generating T cell lines. The cytotoxic activity of the CTL 
lines generated against MCL-APC was measured using the CFSE-based cytotoxicity assay 35 (see 
Material and methods) with CFSE-labeled primary MCL cells, MCL-APC cells, and PHA blasts from 
the patients and donors as target cells. As illustrated in figure 4, the CD8+ CTL lines derived from the 
donors effectively killed the primary MCL cells, the MCL-APC, the PHA blasts from the patient, and not 
the PHA blasts from the donor in a 12 hours CFSE cytotoxicity assay.
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Figure 4. The proliferation and cytotoxicity of allogeneic CD8+ T cells in response to primary MCL and 
MCL-APC cells.(A) In contrast to primary MCL, MCL-APC cells as stimulators induced strong proliferation of 
CD8+ donor T cells in the URD anti-MCL-APC 3 and URD anti-MCL-APC 4 combinations.(B) cytotoxic activity of 
the CTL lines generated against MCL-APC 3 or MCL-APC 4 measured in a 12-hours CFSE-based cytotoxicity 
assay. Although there was an HLA-C locus mismatch in the MCL 4/donor combination and although the primary 
MCL 4 had some expression of CD80 and CD83 (see table 2) this was insufficient to overcome T cell anergy and 
to induce antigen-driven proliferation. In contrast, using MCL-APC cells as stimulators, vigorous expansion of 
CD8+ T cells was observed in both patient/ donor combinations tested.
To estimate the precursor frequency of MCL-reactive T cells in the CTL lines, and to determine 
whether the cytotoxicity of the CTL lines was exerted by cytotoxic T cells with different specificities 
CTL clones were generated. In the URD -MCL-APC 3 combination 13% of the 1 cell/well and 8% of 
the 0.3 cell/well showed proliferation. 29 out of 91 proliferating CD8+T cell clones showed specific lysis 
of primary MCL at an E/T ratio of 10:1 (36  14%, mean  SD, n=29) in a 12 hours CFSE cytotoxicity 
assay. The plating efficiency in the second combination (URD -MCL-APC 4) was 12%, resulting in 60 
out of 89 CD8+CTL clones, recognizing primary MCL cells (65  20%, mean  SD, n=60). These 
results indicated that in both CTL lines high frequencies of MCL-reactive T cells were present.
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Figure 5. Cytotoxicity and specificity of representative MCL-reactive CD8+ CTL clones, derived from HLA-
matched donors. (A1.and A2.) High numbers of CD8+ CTL clones recognizing primary MCL in a 12-hours CFSE 
cytotoxicity assay were generated from both URD (B1. and B2.) Four representative CTL clones from each 
donor/patient pair were analyzed for specific cytolytic activity against MCL, MCL-APC, and PHA blasts from donor 
and patient in a 12-hours CFSE cytotoxicity assay. All clones recognized MCL-specific as well as patient-derived 
targets and not PHA blasts or EBV-LCL from the donor. One representative example of these CTL clones from 
each combination is demonstrated. (C.). HLA class I-restriction of the cytotoxicity was demonstrated by blocking 
experiments using primary MCL as target at an E/T ratio of 10:1. Target cells were 30 minutes preincubated with 
anti-HLA class I (W6/32) or anti-HLA class II (PdV5.2) antibodies prior to the CTL assay using clone 32, derived 
from URD 3 and clone 47, derived from URD 4 as effector cells. 
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To analyze whether the MCL-reactive CTL clones were MCL-, B cell- or mHag-specific, four 
representative clones in both patient/donor pairs were tested for cytotoxicity against MCL-specific 
targets, patient- and donor-derived T lymphoblasts (PHA blasts) and B-cell-specific targets (EBV-LCL) 
from patient and donor. As shown in figure 5, CTL clones generated from the CTL lines from both 
donors were reactive against MCL, MCL-APC, and EBV-LCL of the patient, and not against donor-
specific targets. The clones also killed T cell-derived targets indicating that these T cell clones were 
probably mHag-specific and that the recognized mHag is not B-lineage-restricted. To confirm HLA 
class I-restricted recognition of the targets by the CD8+ CTL lines and clones, and to exclude HLA 
class II-restricted killing by contaminating CD4+ T cells, blocking studies were performed using 
representative examples of the generated MCL-reactive CTL lines and clones. Cytotoxicity of both 
CTL lines was completely blocked by anti-HLA class I or anti-CD8 antibodies and not by the addition 
of anti-HLA class II (data not shown). Cytolytic activity of the CTL clones could partially or completely 
be abrogated using the anti-HLA class I antibodies (figure 5).
Discussion
RIC allogeneic SCT is considered as a new promising treatment modality for patients with advanced 
MCL. After allogeneic SCT adoptive transfer of donor T cells, capable of killing MCL cells may 
eliminate residual malignant cells resulting in long-term remissions. In this context, this experimental 
study was performed to evaluate whether donor T cells can be triggered to preferential kill MCL-
specific targets using MCL cells as stimulator cells. As illustrated in the results, we demonstrated that 
primary MCL cells as stimulator cells failed to induce proliferation and to generate a T-cell response, 
even in the presence of IL-12, probably due to the lack of expression of costimulatory molecules. 
Thus, to generate donor T cells with high avidity for MCL cells, modification of the MCL cells into 
professional APC with high expression of costimulatory and adhesion molecules was hypothesized to 
be essential. Treatment of MCL cells with proinflammatory cytokines, B-cell activating cytokines, and 
also the MCL-stimulating cytokine IL-10 did not significantly induce phenotypic changes of the MCL 
cells. In accordance with a recent report 36, we observed limited activation of MCL cells upon 
stimulation with CpG ODN 2006, probably due to the low expression of TLR9 on MCL cells.
Since CD40 engagement is the major signal that induces B cells to efficiently present antigen to T 
cells 16,18,37, and since malignant B cells strongly express CD40, activation through CD40 can be an 
effective tool to transform tumor B cells into an antigen-presenting phenotype 15,17,20,27,28. In the 
present study, we show that CD40-ligation could modify MCL cells into phenotypically professional 
APCs with high expression of CD80, CD86, and the adhesion molecules, and induced some 
expression of CD83. Additional stimulation through TLR9 and cytokine receptors did not further 
enhance expression levels. In contrast with recent cytokine gene expression studies suggesting that 
both primary as well as CD40-activated MCL cells cannot produce IL-12p40 and assemble the IL-12 
heterodimer 38, we illustrated in the present study the capacity of MCL cells to synthesize IL-12. MCL 
cells were only capable of producing IL-12 in response to CD40 stimulation. The MLR experiments 
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demonstrated that using MCL-APC as stimulator cells an increase in IL-12 concentrations did not 
further enhance T-cell proliferation.
Next, the stimulatory capacity of the generated MCL-APC to induce vigorous allogeneic MCL-specific 
T-cell responses was compared to primary MCL as stimulator cell in two allogeneic donors. In the 
HLA-C locus mismatched setting (URD αMCL 4) the unmodified MCL cells as stimulators did not 
induce any antigen-driven proliferation. Although MCL 4 showed some expression of the costimulatory 
molecules, this was apparently insufficient to induce an appropriate T-cell response over a major MHC 
mismatch barrier. In contrast, the MCL-APCs were capable of provoking vigorous expansion of the 
donor-derived T cells and of eliciting a sustained primary allogeneic MCL-reactive immune response. 
These results illustrate that primary MCL cells can be adequately killed by T cells generated against 
MCL-APCs. To evaluate whether MCL-specific CD8+ T-cell responses could be generated in a fully 
HLA-class I-matched setting MNC from the URD were stimulated with primary MCL 3 or MCL 3-APC.
Again no T-cell proliferation was observed against primary MCL and cytotoxic MCL-reactive CD8+ T-
cell lines and clones could be generated against MCL-APC, indicating that MCL-APCs are essential to 
induce an efficient anti-leukemic T-cell response. Allo-HLA-class II responses were eradicated by CD4 
depletion and blocking experiments confirmed HLA class I-restricted recognition of the target cells. To 
further elucidate the different specificities of the leukemia-reactive T cells and to determine the 
precursor frequencies of these T cells in the CTL line, cloning experiments were performed. This 
resulted in high clonal expansion efficiency of 6-18% of the cells isolated, suggesting that MCL-APCs 
as stimulator cells enrich for MCL-reactive T cells. MCL-specific targets, but also patient-derived 
targets from T-cell (PHA blasts) and B-cell origin (EBV-LCL) were recognized by the CTL clones, 
indicating that the immunogenic antigen is not MCL- or B-cell-specific, but most likely mHag-specific. 
As we previously illustrated for patients with acute leukemia's 14,39,40, repeated stimulation of donor T 
cells with leukemic cells results in the generation of T-cell responses against mHag with relative 
specificity for the malignant cells. Therefore, although other patient-derived APC may be capable of 
eliciting mHag specific T-cell responses, MCL-derived APC likely will skew the immune response 
toward recognition of MCL-specific antigens or mHags highly expressed on the MCL cells thus leading 
to a more specific and efficient T-cell response.
In summary, our study shows that T cell anergy to primary MCL cells can be reversed by transforming 
MCL cells into professional malignant APCs using CD40 ligation and provides the first evidence that 
using these MCL-APCs as stimulators MCL-reactive mHag-specific CD8+ CTL lines and clones can be 
readily generated from MNC of HLA class I-matched donors. Two recent reports demonstrated the 
feasibility of RIC allogeneic SCT as salvage therapy in patients with advanced MCL 41,42. After 
allogeneic SCT sensible RT-PCR techniques for minimal residual disease and donor chimerism 
analysis enable to predict disease recurrence. The administration of DLI can lead to long-term 
remissions, but effectiveness may be limited due to low immunogenicity of MCL cells and the 
development of acute or chronic GvHD, caused by non-selected donor T cells. In this setting the 
application of mHag-specific CTLs, which preferently kill MCL cells and not non-hematopoietic targets 
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14 could be of great value and could prevent or treat disease recurrence after allogeneic SCT. The 
magnitude and specificity of the immune response against MCL cells without causing concomitant 
GvHD may be maximized.
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Abstract
We here report the results of 12 patients suffering from chronic lymphocytic leukemia (CLL), treated 
with in vitro T-cell depleted reduced-intensity conditioning allogeneic SCT followed by donor 
lymphocyte infusions (DLI). Four patients achieved a complete remission (CR) after the administration 
of DLI demonstrating the curative potential of this procedure. In two representative patients graft-
versus-leukemia activity was analyzed by isolating T cells producing IFNγ in response to CLL or CLL 
antigen-presenting cells (CLL-APC). From a patient suffering from progressive disease no leukemia-
reactive T-cell responses could be isolated. Primary CLL-reactive T-cell responses were inducible in 
the unprimed donor only in response to CLL-APC but not to unmodified CLL. These results indicate 
that precursor CLL-reactive T cells were present in the DLI, but in vivo inadequately stimulated by the 
low immunogenic primary CLL. The other patient had a CR after DLI. In post-DLI experiments using 
peripheral blood, leukemia-reactive CTL clones with different specificities could be isolated, but only in 
response to CLL-APC indicating that CLL-reactive T cells were probably cross-primed by APC from 
recipient- or donor origin. These results suggest that persistent primary CLL after allogeneic SCT and 
DLI may escape from T-cell surveillance due to the lack of APC function. 
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Introduction
In spite of the spectrum of currently available chemotherapeutic agents and monoclonal antibodies 
(MoAb) 1-6, once CLL becomes therapy-resistent the prognosis is poor 2,3. Adverse biological risk 
factors such as the mutation status of the immunoglobulin variable heavy (VH) genes, expression of 
ZAP-70 and unfavourable cytogenetics enable to early identify patients with a more rapid fatal course 
7-11. For these patients allogeneic stem cell transplantation (SCT) may be a potential curative 
treatment modality 12-14. Recently, several reports have shown that allogeneic SCT following reduced-
intensity conditioning (RIC) significantly diminished treatment-related mortality (TRM) while preserving 
the graft-versus-leukemia (GvL) effect 13,15-18. However, considerable toxicity due to a high incidence
of acute graft-versus-host disease (GvHD, 42%) and extensive chronic GvHD (>50%) was observed 
16,17. The use of alemtuzumab to deplete for donor and recipient T cells as part of the RIC strategy 
effectively reduces GvHD, while the administration of alemtuzumab with the stem cell graft may also 
result in a profound anti-CLL effect 13,19,20. Once durable donor engraftment is achieved, adoptive 
immunotherapy with donor lymphocyte infusion (DLI) can be administered to promote and enhance 
the GvL effect. Since recipient-derived antigen-presenting cells (APC) appear to play an important role 
in the induction of GvHD the incidence and severity of GvHD after DLI may be less in T-cell depleted 
allogeneic SCT than the incidence of GvHD after unmodified allogeneic SCT following RIC 21. We and 
others have demonstrated the feasibility of this approach 13,22. 
Because CLL is a slowly progressive disease offering a time frame after allogeneic SCT to optimize 
the potential of adoptive immunotherapy, this transplantation protocol facilitates the analysis of graft-
versus-CLL. Here, we report the result of a study including 12 patients with chemo-refractory CLL 
treated with this in vitro T-cell depleted RIC allogeneic SCT followed by the postponed administration 
of DLI. To characterize allogeneic immune reponses and the possible graft-versus-CLL activity, T cells 
from a patient successfully treated with DLI (patient 6), and T cells from a patient refractory to several 
applications of DLI after an initial partial response (patient 10) were studied. We have previously 
demonstrated that by CD40 triggering in the presence of IL-4, CLL cells can be modified into efficient 
malignant APC (CLL-APC) capable of inducing allogeneic T-cell responses 23. In this study, T cells 
isolated from peripheral blood (PB) of the patients during clinical response to DLI were stimulated with 
primary CLL cells or CLL-APC derived from the patients. As described recently, T cells responding to 
the malignancy or the malignant APC by secreting interferon γ (IFNγ) were selected, directly cloned 
and expanded 24. From the patient with progressive disease despite DLI (patient 10), no CLL-reactive 
T cells responding to stimulation by primary CLL or CLL-APC could be isolated. However, precursor 
CLL-reactive T cells were present in the unprimed donor but these T cells could only be induced to 
proliferate in response to CLL-APC, illustrating the lack of APC function of the unmanipulated 
leukemic cells. From the PB of the patient with an excellent clinical response after DLI (patient 6), 
leukemia-reactive CTL clones could be isolated. From this patient, stimulation with CLL-APC 
appeared to be more efficient to isolate CLL-reactive T cells. In accordance with our previous data, 
this study illustrates that the inappropriate APC function of primary CLL cells may result in T-cell 
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tolerance towards persistent CLL cells after allogeneic SCT 23. The observed GvL reactivity resulting 
in good clinical responses may be mediated by T cells reactive against alloantigens expressed on 
recipient dendritic cells, or donor dendritic cells cross-primed with CLL cells.
Patients, materials and methods
Eligibility criteria 
Patients with progressive CLL after conventional chemotherapy with ages between 18 and 70 years 
with an HLA-identical sibling donor or an HLA-compatible unrelated donor (MUD) were eligible for this 
study. This single center study was approved by the institutional Ethics Committee and patients gave 
written informed consent for participation in the protocol as well as for scientific research performed 
using their PB and bone marrow (BM) cells.
Patients characteristics
Between May 2000 and September 2005 twelve patients with advanced CLL were enrolled. Patients 
and transplantation characteristics are summarized in Table 1. 
Table 1. Patient and transplant characteristics.
Characteristics No.
Total patients 12
Men / women  8/4
Median age at transplantation, y (range) 56 (45-59)
Time diagnosis to alloSCT, y (range) 4.9 (2.3-9.7)
Previous chemotherapy regimen  ≤ 3 5
 > 3 7
Fludarabine refractory 11
Unfavourable cytogenetics (n=10) 5
Disease status after last therapy at transplantation  CR 1
 PR 9
 refractory / PD 2
Donor HLA-identical related 10
Matched unrelated 2
Stem cell dose CD34+ (106/kg): median (range) 12.3 (7.9-16.5)
The conditioning regimen consisted of fludarabine 30 mg/m2/day intravenously on days –10 to –6, 
busulphan by intravenous infusion of 3.2 mg/kg/day on days –6 and –5, and antithymocyte globulin 
(horse, IMTIX Sangstat, Lyon, France) by intravenous infusion of 10 mg/kg/day on days –4 to –1. A 
dose of 15 x 106 CD34+ cells/kg of the recipient body weight was targeted for SCT. T-cell depletion of 
the stem cell product was performed by incubation with 20 mg alemtuzumab for 30 minutes at room 
temperature under continuous agitation. No post-transplant GvHD prophylaxis was administered. 
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Donor lymphocyte infusions
In this study DLI was anticipated to be administered in all patients. Patients with persistent disease, 
minimal residual disease, or incomplete donor chimerism at six months after allogeneic SCT received 
5 x 106 CD3+ cells/kg. Escalating doses of CD3+ T cells were administered at 3-6 months intervals in 
the absence of development of GvHD if mixed chimerism or CLL persisted. 
Study endpoints and statistical analysis
Data were analyzed by April 1, 2006. The median follow-up was 21 months (range, 7–61 months). 
Neutrophil engraftment was defined as the first of 2 consecutive days with an absolute neutrophil 
count > 0.1 x 109/l. Platelet engraftment was defined as the first of 7 consecutive days with a platelet 
count of > 20 x 109/l without transfusion. Acute and chronic GvHD was graded according to consensus 
criteria 25. Chimerism analysis was performed in BM samples at fixed time points (day +30, 60, 90, 
180, 270, 365, 455, 545) as previously described 13. Disease response was assessed using National 
Cancer Institute Working Group (NCI-WG) criteria 26 with the following additions. CR or PR required 
complete or at least 50% clearance of CD5/CD19-coexpressing CLL cells from both BM and PB as 
detected by flow cytometry, respectively. Patients receiving DLI were evaluable for response to 
therapy if they survived at least 90 days following the first infusion. Kaplan-Meier survival estimates 
were calculated from allogeneic SCT until death from any cause. 
Isolation of in vivo primed CLL-reactive T cell clones
Two patients (patient 6 and patient 10) were selected for further analysis of the presence of GvL-
mediating T cells. Both patients received DLI for persistent CLL and mixed chimerism. Patient 6 
achieved a CR after DLI, patient 10 failed to respond to DLI. PB samples containing more than 90% of 
CLL cells, as assessed by flow cytometric analysis were obtained at diagnosis. In addition, BM and PB 
were obtained from the patients shortly before allogeneic SCT, and before and after the administration 
of DLI at regular time intervals. PB was also obtained from their HLA-identical sibling donors. 
Mononuclear cells (MNC) were isolated from the samples by Ficoll density separation, and 
cryopreserved. Patient- and donor-derived PHA blasts and donor-derived EBV-LCL were generated 
as described previously 27. Due to very low (<1%) normal B-cell counts, no EBV-LCL could be 
generated from the patients. The CLL cells of the patients were modified into APC by IL-4 and CD40 
stimulation as recently described 23. After 4 days of stimulation the CLL cells were harvested, counted 
using eosin exclusion, analyzed by flow cytometry, and used as stimulator cells. T cells, isolated from 
the patient, were enriched from MNC by negative selection using the pan T isolation kit (Miltenyi 
Biotec GmbH, Bergisch Gladbach, Germany). Quantities of 0.5x106-2.5x106 purified in vivo primed T 
cells were stimulated with irradiated (15 Gy) primary CLL or CLL-APC at a responder/stimulator (R/S) 
ratio of 10:1. After 16 hours of stimulation, IFNγ secreting T cells were stained using the IFNγ 
secretion assay (Miltenyi Biotec GmbH) according to the manufacturer’s specifications, and isolated 
by single cell per well FACsorting as described previously 24. Proliferating T cell clones were 
restimulated with feeder-mixture. From day 21 the clones were functionally analyzed. The 
nomenclature used for each T cell clone represents the patient number followed by clone number. For 
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flowcytometric analysis, cells were stained with FITC-conjugated anti-CD3 (BD), anti-CD4, PE-
conjugated anti-CD8 (Caltag, Burlingame, USA) or anti-CD56 (BD), and Cy5-conjugated anti-CD8 
(DAKO, Glostrup, Danmark), and analyzed on a FACScan (BD). 
In vitro generation of CLL-specific CTL from the unprimed donors
Since non-synchronized production of IFNγ by T cells in primary anti-leukemia responses was found 
to hamper the effectiveness of isolation of these cells, the following procedure was adapted (Jedema 
et al., Blood 2003, 102, 722 abstract). After CD14 depletion MNC from the HLA matched sibling 
donors were plated at a concentration of 1 x 106 cell/well in 24-well plates (Costar), and stimulated 
with irradiated CLL or CLL-APC derived from the recipient at a responder/stimulator (R/S) ratio of 
10:1. Low dose IL-2 (10 IU/mL, Chiron) was added at day 7 and 11 to ensure survival but to prevent 
non-specific proliferation of the T cells. At day 14 T cells were specifically restimulated with the 
irradiated CLL-APC or primary CLL. After 16 hours of stimulation the IFNγ secretion assay and the 
single cell per well cloning procedure was performed as described above. The proliferating T cell 
clones were functionally analyzed.
Cytotoxicity assay
To determine the cytotoxicity of the T cell clones standard 4 hours and overnight 51Cr-release assays 
were performed as described previously 23. Primary CLL cells, CLL-APC cells, PHA blasts from patient 
or donor, and/or EBV-LCL from unrelated individuals were used as target cells. T cell clones showing 
more than 10% specific lysis of target cells were considered cytotoxic. To determine HLA class I- and 
II-restriction of the recognition of the target cells, blocking studies were performed by incubating target 
cells with saturating concentrations of α-HLA class I antibodies (W6/32) or α-HLA class II antibodies 
(PdV5.2) for 30 minutes before effector cells added 23. To further analyze the HLA class-restricting 
element of the CTL clones, the clones were tested for reactivity against a panel of EBV-LCL from 
unrelated individuals that shared an HLA molecule with the recipient. For blocking studies α-HLA A2 
(SN66.E3), α-HLA A3 (MUL2.C6), α-HLA BC (B1.23.2), α-HLA DR (B8.11.2) and α-HLA DP (B7.21) 
antibodies (kindly provided by Dr. A. Mulder, Department of Immunohematology and Bloodtransfusion, 
Leiden) were used.
Analysis of cytokine production
For analysis of IFNγ and IL-4 production, 5,000 T cells were cocultured with 30,000 target cells in a 
final volume of 150 µl IMDM supplemented with 10% human serum and 50 IU/mL IL-2. After 24-hours, 
supernatant was harvested, and the concentration of IFNγ and IL-4 was measured in triplicate by 
ELISA (CLB, Amsterdam, The Netherlands). As a negative control T cells were incubated without 
target cells.
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Results
Toxicity and graft-versus-host disease after allogeneic SCT and DLI 
Patients received a median dose of 12.3 x106 CD34+ cells/kg recipient body weight (range 7.9-16.5). 
All patients had sustained neutrophil (>0.1 x 109/L) and platelet recovery (>20 x 109/L) with a median 
time to engraftment of 12 days (range, 10-18 days and 11-18 days, respectively). No graft failures 
were observed. All patients were assessable for toxicity. As shown in table 2, prior to administration of 
DLI no significant GvHD was observed. Only one patient developed grade I acute GvHD of the skin. 
Of the 12 patients, one patient did not receive DLI because of infectious complications after allogeneic 
SCT. The indications for DLI were mixed chimerism (n=1), mixed chimerism and persistent disease 
(n=7) and progressive disease (n=3). According to the protocol, the DLI was given at a median of 6 
months (range 5-13 months). Four patients received one dose of 5 x 106 CD3+ T cells/kg, two patients 
received a lower dose (2.5 x 106 CD3+ T cells/kg because of a MUD allogeneic SCT. Four patients 
received 2 doses and one patient (patient 10) received 5 doses of DLI with a maximum dose of 
1.5x108 T cells/kg because of refractory disease. Four patients developed acute GvHD after DLI (1 
grade I, 2 grade II and 1 grade IV). All four patients developed limited chronic GvHD. Two patients 
died of causes not related to relapse. One patient died at 8 months after allogeneic SCT due to sepsis 
of unknown origin and one patient died at 11 months due to CMV disease with concurrent GvHD after 
the administration of DLI (Table 2). The actuarial probability of TRM at 100 days was 0%, and at the 
end of follow-up (median 21 months) 19%.
Chimerism analysis and disease response to allogeneic SCT and to DLI 
Sequential chimerism studies of BM cells, performed 6 months after allogeneic SCT and before the 
administration of DLI, showed sustained mixed chimerism with a median donor percentage of 68% 
(n=11 range, 1-99 %). Five patients showed conversion to full donor chimerism within 6 months after 
the administration of DLI, and maintained their full donor chimerism status at the time of last 
assessment (see Table 2). In three patients low percentages of donor chimerism after the allogeneic 
SCT and DLI was observed due to rapidly progressive disease. In most cases a reduction of CLL cells 
was observed in flow cytometric analysis of BM before and shortly after allogeneic SCT (data not 
shown). Six months after allogeneic SCT and before the administration of DLI one patient was in CR 
(8%), eight patients had persistent disease (perD, 67%) and three patients had progressive disease 
(PD, 25%). One patient (patient 3) was in CR at the time of allogeneic SCT and remained in CR during 
follow-up of 25 months. In four out of eight patients with perD, the elimination of CLL cells in BM was 
observed after the administration of DLI, resulting in an ongoing CR. In one of these four patients, the 
CR was unconfirmed because of persistent abdominal lymphadenopathy (patient 5). This patient died 
of infectious complications related to the DLI. Patient 1 had still perD 3 months after DLI. Patient 4 and 
11 with perD were not evaluable for disease response because of too short follow-up after DLI and 
death, respectively. Patient 10 developed PD despite the administration of escalating doses of DLI. 
Three patients suffered from PD shortly after allogeneic SCT. None of them showed any disease 
response upon the cellular adoptive therapy. Two of these patients (patient 2 and 8) received a 
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second transplant from the orginal donor with a myeloablative conditioning. Patient 2 ultimately died 
from PD. At a median follow-up time of 21 months (range, 5-61 months) nine patients are alive. 
Kaplan-Meier estimated probabilities of overall survival (OS) and event-free survival (EFS) are shown 
in Figure 1. At 2 years the OS was 67% and EFS was 33%.
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Figure 1. Overall survival, event-free survival and treatment-related mortality after in vitro T-cell depleted 
allogeneic SCT and the administration of DLI. OS, overall survival, ESF, event-free survival, TRM treatment-
related mortality.
Isolation of CLL-reactive T cells in patients with clinical responses
To analyze graft-versus-CLL responses two patients were studied in detail. Patient 6 responded to 
DLI, whereas patient 10 failed. As shown in figure 2A, patient 6 converted to full donor chimerism after 
the application of two doses of DLI and flow cytometric analysis of the BM remained negative for CLL 
cells. In contrast, patient 10 initially partially responded to DLI but despite 5 doses of DLI (maximum 
dose 1.5x108 T cells/kg) he suffered from progressive disease (Figure 2B). He developed grade I 
GvHD of the skin for which local corticosteroid ointment was applied. 
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Figure 2. Patients chimerism, measured in BM and % of CLL cells in BM as determined by flow cytometry 
after allogeneic SCT and the administration of DLI. (A) In patient 6 disappearance of CLL cells in BM was 
observed after the administration of DLI and the patient converted to full donor chimera, resulting in a durable 
complete remission. (B) Patient 10 suffered from progressive disease after an initial response to DLI. (* timepoints 
of withdrawal of blood samples for in vitro postDLI experiments)
T cells responding to in vitro stimulation with the leukemia by the production of IFNγ were sorted one 
cell per well. As illustrated in figure 2, the T cells were isolated from the two patients 6-7 weeks after 
the application of DLI. The percentages of IFNγ secreting T cells in the purified T cell population from 
patient 6 after 16 hour of stimulation with primary CLL was 0.04% and with CLL-APC 0.22%. From 
patient 6, 23 proliferating clones out of 192 sorted T cells were obtained in response to primary CLL 
(plating efficiency 12%), and three of these clones exerted cytolytic activity against CLL-APC but not 
against primary CLL (data not shown). Using CLL-APC as stimulators, 148 T cell clones were isolated 
out of 1346 sorted T cells, resulting in a plating efficiency of 11%. As illustrated in Figure 3A, 13 out of 
these 148 proliferating clones showed specific lysis of CLL-APC (46% ± 14%, mean ± SD) and 8 of 
these CTL clones showed reactivity against primary CLL (24% ± 17%) in overnight 51Cr assays 
indicating that they recognized CLL targets. IFNγ was produced by all of these cytotoxic clones in 
response to CLL and CLL-APC (255 ± 197pg/mL and 546 ± 375 pg/mL respectively, Figure 3B) 
whereas no production of IFNγ was found by randomly tested non-cytotoxic T cell clones. None of the 
CTL clones produced IL-4. All clones were CD8+ except for two CD4+ clones (clone 6.28 and 6.96). 
Three CTL clones (clones 6.15, 6.70 and 6.85) recognized PHA blasts of the patients (lysis 59%, 66% 
and 23% respectively). No reactivity with donor PHA blasts was observed.
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Figure 3. Characterization of CLL-reactive and mHag-specific CTL clones, derived from patient 6 six 
weeks after the application of DLI. (A) Cytolytic activity of CTL clones generated by stimulation of T cells, 
obtained from the patient six weeks after DLI with CLL-APC of the patient. All clones were CD8+ except for the 
two CD4+ clone 6.28 and clone 6.96. The percentage of lysis against different targets was measured in an 
overnight 51Cr-assay at an E/T ratio of 10:1. (B) All cytotoxic clones (n=13) produced significant amounts of IFNγ 
in response to CLL and CLL-APC (255 ± 197 pg/mL and 546 ± 375 pg/mL, respectively). (C) HLA class I- and II-
restricted recognition of the cytotoxicity was shown by blocking experiments using CLL-APC or PHA blasts of the 
patients (clone 6.15) as target at an E/T ratio of 10:1. Anti-HLA-BC MoAb blocked the recognition of clone 6.15 
and 6.70 but not the cytotoxicity of clone 6.49. (D) Cytolytic activity of clone 6.28 and clone 6.96 was abrogated 
by anti-class II MoAb. The cytotoxicity of clone 6.96 could be blocked by anti-HLA-DP MoAb.
To further characterize the CTL clones obtained, blocking studies were performed. Cytolytic activity of 
three representative CD8+ clones 6.15, 6.49 and 6.70 could be abrogated using the α-HLA class I 
MoAb (figure 3C) confirming HLA-restricted recognition. Additional experiments showed that α-HLA 
BC MoAb could block the recognition by clone 6.15 and 6.70 and not the cytotoxicity of clone 6.49 
(figure 3C). A blocking study using α-HLA A2 MoAb (SN66.E3) showed HLA-A2-restricted recognition 
of clone 6.49 (data not shown). To further analyze and confirm the HLA-restricting molecule, clones 
6.15, 6.49 and 6.70 were tested for reactivity against a panel of EBV-LCL from unrelated individuals 
that shared an HLA allele with the recipient. Clone 6.15 demonstrated HLA-B51-restricted recognition, 
clone 6.49 HLA-A2-restricted recognition and clone 6.70 exerted its reactivity in a HLA-B53-restricted 
way. The cytotoxicity of the CD4+ clones 6.28 and 6.96 could be blocked by α-HLA class II MoAb 
(figure 3D). Cytolytic activity of clone 6.96 could be blocked by α-HLA DP MoAb (figure 3D). In patient 
CD4
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10 T cells obtained 6-7 weeks after the first, and 6-7 weeks after the second application of DLI were 
stimulated for 16 hours with primary CLL or CLL-APC in three independent experiments. The 
percentages of IFNγ secreting T cells in the purified T cell population were 0.07% to 0.11% in 
response to primary CLL and 0.09% to 0.16% in response to CLL-APC. After single cell per well 
sorting of the viable IFNγ-PE+ cells, no proliferating clones were obtained in response to primary CLL 
and a total of 13 proliferating T cell clones were obtained using CLL-APC as stimulator cells. None of 
these T cell clones, recognized CLL-specific and/or patient-specific targets nor did they produce any 
IL-4 or IFNγ upon stimulation (data not shown). In summary, the experiments performed with the in 
vivo primed T cells from patient 6 showed that comparable percentages of proliferating T cell clones 
were obtained in response to primary CLL and CLL-APC. However, the stimulation with CLL-APC 
resulted in a more efficient isolation of CTL clones reactive to primary CLL, suggesting that primary 
CLL as weak immunogenic APC has limited capacity to activate CLL-reactive T cells. From patient 10 
suffering from PD despite the administration of several doses of DLI, no CLL-reactive CTL clones 
could be obtained in response to primary CLL or CLL-APC.
In vitro generation of CLL-reactive CTL clones from the unprimed donors
We have previously demonstrated that CLL-APC were immunogenic and capable of inducing mHag-
specific and CLL-reactive T-cell responses in unprimed HLA-matched sibling donors (Hoogendoorn et 
al., Blood 2002, 100, 387abstract). To investigate whether a precursor CLL-reactive T-cell repertoire 
was present in the transplant donor of patient 10 despite the absence of a persistent clinical response 
to DLI in patient 10, a primary T-cell response against CLL-APC and primary CLL was generated. T 
cells derived from the specific donor were stimulated with CLL or CLL-APC. After 14 days of culture 
the T cells were specifically restimulated and responding T cells were selected on basis of their IFNγ 
production. Using CLL as stimulator cells, 67 proliferating clones could be tested for cytotoxicity 
resulting in one CD4+ CTL clone with reactivity against CLL-APC (data not shown). After stimulation 
with CLL-APC 129 proliferating clones were obtained, reflecting a high plating efficiency of 44 %. Of 
these clones 35 (34 CD8+ and one CD4+ clone) showed cytotoxicity against CLL-specific and/or
patient-specific targets. As illustrated In Figure 4A representative CD8+ CTL clones and the CD4+ CTL 
clone effectively lysed the primary CLL, the CLL-APC and PHA blasts from the patient and not donor 
PHA blasts in 4 hour and overnight 51Cr assays indicating that the majority of these clones were 
mHag-specific. HLA-restricted recognition was demonstrated by blocking experiments (Figure 4B). 
Additional experiments demonstrated that several clones (e.g. clone 10.6, 10.9 and 10.37) had the 
same HLA-restriction element. The cytolytic activity of these clones could be abrogated with α-HLA-A3 
antibodies (figure 4B). Other clones (clone 10.107 and clone 10.131) exerted their activity in a HLA-
B35-restricted way (data not shown). In conclusion, we demonstrated the feasibility to generate a CLL-
reactive mHag-specific CTL response from the stem cell donor of patient 10, illustrating the presence 
of precursor leukemia-reactive T cells in the unprimed donor. The T-cell responses could only be 
induced against CLL-APC indicating the limited APC function of the primary CLL which might in part 
underlie the absence of the clinical response.
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Figure 4. Cytotoxicity of CTL clones, derived from the unprimed donor of patient 10, using CLL-APC as 
stimulator cells. (A) Percentage lysis of CLL-specific targets and patient- and donor-derived PHA blasts in an 
overnight 51Cr-assay at E/T ratio of 3:1. All clones were CD8+ except for the two CD4+ clones 10.15 and 10.120. 
(B) Blocking experiments confirmed HLA-restricted recognition by the CTL clones, and showed that the HLA-
restricted element for clone 10.6, 10.9 and 10.37 was A3.
Discussion
Our study demonstrates that in vitro T-cell depletion using alemtuzumab “in the bag” and high doses 
of donor stem cells resulted in sustained donor engraftment and high percentages of donor chimerism 
after allogeneic SCT without causing significant GvHD. This T-cell depleted RIC regimen was well 
tolerated in this older patient population (median age, 56 years), and was associated with acceptable 
toxicity and no TRM after 3 months 19,20,22,28. Nine patients had improvement of percentages of CLL 
cells in the BM after allogeneic SCT suggesting that alemtuzumab “in the bag” may exert its anti-CLL 
effect in vivo thus offering a window of 6 months after allogeneic SCT to allow postponed cellular 
adoptive therapy. This time frame may be necessary to replace the majority of the dendritic cells of the 
patient by donor dendritic cells thereby diminishing the occurrence of GvHD after DLI administration 21. 
All patients were mixed chimeras and 11 out of 12 had persistent CLL cells in the BM 6 months after 
allogeneic SCT indicating that after the depletion of graft T cells by alemtuzumab, the application of 
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DLI is pivotal to achieve maximal disease responses and full donor chimerism. In our study DLI was 
projected to be administered in all patients. The sufficient high levels of donor chimerism and low 
incidence of GvHD after in-vitro T-cell depleted RIC allogeneic SCT was a prerequisite for this two-
step approach. 
Eleven out of 12 patients received DLI, and 6 out of these 11 patients could be evaluated after a long 
follow-up time post-allogeneic SCT (≥ 18 months) and post-DLI (≥ 12 months). Five patients converted 
to full donor chimerism after DLI. Four of these patients had an excellent and durable clinical 
response, clearly illustrating that CLL is susceptible to a GvL effect, and that GvL-mediated disease 
control is durable and has the potential to cure. Other patients experienced PD despite several 
administrations of DLI. To analyze the graft-versus-CLL effect and to elucidate discrepancies of 
clinical responses in patients subjected to DLI for persistent disease, we performed experiments using 
PB from patient 6 successfully treated with DLI and from patient 10, suffering from disease 
progression despite DLI. T cells reactive against primary CLL or the CLL-APC by producing IFNγ were 
isolated and cloned from the PB derived from the patients at the time of clinical response to DLI. We 
and others have demonstrated that this method enriches for tumor-reactive T cells, and allows 
characterization of the T-cell repertoire involved in the immune response against the original leukemia 
24,29,30. 
Our post-DLI experiments demonstrated that the stimulation of the in vivo primed T cells of patient 10 
with primary CLL cells or CLL-APC did not result in the isolation of CLL-reactive CTL clones. The 
clinical course of patient 10 may be illustrative for patients with CLL, treated with a RIC allogeneic 
SCT in which persistent disease or relapses are frequently reported 19,20,30,31. As demonstrated in 
figure 2B, after DLI donor chimerism initially gradually increased from 75% to 96% with concurrent 
very low percentages of CLL cells in the BM, but the initiated T-cell response was then apparently 
incapable of definitely eradicating the leukemia. These results suggest that the persistent primary CLL 
cells did not have the capacity to induce or further amplify a CLL-specific immune response. To further 
differentiate whether our observations in this patient can be explained by low immunogenicity of the 
CLL cells or whether precursor CLL-reactive and/or mHag-specific T cells were absent in the donor, a 
primary immune response was induced. Similar to results previously published 23, no CLL-reactive T-
cell responses could be generated against primary CLL cells. As illustrated in figure 4, CD8+ and CD4+
CTL clones, reactive to CLL-specific targets could be isolated from the primary allogeneic T-cell 
response against CLL-APC. Several CD8+ mHag-specific CTL clones, effectively killing CLL- and 
patient-derived targets were further analyzed, and were determined to be HLA-A3 (clone 10.6, 10.9 
and 10.37) and HLA-B35 restricted (10.107 and 10.131). These results demonstrate that precursor 
CLL-reactive mHag-specific T cells present in the donor can not be adequately stimulated by the low 
immunogenic primary CLL cells. Thus, after allogeneic SCT and the application of DLI, the persistent 
or recurrent primary CLL cells may escape T-cell surveillance probably due to the lack of APC 
function, and this may result in the absence of a clinical response. 
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From PB derived from patient 6 six weeks after the application of DLI a diversity of CLL- and patient-
reactive CD4+ and CD8+ CTL clones were isolated after in vitro stimulation with CLL-APC, and a few 
CTL clones reactive to CLL-APC were isolated after stimulation with primary CLL. Although stimulation 
with primary CLL cells did result in the isolation of a limited number of CLL-reactive T cells, a higher 
proportion of CLL-reactive T cells was induced to proliferate in response to CLL-APC resulting in a 
more effective isolation of these cells. As illustrated in figure 3, the CTL clones isolated in response to 
CLL-APC were probably directed against different mHags, and showed HLA-B51-(clone 6.15), HLA-
B53-(clone 6.70) and HLA-A2-(clone 6.49) restricted recognition by the CD8+ CTL clones, and HLA-
DP-restricted recognition by a CD4+ CTL clone (6.96). In accordance with our previous reports, this 
study confirms that T cells involved in efficient immune responses after the application of DLI are often 
directed against different distinct mHags 24,30. Furthermore, these data suggest that the good clinical 
response after DLI in this patient is related to the presence of multiple CLL-reactive mHag-specific T 
cells. Our results provide direct evidence for the GvL reactivity, and illustrate the susceptibility of CLL 
cells to a GvL effect. However, our data also illustrate that the primary CLL cells may not efficiently 
stimulate the proliferation of the mHag-specific CLL-reactive T cells, even after in vivo priming. In vivo
an adequate alloimmune response in this patient against patient-derived hematopoiesis including the 
primary CLL was observed, resulting in an excellent durable clinical response. The primary CLL cells 
from this patient were also not capable of inducing CLL-reactive T-cell responses in vitro. We 
hypothesize that the GvL effect in this patient is largely mediated by donor T cells, showing 
alloreactivity against mHag expressed on residual recipient APC, or engrafted donor APC efficiently 
cross-presenting alloantigens expressed on CLL cells.
In conclusion, in this study we illustrated the feasibility of in vitro T-cell depleted RIC allogeneic SCT 
followed by DLI in patients with advanced CLL. We characterized the GvL effect in a patient with a 
continuing CR and analyzed a patient with treatment failure both after the application of DLI. In the 
patient with progressive disease, although an initial partial response was suggested, the primary CLL 
cells ultimately escaped from T-cell mediated recognition. Experiments with in vivo primed T cells, 
isolated from that patient after DLI, illustrated the incapacity of these T cells of inducing an appropriate 
immune response against primary CLL and even against CLL-APC. These results showed that the 
inappropriate APC function of primary CLL might in part underlie the absence of a clinical response. 
We further demonstrated that precursor CLL-reactive T cells were present in the unprimed donor but 
these T cells could only be activated in response to CLL-APC. We hypothesized and provided 
evidence that the observed GvL effect in patient 6 was mediated by CLL-reactive mHag-specific T 
cells which were probably cross-primed by recipient- and/or donor APC. New cellular 
immunotherapeutic approaches to DLI necessary to improve specificity and efficacy of the GvL 
response, may be the in vitro generation of CLL-reactive T cell lines and clones from the donor using 
CLL-APC as stimulator cell 23. The repetitive stimulation with CLL-APC may ultimately result in a 
relatively enrichment of leukemia-reactive T cells compare to GvHD-mediating T cells. Furthermore, by 
in vitro priming of CLL-reactive donor T cells against CLL-APC T-cell anergy towards primary CLL may 
be minimized.
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Summary
Patients with chronic B-cell malignancies such as chronic lymphocytic leukemia (CLL) or mantle cell 
lymphoma (MCL), who have failed to respond to anthracycline- or fludarabine-based chemotherapy 
have a poor prognosis. For these patients new effective therapies with the potential to cure are 
needed. Prolonged remissions have been achieved with conventional allogeneic stem cell 
transplantation (SCT). Unfortunately, this procedure is hampered by a high treatment-related mortality 
(TRM) rate and thus only suitable for younger patients 1. In patients treated with an allogeneic SCT 
long-term survival curves approach a plateau, and the achievement of a molecular remission is more 
likely than after autologous SCT, suggesting a graft-versus-leukemia (GvL) effect. Complete 
remissions after the administration of donor lymphocyte infusions (DLI) further provide evidence for 
susceptibility of CLL cells to a GvL effect 1-5 . Because the graft-versus-CLL effect is crucial for 
eradication of the disease, the intensity of the conditioning regimen may not be as important in CLL as 
in other diseases. In this regard, reduced intensity conditioning (RIC) regimens are being extensively 
investigated 3,6. RIC regimen may reduce the TRM and extend the age limit of the procedure 6. Donor-
derived alloreactive T cells are not only responsible for GvL, but may also mediate graft-versus-host 
disease (GvHD) which accounts for considerable morbidity and mortality. The incorporation of 
alemtuzumab in the conditioning regimen to deplete recipient and donor T cells significantly reduces 
the risk for GvHD but may potentially impair the GvL effect. The early administration of sequential DLI 
after transplantation is then pivotal to achieve durable disease control 4,7-9. Although DLI can be 
effective in reversing mixed chimerism in patients treated with a T-cell depleted RIC allogeneic SCT, it 
may not be sufficient to control relapsed or progressive disease 4,9. One of the explanations for the low 
efficacy of DLI in CLL and MCL may be the lack of costimulatory signals on these malignant cells, 
resulting in an impaired T-cell activation and recognition. T cells recognize their targets through their 
antigen-specific T cell receptor (TCR) that recognizes peptides in the context of HLA molecules. For 
further T-cell activation and proliferation the expression of costimulatory and adhesion molecules on 
the stimulator cells are essential. In this thesis we investigated methods to modify primary CLL and 
MCL cells into an antigen-presenting cell (APC) phenotype capable of inducing an anti-leukemic T-cell 
response of donor T-cells in vitro. To further analyze graft-versus-CLL activity in patients treated with 
allogeneic SCT and DLI, T-cell responses after DLI were characterized.
In chapter 2 we described the expression levels of several costimulatory and adhesion molecules on 
CLL cells of 14 patients and showed high expression of HLA class I and II, and CD40 but lack of 
expression of CD80, CD86 and CD83 and minimal expression of the adhesion molecules CD54 and 
CD58. To improve the immunogenicity of the CLL cells several cytokines were tested for their 
upregulating capacity. No significant upregulation of adhesion and costimulatory molecules with the 
cytokines or cytokine combinations was found. Since malignant B cells abundantly express toll-like 
receptor (TLR) 9 and since signalling through TLR can activates APC, CpG an agonist of TLR 9 was 
tested for its stimulatory capacity. CpG in combination with IL-4 induced an increased expression of 
costimulatory and adhesion molecules. However, CD40 activation by crosslinking using murine 
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fibroblasts transfected with human CD40L was superior in activating primary CLL cells and 
transformed these cells into characteristic APC phenotypes. The addition of IL-4 further enhanced 
expression levels. Time kinetic studies determined that 4 days of stimulation caused the strongest 
upregulation of costimulatory signals. After CD40 and IL-4 stimulation, the CLL cells were induced to 
produce significant amounts of IL-12. To test the allostimulatory capacity of the generated CLL-APC T 
cells from HLA class I-matched donors were repetitively stimulated with the primary CLL or CLL-APC. 
In contrast to primary CLL cells, CLL-APC as stimulator cells were capable of generating CLL-reactive 
cytotoxic T lymphocytes (CTL) lines and clones.
To investigate whether CD40 and IL-4 stimulated CLL cells are sufficiently immunogenic to initiate an 
adequate alloimmune response in vitro in a complete HLA-matched setting representing a clinical 
applicable transplantation model, primary induction of immune responses were performed using the 
generated CLL-APC as stimulator cells and using T cells from complete HLA-matched siblings. As 
described in chapter 3, only CLL-APC could stimulate precursor CLL-reactive donor-derived T cells to 
proliferate. In all three donor/patient pairs leukemia-reactive CD8+ and/or CD4+ CTL clones could be 
obtained, recognizing their targets in a MHC-restricted way. Further characterization of these clones 
revealed that primary CLL, CLL-APC as well as patient-derived targets such as phytohemagglutinin 
activated T cells (PHA blasts) and stable EBV transformed B cells (EBV-LCL) and no donor cells were 
recognized. Thus these clones were minor histocompatibility (mHag)-specific and the recognized 
mHag was not B lineage-restricted. Mhag are immunogenic alloantigens capable of eliciting an 
allogeneic T-cell response between HLA-matched individuals. For one CD8+ CTL clone panel studies 
were performed, illustrating that the recognition of the targets by this clone was HLA-B8-restricted.
These results showed the feasibility of CLL-APC to initiate CLL-reactive T-cell responses in HLA-
matched settings thereby translating the results from chapter 2 into a transplantation model mimicking 
clinical practice. Hence, based on these results, the application of in vitro generated CLL-reactive CTL 
clones as adoptive immunotherapy to treat disease recurrence after allogeneic SCT may be an 
effective potential curative approach.
In chapter 4, the modification of MCL cells into APC was analyzed. The MCL-specific cytokine IL-10 
and B-cell specific cytokine IL-4, as well as CpG and CD40 activation were tested for their MCL-
stimulating capacity. Ligation of CD40 on MCL cells was essential to upregulate costimulatory 
molecules and to induce the production of high amounts of IL-12. In response to these MCL-APC, 
from HLA class I-matched donors, high numbers of CTL clones could be generated capable of 
efficiently killing the MCL- and patient-specific targets and not donor-derived targets. Thus, the primary 
induction of MCL-reactive immune responses against MCL-APC was shown to be feasible.
In chapter 5 we report the results of 12 patients with advanced CLL, treated with a T-cell depleted 
RIC allogeneic SCT, using alemtuzumab in the graft to deplete for donor and recipient T cells to 
reduce GvHD, followed by DLI. The administration of DLI was anticipated to promote GvL activity and 
achieve disease control. Using this transplantation protocol sustained donor engraftment without 
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GvHD prior to the administration of DLI was observed. It was shown that in some patients long durable 
remissions were obtained whereas in other patients persistent or progressive disease, despite the DLI 
was observed. To further characterize these differences in clinical response, in vitro experiments were 
performed using T cells, isolated from patients responding and non-responding to DLI and using T 
cells from the unprimed donor. The T cells were stimulated with the primary CLL or the CLL-APC.
Enrichment of leukemia-reactive T cells was achieved using a new developed protocol, selecting IFN 
γ-producing T cells in response to the primary CLL or the CLL-APC. In accordance with data 
presented in chapter 2 and 3, we showed that primary CLL cells as stimulators could not activate in 
vivo primed CLL-reactive T cells. Only CLL-APC could induce CLL-reactive mHag-specific T-cell 
responses in the patient with a good clinical response, but not in the patient who failed to respond to 
DLI. In the unprimed donor from the nonresponding patient precursor CLL-reactive T cells could be 
activated in response to CLL-APC and CTL clones were obtained. These results demonstrated that 
precursor CLL-reactive T cells present in the donor could not be adequately stimulated by primary CLL 
illustrating the lack of APC function of the leukemic cells. The CLL-reactive T cells were therefore 
incapable of mounting an adequate immune response against residual CLL applying evidence for the 
clinical observations of continuous relapses after allogeneic SCT and the administration of DLI in 
patients suffering from CLL. From the patient with an excellent clinical response CLL-reactive mHag-
specific T cell clones could be isolated in response to CLL-APC and not in response to primary CLL. 
We hypothesized that in this patient CLL-reactive T cells were probably stimulated by professional 
APC cells from donor or patient origin and that these alloreactive T cells had the capacity to definitely 
eradicate residual disease.
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General Discussion
Several studies have shown that allogeneic SCT has the potential to cure patients with advanced B-
cell malignancies. Survival curves of patients, treated with an allogeneic SCT show a plateau phase 
and complete molecular remissions have been reported after the application of DLI, suggesting the 
existence of GvL reactivity. Allogeneic SCT can be complicated by GvHD due to donor T cells in the 
graft, alloreactive to major or minor histocompatibility antigens (mHag). We and others have 
demonstrated that GvHD can be reduced by T-cell depletion of the stem cell graft but this also results 
in a higher incidence of relapse of the disease. The administration of donor T cells is then pivotal to 
mediate GvL activity and achieve disease control, but successful DLI is often associated with 
concurrent GvHD. Infusion of low numbers of DLI may reduce the incidence of GvHD while 
maintaining the GvL effect 7,10. Ideally, selection, isolation and the application of donor T cells, that are 
specifically reactive with the malignant cells or with the recipient hematopoietic cells including 
leukemic cells may result in the separation of the beneficial GvL effect from the detrimental GvHD. In 
chapter 5 we reported the outcomes of 12 patients with CLL treated with an RIC allogeneic SCT 
followed by the infusions of escalating doses of DLI. In line with other reports we showed that some 
patients experienced an excellent clinical response, whereas other patients were unresponsive to DLI 
and suffered from continuous relapses 4,8,9. In vitro experiments in an unresponsive patient, described 
in chapter 5, showed that CLL-reactive T-cell responses could be evoked by CD40 and IL-4 stimulated 
CLL (CLL-APC) cells and not by primary CLL in the unprimed donor. Experiments with T cells, isolated 
from that patient after DLI and thus donor T cells in vivo primed with primary CLL, illustrated the 
incapacity of these T cells of inducing an appropriate immune response against primary CLL and even 
against CLL-APC. These results showed that the inappropriate APC function of primary CLL might in 
part underlie the absence of a clinical response. Furthermore precursor CLL-reactive T cells might be 
silenced in vivo by primary CLL and could not be activated ex vivo by CLL-APC. In other patients 
excellent clinical responses were observed after allogeneic SCT and the application of DLI. In 
experiments using T cells isolated from a patient successfully treated with DLI, CLL-reactive T-cell 
responses could be evoked against CLL-APC but not against primary CLL suggesting that these 
leukemic-reactive T cells are probably in vivo stimulated by professional APC from the donor or the 
patient. These results illustrated that clinical responses to DLI are difficult to predict and that the 
efficacy of adoptive cellular immunotherapy in chronic B-cell malignancies needs to be improved.
An important reason for the limited GvL activity after DLI in CLL and/or MCL might be the inability of 
these malignant cells to properly function as APC and thus initiate an adequate T-cell response. In the 
chapters 2 and 4 several methods were analyzed to improve the immunogenicity of the neoplastic B 
cells. Primary CLL and MCL cells could be phenotypically and morphologically transformed into APC 
with high expression of costimulatory and adhesion molecules by CD40 stimulation using murine 
fibroblast cells transfected with human CD40L. The malignant APCs produced significant amounts of 
IL-12, a pivotal cytokine for T cell activation and neglectable amounts of IL-10. Since the transfected 
fibroblasts are not clinical grade, modification of the leukemic cells into APC using clinical grade 
available cytokines or microbial components, capable of triggering TLRs on the malignant cells, was 
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investigated. The CD40/CD40L pathway appeared to be critical for the stimulation of CLL and MCL 
cells. Therefore, effort should be put into the development of CD40 system under good manufacturing 
practice (GMP) conditions, permitting clinical application of the obtained malignant APCs. As 
alternative for the transfected murine fibroblasts, several candidates are under development such as 
anti-CD40 beads or humanized trimeric soluble CD40L 11,12. Preliminary results showed that these 
products are inferior to the CD40L transduced fibroblasts. Autologous T cells activated to express 
CD40L can after engagement of CD40 on the leukemic cell induce upregulation of costimulatory 
molecules. Another approach to enhance the immunogenicity of primary CLL cells can be the direct 
gene transfer of CD40L into CLL cells via adenovirus vectors or the in vitro infection of CLL cells with 
vectors encoding for the costimulatory molecules 13,14.
The stimulatory capacity of the malignant APCs to induce tumor-reactive T-cell responses using HLA-
matched donors was analyzed in chapter 2, 3 and 4. In contrast to the primary malignant B cells, CLL-
APC and MCL-APC induced vigorous expansion of tumor-reactive CD8+T cell lines in HLA class I-
matched donors. Single cell per well sorting resulted in CLL-reactive and MCL-reactive T cell clones. 
These clones recognized also other patient-derived lymphohematopoietic targets and not donor cells 
indicating recognition of tumor-associated mHags. In chapter 4 we showed that the obtained CLL-APC 
were sufficient immunogenic to initiate an adequate alloimmune response in vitro in a complete HLA-
matched setting representing a clinical applicable transplantation model. These results illustrate that 
by modifying the B-cell malignancies into appropriate malignant APCs, T-cell anergy can be 
overcome. Our method of repetitive in vitro stimulation of donor T cells with the generated malignant 
APC and the extensive culture period needed for the enrichment, selection, and expansion of 
leukemia-reactive T cells is time consuming, inefficient and may have lead to the selection of a 
population of T cells with a limited residual capacity to survive and expand in vivo. We have 
demonstrated the possibility to early detect and isolate leukemia-reactive T cells in peripheral blood of 
patient treated with DLI based on the production of interferon (IFN) γ in response to the leukemic cells 
15. This procedure using the IFNγ-secretion assay appeared to select for a population of T cells 
containing high frequency of leukemia-reactive T cells with direct cytolytic activity against 
hematopoietic cells from the patient. As illustrated in chapter 5, using the IFNγ-secretion assay and 
CLL-APC as stimulator cells, CLL-reactive T cells could be isolated from patients, treated with DLI. 
Recently, we adapted this procedure for the early detection and isolation of leukemia-reactive T cells 
from primary immune responses using phenotypically appropriate APC, generated from the primary 
leukemia. HLA-matched donor T cells were cocultured with the leukemic APC for two weeks under 
mild stimulatory conditions to enrich for the leukemia-reactive T cells. These T cells were then 
specifically restimulated with the leukemic APC resulting in a synchronized IFNγ by the responding T 
cells16. The feasibility of this strategy was illustrated by the experiments in chapter 5 demonstrating the 
generation of CLL-reactive T cells from an unprimed donor. Furthermore our data showed that the in 
vitro culture periods could be significantly shortened using this method.
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As described in the chapters 2, 3 and 4, the CLL-reactive and MCL-reactive CTL clones were further 
characterized for their specific recognition of leukemic cells. The obtained CTL clones were cytotoxic 
against tumor-specific targets as well as patient-derived targets such as PHA stimulated lymphocytes 
and EBV-transformed B-cells patient- and not donor-specific targets, indicating that these clones were 
mHag-specific. Based on these experiments, we could exclude that the recognized mHags were B-cell 
lineage restricted. Blocking studies confirmed the HLA restricted recognition and in chapter 3 the 
restriction allele of a CTL clone could be determined using panel studies. In this thesis we illustrated 
the capacity of malignant APC of eliciting CLL- and MCL-reactive mHAg-specific T-cell responses in 
vitro, thereby showing the immunotherapeutic potential of such approach. However, the clinical 
outcome of T-cell responses against mHags may be largely determined by the tissue distribution of 
these mHags. T-cell responses against mHags that are selectively expressed in hematopoietic cells, 
including malignant cells such as HA-1, HA-2, BCL2A1, HB-1, endothelial-cell growth factor-1 
(ECGF1) or PANE1 but not widely expressed in non-hematopoietic tissues may be preferentially 
associated with GvL activity 17-23. Molecular characterization studies of human mHag showed that 
most non-sex-linked mHags are created by single nucleotide polymorphisms in the coding sequences 
of cellular genes. Since such polymorphisms are frequently encountered in the human genome, one 
might suggest that the total number of human mHags is likely to be quite large. Unfortunately, only a 
small number of mHags with the requisite tissue distribution to evoke a selective GvL response has 
been identified 19,21,22. The allele frequency and the MHC restriction of the identified hematopoietic-
restricted mHag further limit the clinical application. The identification of novel hematopoiesis-
restricted mHags should have the highest priority. A strategy to partially circumvent these problems 
may be the retroviral transduction of T cells with T cell receptors that recognize hematopoiesis-
resticted mHag. Unfortunately, this transduction technique is yet not clinical grade available 24. 
Recently, a promising novel HLA-A3-restricted mHag, which is preferentially highly expressed in 
resting B-lymphoid cells including CLL cells, has been identified 20. This mHag might be an attractive 
target for adoptive immunotherapy but the clinical implications may be limited due to infrequent 
donor/recipient disparity.
We and others have previously shown that low numbers of non-selected donor T cells, infused 6 
months after an allogeneic SCT may cause minimal GvHD while GvL activity is achieved 7,10. An 
explanation may be the replacement of recipients APC by APC of donor origin thereby diminishing the 
likelihood of development of GvHD caused by specific recognition of professional APC 25. Once 
recipient hematopoiesis and the professional APC of the recipient are completely replaced by donor 
hematopoiesis, relapsing leukemic cells may be the only allogeneic trigger to activate alloreactive 
donor T cells. However, as illustrated in experiments performed in chapter 5, despite the present of a 
CLL-reactive mHag-specific T-cell repertoire in the donor, the naïve CLL cells were not recognized by 
these T cells probably due to low immunogenicity of the leukemic cells. Next, we demonstrated that 
the inability of the precursor CLL-reactive T cells to proliferate in response to the primary CLL cells 
can be overcome by the repetitive in vitro stimulation of these T cells against CLL-APC. We now 
hypothesize that these in vitro generated leukemia-reactive T cells may eradicate residual CLL cells in 
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vivo and may mediate only minimal or no GvHD. The repetitive stimulation with CLL-APC may 
ultimately result in a relatively enrichment of leukemia-reactive T cells compare to GvHD-mediating T 
cells. Furthermore by in vitro priming of CLL-reactive donor T cells against CLL-APC, T-cell anergy 
towards primary CLL may be minimized. In case of minimal residual disease this highly specific 
cellular immunotherapy may be appropriate to eliminate persistent tumor cells. However, for 
progressive disease after allogeneic SCT this intervention may not be sufficient and higher T cell 
doses may be necessary to increase the efficacy. In this setting several strategies to limit the 
occurrence of severe GvHD while preserving GvL activity can be considered. High doses of specified 
T cells or low dose DLI in combination with leukemia-reactive T cells can be administered. In addition, 
CD8+ alloreactive T-cells are considered to be main effectors of GvHD and may not be necessary for 
the GvL reactivity 26. Non-selected CD4+T cells as DLI may exert some cytolytic activity against the 
neoplastic B cells and may in combination with in vitro generated tumor-reactive CTL provide 
activating cytokines and help for the cytotoxic T cells. Alternatively, the generation of purified CD4+
leukemia-reactive cytotoxic T cells using the IFNγ capture assay may also be feasible.
Another immune-based strategy bypassing the risk for GvHD may be the induction of tumor-antigen-
specific T-cell responses. Several tumor-associated antigens such as the tumor-specific idiotype, 
fibromodulin, murine double minute 2 (MDM2), Survivin or KW-13 can be expressed in CLL and MCL 
cells 27-32. CD34+-derived and/or CD14+-derived APC from donor origin may be pulsed with the 
peptides, encoding for the tumor-antigens. Hence, antigen-specific donor T-cell responses can be 
induced and may be infused in the patient. However, probably due to low avidity of the T cell receptor 
for the specific tumor-antigen, these induced T-cell responses are often not robust and do not result in 
a powerful antileukemic effect. Furthermore tumor-antigen expression is variable among on the 
malignant cells, the tumor cells can escape recognition by specific T cells by downregulating the 
antigens or selection of leukemic cells lacking tumor-antigen expression may occur. Finally these 
procedures require extensive in vitro manipulation, are time consuming and are not clinical grade 
available yet. Vaccine strategies to induce leukemia-reactive T-cell responses in vivo are subject of 
many studies 13,33,34. In autologus setting vaccinations with retroviral CD40L-transduced CLL cells 
showed an effective T-cell response against autologous leukemic cells but these T-cell responses 
were transient and no memory response could be evoked. Antileukemic vaccines composed of the 
leukemic blast fused with skin fibroblasts transduced to express human CD40L and IL-2, applied after 
allogeneic SCT was shown to be feasible without inducing GvHD 34. Leukemia-reactive immune 
responses with a clinical response were observed. Several vaccine-based strategies in patients 
treated with a RIC allogeneic SCT for advanced chronic B-cell malignancies, using our in vitro
generated CLL-APC or MCL-APC as vaccines can be developed. Because vaccination of the donor 
using vaccines composed of the malignant cells of the patients is unethical, the vaccines should be 
applied to the patient after the RIC allogeneic SCT. Most clinical trials with cancer vaccines conducted 
in patients with bulky or progressive disease are disappointing, suggesting that such a strategy 
reduces the likelihood of observing prolonged anti-tumor T-cell responses. According these 
observations, it may be therefore preferable to immunize patients with only minimal residual disease 
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after allogeneic SCT. Our T-cell depleted conditioning regimen followed by the postponed 
administration of DLI has the advantage that no immunosuppressive agents which may potentially 
impair the T-cell compartment are applied to the patient. However, due to prolonged T-cell 
suppression by the conditioning regimen vaccination of the patient should be performed concomitant 
with or shortly after the application of DLI. For the implementation of such a protocol, it is pivotal that 
disease control after allogeneic SCT is achieved for a longer period, thereby enabling the induction of 
efficient anti-leukemia T-cell responses through vaccination and DLI. Once complete remissions are 
obtained, vaccine boosts to induce re-expansion of the memory T-cell compartment may be useful. 
Whether such vaccine-based strategies using the in vitro generated malignant APC in combination 
with adoptive cellular therapy are ultimately capable of definitely eradicating minimal residual disease 
should be subject of future fase II and fase III studies.
In conclusion, in this thesis we illustrated both the curative potential of graft-versus-CLL activity by 
alloreactive T cells present in the allograft and/or in the DLI and the necessity to improve the efficacy 
of cellular adoptive immunotherapy because relapses of the disease after allogeneic SCT were 
frequently encountered. We showed the feasibility to transform primary CLL and MCL cells into 
malignant professional APC, capable of producing significant amounts of IL-12. The allostimulatory 
capacity of these APC was demonstrated by the induction of vigourous CLL- and MCL-reactive T-cell 
responses. The tumor-derived APC were sufficient immunogenic to evoke tumor-reactive CTL 
responses in HLA-matched sibling donors. Further characterization showed that these CTL were 
mHag-specific. The development of a clinical grade CD40 system is now pivotal to allow clinical 
application of these CTL lines. The further implementation of more sophisticated T cell selection 
techniques may result in the application of this highly specific, and probably highly effective adoptve 
cellular immunotherapy in the context of allogeneic SCT in patients with advanced chronic B-cell 
malignancies.
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Chronische B-cel leukemie
In het beenmerg bevinden zich hematopoietische stamcellen die de continue aanmaak van bloed- en 
afweercellen, ook wel hematopoiese, verzorgen. Bij maligne ontaarding van de hematopoietische 
stamcel kan de diagnose leukemie gesteld worden. Afhankelijk van de ontwikkelingsrichting, het 
ontwikkelingsstadium, waarin de maligne cel zich bevindt en de snelheid van deling van de 
kwaadaardige cel, kan leukemie verder geclassificeerd worden. Bij acute leukemie is er meestal 
sprake van een snelle proliferatie van de leukemiecellen in bloed en beenmerg met daarbij verdringing 
van de normale hematopoiese. Chronische vormen van leukemie, zoals chronische myeloïde 
leukemie (CML) en chronische lymfatische leukemie (CLL) kunnen zich in eerste instantie indolent 
gedragen. Dit proefschrift gaat over chronische leukemie waarbij de maligne kloon ontstaan is uit de 
rijpere B-cel lymfocyt.
Chronische lymfatische leukemie
Chronische lymfatische leukemie (CLL) is de meest voorkomende leukemie bij volwassenen en komt 
voornamelijk op oudere leeftijd voor. Deze chronische ziekte wordt gekarakteriseerd door klonale 
proliferatie en opeenhoping van maligne B-cellen in bloed, beenmerg en lymfeklieren. Dit kan leiden 
tot lymfadenopathie, splenomegalie, cytopenieën en een verhoogde gevoeligheid voor infecties. De 
ziekte gedraagt zich heterogeen. Een groot percentage van de patiënten met CLL is en blijft 
asymptomatisch, behoeft geen behandeling en heeft een goede prognose. In tegenstelling tot 
patiënten die bij presentatie symptomatisch zijn. Zij hebben ondanks behandeling met chemotherapie 
een snel progressieve ziekte. Met behulp van nieuwe moleculaire en cytogenetische technieken is het 
momenteel mogelijk om bij het stellen van de diagnose een inschatting te maken ten aanzien van de 
agressiviteit van de ziekte. 
Ondanks dat het beschikbaar therapeutische arsenaal tegen CLL is uitgebreid met zeer effectieve 
chemotherapie en monoklonale antistof therapie, heeft dit in deze patiëntencategorie nog niet geleid 
tot genezing van de ziekte. Een nieuwe veelbelovende behandelmodaliteit die mogelijk kan leiden tot 
curatie van de CLL is een stamceltransplantatie (SCT) met stamcellen afkomstig van een gezonde 
donor (allogene SCT).
Mantel cel lymfoom
Mantel cel lymfoom (MCL) is een agressieve en ongewone vorm van non-Hodgkin lymfoom (NHL), die 
vooral optreedt bij mannen van middelbare leeftijd. Door een chromosomale translocatie (t(11;14)) van 
een B-cel die zich in de mantel van de lymfklier bevindt, ontstaat een sterk toegenomen celproliferatie 
met als eindresultaat een maligne ontaarding. Bij diagnose is er meestal sprake van uitgebreide ziekte 
met gegeneraliseerde lymfadenopathie. Veelvuldig is de ziekte leukemisch met uitgebreide 
accumulatie van maligne mantelcellen in bloed en beenmerg.De ziekte reageert initieel vrijwel altijd 
goed op agressieve chemotherapie. De ziekte keert echter bij vrijwel iedereen terug, met het 
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overlijden van de patiënt als resultaat. Om de overleving te verbeteren wordt nu bij de conventionele 
chemokuren specifieke monoklonale antistoftherapie in de vorm van rituximab gegeven. Als 
consolidatie behandeling wordt vervolgens een hoge dosis chemotherapie gegeven gevolgd door een 
autologe SCT. Deze intensieve therapie heeft geleid tot betere ziekte-vrije overleving, maar niet tot 
genezing. Allogene SCT wordt momenteel onderzocht als curatieve behandelingsoptie voor patiënten 
met MCL.
Cellulaire immuunreacties tegen CLL en MCL
Ondanks het feit dat CLL en MCL cellen rond circuleren in het bloed en voortdurend in contact zouden 
moeten komen met T cellen vindt er kennelijk geen adequate immuunreactie plaats en ontsnappen zij 
aan de specifieke afweer. Het ontbreken van een efficiënte T cel respons zou verklaard kunnen 
worden door het feit dat CLL en MCL cellen niet goed functioneren als antigeen presenterende cellen 
(APC). Zij ontberen expressie van costimulatoire moleculen op hun celoppervlak die noodzakelijk zijn 
voor T cel activatie. Verder worden ook geen relevante immuunresponsen tegen tumor-specifieke 
antigenen geobserveerd ondanks de aanwezigheid van die antigenen op de CLL cel. Aangezien in 
autologe setting immunotherapie tegen CLL en MCL niet succesvol is, kan het aantrekkelijk zijn om 
een compleet nieuw T cel repertoire te introduceren door middel van een allogene SCT.
Allogene stamceltransplantatie
Bij allogene SCT wordt de hematopoiese van de patiënt vervangen door donor hematopoiese. Om 
allogene donor stamcellen te laten prolifereren in de patiënt en om afstoting van het transplantaat te 
voorkomen dienen de T cellen van de patiënt op het moment van transplantatie geëradiceerd te 
worden middels een vorm van myeloablatieve behandeling met chemotherapie en/of totale 
lichaamsbestraling. Hoewel deze conditionering van de patiënt voor allogene SCT zeker een leukemie 
reducerend effect heeft, worden de immuunreacties die optreden na de allogene transplantaties, 
beschouwd als de belangrijkste oorzaak voor het curatieve effect van een allogene SCT. Indien in het 
stamceltransplantaat naast stamcellen ook donor T cellen aanwezig zijn, kunnen deze donor T cellen 
weefsels van de patiënt als lichaamsvreemd beschouwen en aanvallen. Deze immuunreactie kan 
ernstige schade geven aan huid en organen en staat bekend als graft-versus-host disease (GvHD). 
GvHD kan grotendeels voorkomen worden door de T cellen uit het transplantaat te halen (T cel 
depletie) voorafgaand aan de toediening. T cel gedepleteerde allogene SCT leidt echter tot een 
grotere kans op terugkeer van de leukemie. De T cellen in het transplantaat zijn dus blijkbaar in staat 
ook de leukemiecellen te herkennen die na de chemotherapie en bestraling nog aanwezig kunnen 
zijn. Deze gunstige reactiviteit van donor T cellen tegen leukemiecellen wordt graft-versus-leukemia 
(GvL) reactiviteit genoemd, en is waarschijnlijk het belangrijkste mechanisme voor het curatieve effect 
van een allogene SCT. 
Cellulaire immunotherapie na allogene stamceltransplantatie
Veel onderzoek vindt plaats om enerzijds de toxiciteit en morbiditeit van GvHD na transplantatie te 
beperken en anderzijds de GvL-reactiviteit te behouden of verder te maximaliseren. Veel 
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transplantatie centra gebruiken protocollen waarbij donor T cellen bij het transplantaat worden 
toegediend teneinde optimale GvL-reactiviteit te verkrijgen met als prijs veel GvHD die vervolgens 
onderdrukt wordt met krachtige afweeronderdrukkende medicatie. Een alternatieve benadering 
bestaat uit het toedienen van een T cel gedepleteerd transplantaat na voorbehandeling van de patiënt 
waarbij de nadruk ligt op het vestigen van donor hematopoiese in de patiënt. Vervolgens kunnen 
rechtstreeks van de donor verkregen T cellen worden toegediend om de leukemiecellen te 
vernietigen. Deze vorm van cellulaire immunotherapie met allogene SCT als platform staat bekend als 
donor lymfocyten infusie (DLI). Na DLI kan echter ook GvHD optreden door alloreactiviteit van 
ongeselecteerde donor T cellen. Het selecteren en infunderen van donor T cellen die in staat zijn met 
name de leukemiecellen te herkennen en niet de normale weefsels van de patiënt, zou kunnen leiden 
tot optimale GvL-reactiviteit zonder het optreden van GvHD. 
De immuunreactiviteit na allogene SCT kan worden veroorzaakt door de aanwezigheid van verschillen 
in HLA moleculen tussen donor en patiënt. Aangezien er een duidelijke correlatie tussen de 
immuunreacties en de mate van HLA verschillen tussen donor en patiënt is, wordt er bij allogene SCT 
naar gestreefd een HLA-identieke donor te vinden. Desondanks kunnen na HLA-identieke allogene 
SCT immuunreacties optreden tussen donor en patiënt. Dit wordt veroorzaakt door donor T cellen die 
minor histocompatibility antigenen (mHag), gebonden aan HLA moleculen, van de patiënt herkennen. 
Bij een HLA-identieke SCT kunnen de immunogene mHag dus verschillend tot expressie komen 
zowel als in patiënt en donor. De weefseldistributie en expressie van de mHag waartegen de T cel 
reactie is gericht, kan variëren. Sommige mHag komen op vrijwel alle cellen tot expressie. Een donor 
T-cel respons hiertegen zal dus zowel GvHD als GvL-reactiviteit kunnen induceren. Een ander type 
mHag komt alleen tot expressie op hematopoietische cellen inclusief leukemiecellen. Indien dit 
antigeen het doelwit is van de donor T cel kan dit leiden tot een GvL respons zonder het optreden van 
GvHD. Er is recent een mHag geïdentificeerd die selectief tot expressie komt op de normale en 
maligne B cel. Dit zou dus een aantrekkelijk doelwit kunnen zijn voor immunotherapie na allogene 
SCT.
Allogene stamceltransplantatie in patiënten met CLL of MCL 
Patiënten met CLL of MCL die niet meer reageren op chemotherapie al dan niet in combinatie met 
monoklonale antistof therapie hebben een slechte prognose en zouden in aanmerking kunnen komen 
voor een allogene SC. De kans op terugkeer van ziekte na allogene SCT is kleiner dan na een 
autologe SCT en langdurige follow-up heeft laten zien dat er kans is op genezing. Dit betekent dus dat 
de CLL en MCL cellen target kunnen zijn van GvL-reactiviteit. Allogene SCT met standaard 
myeloablatieve conditionering middels totale lichaamsbestraling en hoge dosis chemotherapie leidt 
echter in deze oudere patiëntengroep tot hoge toxiciteit hetgeen resulteert in zeer hoge 
behandelingsgerelateerde mortaliteit. Met behulp van minder intensieve conditionering is het mogelijk 
gebleken de behandelingsgerelateerde mortaliteit sterk te reduceren. Hierdoor kunnen ook oudere 
patiënten in aanmerking komen voor deze in opzet curatieve therapie. Daarnaast heeft de incorporatie 
van alemtuzumab, een monoklonaal middel dat de donor T cellen in het transplantaat voor toediening 
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vernietigt, in het transplantatieprotocol geleid tot een aanzienlijke reductie van GvHD en dus 
morbiditeit. Zoals eerder weergegeven dient in dit transplantatieprotocol dan wel na allogene SCT 
cellulaire immunotherapie in de vorm van DLI gegeven te worden om GvL-reactiviteit te induceren en 
persisterende ziekte zo te bestrijden. Ondanks het feit dat er aanwijzingen zijn dat CLL en MCL 
gevoelig zijn voor GvL-reactiviteit na de toediening van DLI, laten de meeste studies zien dat de ziekte 
bij een groot percentage van de patiënten recidiveert. Om in deze patiëntengroep controle over de 
ziekte te bereiken, is het noodzakelijk om hogere doseringen DLI te infunderen met als gevolg 
aanzienlijke GvHD. Strategieën die de specificiteit van de immuunrespons tegen CLL en MCL 
verbeteren en resulteren in het versterken van de GvL-reactiviteit met daarbij reductie van GvHD zijn 
essentieel om te komen tot betere uitkomsten in deze patiëntengroep.
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Dit proefschrift
De introductie van minder toxische conditioneringschemata (reduced intensity conditioning (RIC)) als 
voorbereiding op een allogene SCT heeft geleid tot sterk gedaalde behandelingsgerelateerde 
mortaliteit. Dit maakt het nu zinvol om RIC allogene SCT als potentiële curatieve behandeling aan te 
bieden aan patiënten met chronische B-cel leukemie die onvoldoende gereageerd hebben op de 
conventionele behandelingen. Echter, na allogene SCT en ondanks toediening van DLI wordt bij veel 
patiënten recidiverende ziekte geconstateerd. De maligne B cellen zijn schijnbaar in staat om te 
ontkomen aan de donor T-cel gemediëerde reactiviteit. Verder zijn de herhaaldelijk toediening van 
steeds hogere doseringen DLI noodzakelijk om persisterende ziekte na allogene SCT te behandelen 
hetgeen resulteert in aanzienlijke morbiditeit door GvHD. De verminderde T-cel herkenning na 
transplantatie zou kunnen worden verklaard door het ontbreken van expressie van belangrijke 
costimulatoire en adhesie moleculen. In dit proefschrift zijn de APC functie van de CLL en MCL cellen 
bestudeerd en is geanalyseerd wat de mogelijkheden zijn om deze maligne B cellen te transformeren 
in professionele APC cellen. Vervolgens is onderzocht in hoeverre deze maligne APC cellen in staat 
waren een T-cel respons tegen de CLL of MCL te induceren met donor T cellen afkomstig van zowel 
onverwante HLA-gematchte als verwante HLA-identieke donoren. In dit proefschrift zijn verder T-cel 
responsen bestudeerd bij patiënten met CLL die behandeld zijn met een T-cel gedepleteerde RIC 
allogene SCT gevolgd door cellulaire immunotherapie middels DLI.
Transformatie van CLL cellen in maligne antigeen presenterende cellen
In hoofdstuk 2 worden de expressieniveaus van verschillende costimulatoire en adhesie moleculen 
op CLL cellen van 14 verschillende patiënten beschreven. CLL cellen hadden een hoge expressie van 
HLA klasse I, II en het costimulatoir molecuul CD40 op hun celmembraan. Expressie van de 
belangrijke costimulatoire moleculen CD80, CD86 en CD83 ontbrak echter volledig. Ook adhesie 
moleculen kwamen minimaal tot expressie. CLL cellen kunnen daardoor, ondanks dat het van 
oorsprong B cellen zijn, slecht functioneren als APC cellen. Om de APC functie te verbeteren, werd 
geanalyseerd in hoeverre bepaalde stimulerende cytokines in staat waren het expressieniveau van de 
costimulatoire moleculen te verhogen. Dit was niet succesvol. Aangezien normale maar ook maligne B 
cellen bepaalde receptoren (toll-like receptor) op hun celmembraan hebben die na activatie de APC 
functie van de B cel kan verbeteren, werd stimulatie van die toll-like receptor getest middels zijn 
agonist CpG. CpG in combinatie met het cytokine IL-4 resulteerde in enige opregulatie maar nog 
steeds geringe expressie van de belangrijkste costimulatoire en adhesie moleculen. Echter, stimulatie 
van het CD40 molecuul op de CLL cel met zijn stimulator CD40 ligand (CD40L) resulteerde in 
superieure activatie van de CLL cel. Dit gebeurde door gebruik te maken van muizefibroblasten die 
middels transfectie het humane CD40L hoog tot expressie hebben. Het toevoegen van IL-4 
maximaliseerde de expressie van alle costimulatoire moleculen en adhesie moleculen. Na vier dagen 
van CD40 stimulatie in aanwezigheid van IL-4 was de expressie het hoogst en veranderde de 
morfologie van de CLL cellen in dendritisch-achtige cellen. Deze maligne APC cellen bleken 
functioneel in staat om het belangrijke immunostimulatoire cytokine IL-12 te produceren. Samengevat 
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kon geconcludeerd worden dat stimulatie van de CD40-receptor op de CLL cel in de aanwezigheid 
van IL-4 voor een periode van vier dagen resulteerde in transformatie van de CLL cel in een 
morfologische en fenotypische karakteristieke CLL-APC cel die de capaciteit had om significante 
hoeveelheden IL-12 te produceren.
Inductie van CLL-reactieve T cel responsen 
Door donor T cellen in vitro te stimuleren met gemanipuleerde leukemiecellen van de patiënt kunnen 
populaties van zogenaamde cytotoxische T lymfocyten (CTL) gegenereerd worden die preferentieel 
leukemie-reactief zijn. Het toedienen van in vitro gegenereerde en geëxpandeerde leukemie-reactieve 
CTL lijnen aan de patiënt na allogene SCT zou kunnen leiden tot een versterkte GvL-reactiviteit en 
mogelijk verminderde GvHD. De proof of principle is aangetoond bij een patiënt met CML in 
geaccelereerde fase, die na toediening van CML-reactieve donor T cellen na allogene SCT in een 
voortdurend complete respons bleef. In hoeverre deze behandelstrategie ook bij patiënten met CLL 
mogelijk is, was onderwerp van studie in hoofdstuk 2 en 3. Allereerst werd onderzocht of de primaire 
ongemanipuleerde CLL cellen en/of de gegeneerde CLL APC cellen zoals beschreven in hoofdstuk 2 
in staat waren om donor T cellen afkomstig van onverwante HLA klasse I-gematchte donoren te 
stimuleren. Aangezien er een HLA klasse II mismatch bestond, vond bij de inductie van de T-cel 
respons depletie plaats van de CD4+ donor T cellen. In alle drie onderzochte donor/patiënten koppels 
konden primaire CLL cellen als stimulator cellen de donor T cellen niet activeren. Stimulatie van de 
donor T cellen met de CLL-APC cellen leidde echter tot sterke proliferatie van die T cellen in alle 
onderzochte koppels. De gegeneerde T cel lijnen vertoonde cytotoxie tegen de primaire CLL en de 
CLL APC cellen gemeten in een standaard 51Cr release assay. De cytotoxie kon volledig geblokkeerd 
worden door toevoeging van antistoffen tegen HLA klasse I aangevend dat herkenning HLA 
gerestricteerd was. In aanvullende experimenten in een donor/patiënten paar werden uit een 
cytotoxische T cellijn door middel van limiting dilution CTL klonen verkregen. Deze CTL klonen 
herkenden naast de primaire CLL en de CLL-APC ook andere patiënt-afkomstige targets en 
herkenden niet targets afkomstig van de donor. Deze resultaten gaven aan dat in tegenstelling tot de 
primaire CLL CLL-APC als stimulator cellen in staat zijn om CLL-reactive CTL lijnen en klonen te
genereren uit onverwante HLA klasse I-gematchte donoren. Om tot klinische implementatie van deze 
immunotherapische strategie te kunnen komen, was het vervolgens noodzakelijk om te onderzoeken 
in hoeverre het induceren van CLL-reactieve T-cel responsen in complete HLA-gematchte 
familiedonoren mogelijk was. 
In hoofdstuk 3 werd gedemonstreerd dat ook in HLA-indentieke setting het induceren van CLL-
reactieve T-cel responsen door gebruik te maken van de stimulerende capaciteit van de gegenereerde 
CLL APC haalbaar was. Zowel CD4+ als CD8+ CTL klonen konden gegeneerd worden. Deze waren in 
staat CLL-specifieke targets maar ook andere B-cel targets en T cel targets van patiëntenorigine te 
doden. Deze klonen herkenden dus mHag die verschillend tot expressie werden gebracht in patiënt en 
donor. Het door de klonen herkende mHag op de patiënt was dus niet CLL-, B-cel, of T cel-specifiek. 
Een mHag-specifieke kloon werd verder geanalyseerd. Deze kloon bleek HLA-B8 gerestricteerd. Door 
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gebruik te maken van mesenchymale stamcellen, gekweekt uit het beenmerg van de patiënt, konden 
vervolgens experimenten verricht worden om te analyseren in hoeverre de door de kloon herkende 
mHag ook in niet-hematopoietisch weefsel tot expressie kwam. De CTL kloon herkende wel alle 
hematopoietische targets en niet de niet-hematopoietische target, de mesenchymale stamcel. Dit zou 
kunnen impliceren dat deze gegenereerde kloon in staat is primaire CLL te doden zonder significante 
GvHD te induceren doordat het herkende mHag vooral tot expressie komt op hematopoiese en niet op 
andere weefsels. Deze resultaten illustreerden de haalbaarheid om met behulp van de CLL-APC als 
stimulators te komen tot initiatie van CLL-reactieve en mHag-specifieke T-cel responsen, die relatief 
hematopoiese-specifiek zijn in een HLA-identieke setting. Deze studie liet verder zien dat de gebruikte 
limiting dilution methode zeer arbeidsintensief was, en leidde tot langdurige in vitro kweekperiodes. 
Om in de kliniek tot toediening van CLL-reactieve CTL klonen na transplantatie te komen, dienen 
meer efficiëntere methodes ontwikkeld te worden die kunnen resulteren in vroege selectie en isolatie 
van CLL-reactieve T cellen.
Genereren van MCL-reactieve T cel responsen 
In hoofdstuk 4 bleken uit experimenten de expressieniveaus van costimulatoire en adhesie 
moleculen op primaire MCL cellen conform primaire CLL cellen onvoldoende te zijn om MCL-reactieve 
donor T-cel responsen op te wekken. Er werd getracht de primaire MCL cellen te transformeren in 
professionele APC cellen door CD40 activatie en door middel van stimulatie met het MCL-specifieke 
cytokine IL-10, met IL-4, CpG. Ligatie van het CD40 molecuul op de MCL cel was essentieel voor de 
opregulatie van costimulatoire moleculen. Vier dagen van CD40 stimulatie resulteerde in de meest 
optimale expressie van costimulatoire en adhesie moleculen en in een hoge productie van het 
belangrijke immunostimulatoire cytokine IL-12. Deze MCL APC cellen als stimulator cellen waren 
vervolgens in staat om MCL-reactieve T-cel responsen op te wekken in HLA klasse I-gematchte 
donoren. Dit resulteerde in de generatie van grote aantallen mHag-specifieke CTL klonen, die in staat 
waren de primaire MCL cellen zeer effectief te elimineren. 
Het karakteriseren van graft-versus-CLL responsen
In hoofdstuk 5 werden de resultaten en uitkomsten besproken bij twaalf patiënten met agressieve 
CLL, die behandeld werden met een T-cel gedepleteerde RIC allogene SCT, gebruikmakend van 
alemtuzumab in het transplantaat dat depleteerde voor donor en ontvanger T cellen. Onderdeel van 
het protocol was het toedienen van DLI na transplantatie om GvL activiteit te induceren en zo 
persisterende ziekte te eradiceren. Na transplantatie werd bij alle patiënten persisterend donor 
chimerisme waargenomen zonder toegenomen incidentie van transplantaat afstoting met verder 
minimale en acceptabele GvHD. Na toediening van DLI voor gemengd chimerisme en/of 
persisterende ziekte werden in sommige patiënten langdurige remissies verkregen, illustrerend dat 
CLL cellen gevoelig zijn voor het GvL effect. Echter, bij andere patiënten werd persisterende of 
progressieve ziekte geobserveerd ondanks het toedienen van oplopende doseringen van DLI. Om 
deze verschillen in klinische responsen verder te karakteriseren, werden in vitro experimenten verricht 
gebruikmakende van T cellen die verkregen zijn van op DLI responderende en niet op DLI 
responderende patiënten. Ook werden T cellen verkregen van de oorspronkelijke donor. De T cellen 
Chapter 7
136
werden gestimuleerd met de primaire CLL cellen en de CLL-APC cellen. Indien T cellen geactiveerd 
worden door de stimulatorcel kunnen zij immuunmodulerende cytokines zoals interferon gamma 
(IFNγ) produceren. In deze studie werden leukemie-reactieve T cellen geïsoleerd op basis van hun 
IFNγ productie in respons op primaire CLL en CLL-APC door middel van de IFNγ secretie assay. In 
overeenstemming met de experimenten in hoofdstuk 2 en 3, bleken primaire CLL cellen onvoldoende 
stimulatoire capaciteit te hebben om CLL-reactive T cellen te stimuleren. CLL-APC cellen konden 
CLL-reactive mHag-specifieke T-cel responsen induceren bij de patiënt met een goede klinische 
respons na allogene SCT en de toediening van DLI. Dit kon niet bij de patiënt die progressieve ziekte 
vertoonde ondanks oplopende doseringen van DLI. Vervolgens werden de experimenten herhaald 
met de T cellen van de oorspronkelijke donor van de niet-responderende patiënt om te onderzoeken 
in hoeverre voorloper CLL-reactive T cellen überhaupt wel aanwezig waren in de donor. Na activatie 
met CLL-APC konden met gebruik van de IFNγ secretie assay CLL-reactieve CTL klonen worden 
verkregen. Deze resultaten demonstreerden dat voorloper CLL-reactive T cellen die aanwezig zijn in 
de donor in vivo onvoldoende gestimuleerd werden door de primaire CLL. Dat berustte waarschijnlijk 
op het ontbreken van een APC fenotype. CLL-reactieve T cellen zijn dus niet in staat om een 
adequate immuun respons tegen persisterende CLL cellen op te wekken. Dit zou de reden kunnen 
zijn voor de klinische observaties van continue recidieven na allogene SCT en na de toediening van 
DLI. 
Inzichten en vooruitzichten
Inzichten
De resultaten in dit proefschrift laten zien dat primaire CLL en MCL cellen onvoldoende in staat waren 
om te functioneren als APC cellen door het ontbreken van voldoende expressie van costimulatoire en 
adhesie moleculen. De primaire CLL en MCL cellen waren daarom niet in staat een relevante 
immuunrespons te induceren. CD40 stimulatie transformeerde deze leukemie cellen in professionele 
maligne IL-12 producerende APC cellen. Deze CLL-APC en MCL-APC cellen hadden de stimulatoire 
capaciteit om CLL- en MCL-reactieve T-cel responsen te initiëren in HLA-gematchte donoren. 
Repetitieve in vitro stimulatie van donor T cellen met de maligne APC cellen resulteerde in de 
generatie van leukemie-reactieve mHag-specifieke CTL klonen die preferentieel hematopoiese-
specifieke targets herkenden. De relevantie van deze resultaten werd gedemonstreerd in een studie 
die de uitkomsten beschreef van patiënten met agressieve CLL die behandeld waren met een T-cel 
gedepleteerde RIC allogene SCT gevolgd door toediening van DLI voor het initiëren van GvL 
reactiviteit. Sommige patiënten hadden een zeer goede klinische respons wat illustreerde dat deze 
behandeling curatieve potentie heeft. Andere patiënten hadden echter continue recidieven na allogene 
SCT en DLI. De in vitro experimenten in een niet-responsieve patiënt demonstreerden dat voorloper 
CLL-reactive T cellen aanwezig waren in de donor maar na transplantatie in vivo niet geactiveerd 
konden worden door de persisterende primaire CLL cellen. Deze observaties suggereerden dat de 
inadequate APC functie van primaire CLL cellen waarschijnlijk deels verantwoordelijk was voor de 
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afwezigheid van een klinische respons. In deze groep patiënten is het daarom noodzakelijk de 
effectiviteit van adoptieve cellulaire immuuntherapie te verbeteren. 
Vooruitzichten
In dit proefschrift werd geïllustreerd dat gemodificeerde leukemiecellen als stimulator cellen in staat 
zijn om donor T-cel reactiviteit tegen de primaire leukemiecellen te induceren. Met behulp van de IFNγ
secretie assay was het vervolgens mogelijk om voorloper leukemie-reactieve T cellen vroegtijdig te 
detecteren en isoleren. Verdere efficiënte proliferatie kon bewerkstelligd worden door repetitieve 
stimulatie met de maligne APC cellen. Deze in vitro gegeneerde leukemie-reactieve T cellen zouden 
na toediening aan de patiënt in staat kunnen zijn om persisterende CLL of MCL cellen te eradiceren 
zonder inductie van uitgebreide GvHD. Immers de repetitieve stimulatie met leukemie APC cellen zou 
kunnen resulteren in een relatieve verrijking van leukemie-reactieve T cellen in vergelijking met GvHD-
mediërende T cellen. 
Met deze nieuw verworven inzichten zijn verschillende cellulaire adoptieve immuuntherapeutische 
benaderingen die het optreden van ernstig GvHD voorkomen en de GvL-reactiviteit versterken te 
overwegen. In vitro gegenereerde leukemie-reactieve T cellen zouden in lage doseringen direct na 
allogene SCT toegediend kunnen worden om toekomstige minimale residuale ziekte te controleren en 
elimineren. Als alternatief zouden hoge doseringen van deze specifieke T cellen later na allogene SCT 
na aantonen van persisterende ziekte toegediend kunnen worden. In hoeverre deze toedieningen 
gecombineerd dienen te worden met lage dosis DLI voor aanvullende immuuntherapeutische 
ondersteuning zou onderwerp van toekomstige studies kunnen zijn. Combinaties van lage dosis DLI, 
waaruit GvHD-inducerende T cellen zijn verwijderd, met GvL-inducerende in vitro gegenereerde T 
cellen zouden zeer synergistisch kunnen werken. Als alternatief zou het identificeren van nieuwe 
hematopoietische-gerestricteerde, bij voorkeur B-cel-gerestricteerde, mHag prioriteit moeten hebben. 
Immers dan zouden mHag-specifieke donor T cellen zonder de inductie van GvHD, gezien het 
ontbreken van expressie van de mHag op niet-hematopoietisch weefsel, na toediening de patiënt 
kunnen genezen van zijn ziekte. Een andere benadering zou kunnen zijn om patiënten na RIC 
allogene SCT te vaccineren met CLL-APC of MCL-APC als vaccin. Aangezien vaccinatiestudies bij 
patiënten met uitgebreide ziekte teleurstellend zijn, zou dit bij voorkeur al gegeven moeten worden bij 
minimaal residuale ziekte. Bij goede respons zou de vaccinatie herhaald kunnen worden om tot 
expansie van het memory T-cel compartiment te komen. 
De uitkomsten van de in vitro experimenten beschreven in dit proefschrift zullen nu vertaald dienen te 
worden naar de klinische setting. In hoeverre de in vitro aangetoonde effectiviteit van de leukemie-
reactieve T cellen ook in vivo in de patiënt werkzaam en relevant zijn, zou onderwerp van toekomstige 
studies en protocollen moeten zijn. Verder zal geëvalueerd moeten worden welke dosis van specifieke 
T cellen en welk tijdspad van toediening na allogene SCT het meest effectief is.
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Floor, Ingrid, Arend en Jenny. Mijn maten in Friesland en Peter in het bijzonder wil ik danken voor de 
ruimte die ze me gegeven hebben om dit proefschrift af te ronden.
Familie en vrienden, dank voor alle begrip, afleiding en ontspanning en morele ondersteuning de 
afgelopen jaren.
Merel, Linde en Hanna, wat is het heerlijk om jullie om mij heen te hebben! Jullie zijn mijn continue 
inspiratiebron.
Lieve Herminka, leven met jou is eindeloos. Zullen we weer …. Let’s get lost, lost in …….
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Curriculum Vitae
Mels Hoogendoorn werd geboren op 19 december 1965 te Zoetermeer. Na het behalen van het 
eindexamen Atheneum B aan het Oranje Nassau College te Zoetermeer in 1984, werd wegens 
uitloting voor de studie Geneeskunde gestart met de studie Biologie aan de Rijksuniversiteit Leiden. 
Na het behalen van het propedeutische examen kon alsnog aangevangen worden met de studie 
Geneeskunde aan dezelfde universiteit. In 1992 werd het artsexamen afgelegd na een half jaar 
onderzoek verricht te hebben in de Faulkner Hospital te Boston, USA (prof.dr. R.L. Murphy). Na een 
jaar als arts assistent chirurgie in het kader van de tropenopleiding gewerkt te hebben in het Spaarne 
Ziekenhuis te Heemstede (opleider dr. H.W.R. Siebbeles), werkte hij aanvankelijk als arts assistent 
niet-in-opleiding voor de interne geneeskunde in het Bronovo ziekenhuis te Den Haag (opleider dr. R. 
Bieger). In datzelfde ziekenhuis werd in 1996 de opleiding Inwendige Geneeskunde aangevangen en 
deze werd afgerond in het Leids Universitair Medisch Centrum (opleider prof.dr. A.E. Meinders). De 
registratie als internist vond plaats in 2001. 
Vanaf 2001 tot 2004 was hij werkzaam als internist op de afdeling hematologie van het Leids 
Universitair Medisch Centrum (opleider prof. R. Willemze). In 2004 volgde registratie als internist met 
het aandachtsgebied hematologie. Vanaf 2001 werd het in dit proefschrift geschreven onderzoek 
verricht op het laboratorium Experimentele Hematologie onder begeleiding van prof.dr. J.H.F. 
Falkenburg. Vanaf december 2004 is hij werkzaam als internist-hematoloog in het Medisch Centrum 
Leeuwarden.
